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Abstract
DNA vaccinology, although still in its infancy, has raised a great wave of interest 
among researchers, due to its wide applicability and the potential advantages it appears to 
offer over traditional methods of vaccination. In this study two independent bacterially 
derived antigens were evaluated as DNA vaccine candidates. The main thrust being to 
determine the potential of these vaccines to express antigen in vitro and stimulate immune 
responses in vivo. In addition, the route of immunisation on the magnitude and 
orientation of the immune response to the encoded antigens was also considered, with 
mice immunized either intramuscularly or intradermally using a Gene Gun.
One of the candidates, a DNA vaccine encoding a Mycobacterium bovis antigen 
(MPB-70) expressed very effectively in vitro when transfected into COS-7 cells. 
However, it failed to stimulate an immune responses in mice, regardless the route of 
immunisation used. In contrast, a second bacterial antigen, Fragment C of tetanus toxin 
produced by Clostridium tetani, expressed poorly in eukaryotic cells but elicited a specific 
immune response in vaccinated mice. Although, the magnitude of these responses did 
not appear to differ when mice were immunized using intramuscular or intradermal 
immunisation using the Gene-Gun, the quality of the immune response generated varied 
considerably. These results demonstrated that vaccination of pcDNA3/tetC by 
intramuscular route was associated with a specific anti-Fragment C humoral and cellular 
response associated with Thl CD4 cells, whilst immunisation using the Gene-Gun 
appeared to bias the response toward a CD4 associated Th2 profile. Moreover, both 
methods were able to prime a specific immune response with a magnitude that could be 
improved when the mice were boosted using the purified Fragment C antigen. Boosting 
these animals in such a manner resulted in an improvement in the magnitude of the 
immune response generated, however, the orientation of this response remained faithful to 
that originally initiated by the original route of DNA vaccination. Interestingly, the Gene- 
Gun mediated immunisation appeared to be far more efficient at stimulating immune 
responses as the magnitude of the immune response to the antigen was unaffected despite 
only a fiftieth of the amount of DNA used for each immunisation. This work highlights 
the potential impact of immunisation route on the quality and magnitude of an immune 
response to Fragment C when delivered as a DNA vaccine.
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Chapter 1 
Introduction
1.1. General Introduction
From the late 18^** century vaccines have had a significant impact on the prevention of 
a wide range of infectious diseases, includmg the world-wide eradication of smallpox. This 
success has led to the expansion of other global vaccination programmes, which, it is hoped, 
will lead to the eradication of other diseases such as poliomyelitis. The utility of other 
vaccines against serious diseases, such as tuberculosis, diphtheria, tetanus, pertussis and 
measles are now commonly accepted and adaptation of vaccination schedules to the 
epidemiological and social circumstances of each country has allowed widespread 
application of such vaccines. Given the remarkable success of this approach, vaccination has 
become one of the most cost-effective health interventions at our disposal.
The provenience of the word “vaccination” and the application of vaccination as a 
prophylactic method against infectious diseases are both attributed to the 18^*^ century 
scientist Edward Jenner. In 1796 he took material fi'om a pustular lesion on the hand of a 
milkmaid infected with cowpox and showed that by inoculation of this substance into the 
skin of a boy, the boy was protected fi'om infection with smallpox. This result confirmed 
that immunisation of a related virus induced an immune response that could protect the host 
against subsequent infection. (The term vaccination has its roots in these experiments as the 
name “vacca” in Latin means “cow” and relates back to these early experiments using 
cowpox). The meaning of the word “vaccination” has by now extended to a larger context, 
implying the administration of substances of any origin capable of eliciting a protective 
response.
Today, our understanding of immunity and mechanisms of activation has extended to 
include the role of both humoral and/or cellular types of immunity in protection against 
disease. Most of the current vaccines available for clinical use today generate a strong
antibody or humoral immune responses that protect against acute phases of infection. Such 
vaccines are very effective against diseases in which the pathogenesis is dependent upon a 
single virulence factor such as tetanus toxin, where antibody is important for neutralisation 
of its effect. However, most existing vaccines do not provide protection against chronic 
infections or intracellular pathogens or protect the mucosal surfaces of the body, the site 
from which many pathogens gain access to the host.
Thus, despite remarkable successes of vaccination over several decades of history, 
new or improved vaccines are still urgently needed. These include ones against diseases for 
which no vaccines currently exist (for example, malaria and AIDS), or improved, more 
efficacious forms of currently available vaccines such as those against Mycobacteria 
tuberculosis.
1.2. Vaccination and Host Immunity
The efficacy of all vaccines is largely dependent on the type and magnitude of 
protective immune response generated in response to the vaccines. In vertebrates, the 
immune system is composed of non-specific (non-adaptive) and specific (adaptive) 
components. Non-adaptive components include a variety of cells, such as natural killer 
(NK) cells, eosinophils, and polymorphonuclear cells, and factors, such as the a-, and 13- 
interferons (IFN) and complement. These cells and components are deployed rapidly and 
non-specifically, thus providing a first line of defence against the invading pathogen. In 
contrast, the specific, adaptive response is carried out by the lymphocytes, which upon 
activation show two critical characteristics: specificity and memory. These features are 
essential in vaccination, as prophylaxis is dependent on the rapid activation of a specific 
protective response to the organism, potentially years after the vaccine is given.
Lymphocytes are generally considered to fall into one of two classes, the first being 
the B lymphocyte, which following specific stimulation, replicate and differentiate into 
plasmocytes that either secrete specific antibodies or become memory cells, which can be 
efficiently evoked at a subsequent infection. The type of immunity governed by B cell 
activation, differentiation and antibody secretion was initially described as “humoral- 
mediated immunity”.
The second class includes the T or “thymus derived” lymphocytes. They have been 
conventionally divided into two main groups, distinguished, in part by specific markers 
(CD4 and CDS) at the cell surface. These cells are responsible for the activation of the “cell- 
mediated” immune response (CMI), but they are also strongly involved in humoral 
immunity, by providing “help” or “assistance” to B cells.
Several functions have been attributed to CD4^ T lymphocytes (or “helper” 
lymphocytes), includmg promotion of B-cell survival and antibody production through 
secretion of cytokines, such as interleukin (IL)-4, IL-5, IL-6, and IL-10 and through cell 
surface interactions (CD40L-CD40) (Banchereau et a/., 1994). They also provide “help” to 
CD8^ T lymphocytes through production of IL-2 and/or through CD40L-CD40 interactions 
(Schoenberger et a l, 1998). Third, they secrete a myriad of cytokines, such as IL-2, IL-12, 
IFN-y, which are important cytokines for the activation of cells such as macrophages, which 
are crucial for clearance of many bacterial infections.
Activated CD4^T lymphocytes can subsequently be subdivided into two distinct 
subsets: T helper-1 (Thl) and T helper-2 (Th2) lymphocytes based on the cytokines they 
secrete. Thl lymphocytes which preferentially secrete IL-2, IL-12, IFN-y, support the 
raising of complement-binding subclasses of IgG (IgG2a), and activate phagocytic cells to 
recognise and kill opsonised-invading microbes. By contrast, Th2 cells that secrete IL-4, IL- 
5, IL-6, and IL-10, support the raising of IgE and non-complement binding subclasses of
IgG (IgGl and IgG2b) and activate non-phagocytic defence mechanisms (such as mast 
cells). Many studies using infection of normal and transgenic animals, suggest that 
activation of Thl cells are important in the control and clearance of mainly bacterial and 
chronic viral infections, whilst induction of Th2 cells appears important in the prevention of 
bacterial infections and in the control of parasitic infection.
Another group of T cells, distinguished from the first two groups by possession of 
receptor CDS on the surface is represented by cytotoxic T cells, which have a broadly 
similar pattern of cytokine secretion to Thl cells. These cells specifically mediate the direct 
killing of cells m particular the killing of virally infected cells.
Activation of both types of lymphocyte (helper and cytotoxic) is dependent upon their 
interaction with specialised cells, named antigen presenting cells (APC). These cells are able 
to internalise, process and present on their surface peptide fragments from antigens from 
infecting pathogen. These peptide fragments are presented on the cell surface of APCs in 
combination with molecules encoded by genes of the major histocompatibility complex 
(MHC). Class I MHC molecules are found on all nucleated cells in the body, whilst class II 
MHC molecules are only found on professional antigen presenting cells (macrophages, 
dendritic cells [DCs], B cells). The type of processing and presentation within APCs 
dictates the type of T-lymphocyte that interacts with the APC, affectiug the subsequent 
downstream events and the type of immune response generated. Peptides bound to class I 
MHC molecules are typically derived from endogenously proteins, such as viral particles or 
proteins belonging to intracellular pathogens and are recognised by CD8^ cytotoxic T 
lymphocytes. In contrast, peptides derived from proteins taken up by the APCs from the 
extracellular environment (exogenous antigens) are displayed in association with class II 
MHC molecules and are recognised by CD4^ T cells.
The majority of vaccines in use today, induce high levels of long-lasting antibody 
responses that protect against disease by either prevention of infection or by control of 
pathogen replication. This type of response is dependent on B-cell activation and 
proliferation, which is dependent on help from CD4^ Th2 cells. Antibody in this context is 
protective as it is able to neutralise the effects of toxins, or to kill bacteria by enhancement 
of the mechanisms of antibody dependent cellular cytotoxicity or complement dependent 
lysis. On the other hand, very few vaccines are available that activate the proliferation of 
CD4^ Thl or CD8^ T cells that are effective in the control and clearance of intracellular 
infections. Therefore, new approaches are required to be able to specifically activate directly 
cell-mediated responses that can lead to the clearance of such pathogens.
1.3. DNA Vaccination
One approach that appears to preferentially enhance cell-mediated immunity is the use 
of ‘naked’ DNA directly to vaccinate individuals. This form of vaccination involves the 
direct transfer and expression of nucleic acid encoding a protective antigen from a 
pathogen, to an eukaryotic host, with the aim of activating a specific response to the 
encoded antigen.
The ability of DNA to activate such responses has only been recognised relatively 
recently and followed the observation that nucleic acid encoding the p-galactosidase 
enzyme could produce fimctional enzyme when injected into the muscle tissue of mice 
(Wolff et a l, 1990). Later, Tang and co-workers reported that plasmid DNA was able to 
mount a sustained immune response to such a plasmid-encoded antigen expressed in muscle 
cells (Tang et a l, 1992). This report led to an explosion of activity, which has resulted in 
the identification and generation of a number of new candidate vaccines. In addition, it has
led to a greater understanding of the mechanisms by which immune responses are activated 
and some of the factors that are likely to influence the type and magnitude of this response.
1.3.1. Advantages and Disadvantages of DNA Immunisation
Further extension of these studies has shown that DNA vaccination may have several 
advantages over current vaccines including the ability to raise protective and long-term cell 
mediated immune responses. Activation of these responses is particularly crucial for 
protection against intracellular pathogens such as HIV, malaria, leishmaniasis, listeriosis, 
and tuberculosis. DNA vaccines also have the potential to deliver multiple epitopes on one 
construct providing the potential to protect against several pathogens. Another advantage is 
that genes that confer pathogenicity or virulence or genes that lead to undesired inhibition 
of immunological responses or cross-reactivity can be excluded using this approach. In 
addition, manufacture of such vaccines can make use of a single production process, they 
can be stored by lyophilisation and transported without the need for cool storage, thus 
reducing cost considerably. Finally, this approach offers the opportunity to manipulate and 
explore the potential for the development of new immunotherapeutic vaccines and gene 
replacement therapy.
Nevertheless, a number of safety concerns remain, including the possible impact on 
the genetic mechanisms of carcinogenesis, which may result from the integration of bacterial 
DNA into the host genome. This event may increase the potential risk of malignancy, either 
by activating oncogenes, or by inactivating tumor suppressor genes. However, despite many 
attempts to measure such events experimentally, most date suggests that integration of 
injected DNA is unlikely, and, moreover, such events appear to occur less frequently than 
the rate of spontaneous mutation that occurs naturally in mammalian genomes (Martin et 
al, 1999).
Another concern is the potential of DNA vaccination to induce autoimmunity by the 
generation of antibody to the host genomic DNA. However, despite the fact that bacterial 
DNA can induce the production of anti-double-stranded, dsDNA-autoantibodies, bacterial 
DNA has been shown to suppress autoimmune response in lupus-prone mice (Gilkeson et 
al, 1995). In addition, hundreds of human volunteers have been exposed to plasmid DNA 
vaccines without serious adverse consequences (MacGregor et a l, 1998; Hanke et al, 
2000, Le et a l, 2000, Tacket et a l, 1999).
Finally, as the immune response to DNA vaccination appears to be relatively long- 
lived, persistence of this response may have consequences upon the host, such as induction 
of tolerance to the antigen or autoimmunity. Such consequences may be overcome by the 
use of an inducible promoter to control in vivo expression of the plasmid-coded (Dhawan et 
al, 1995). For example, using a bacterial tetracycline (tet)-responsive system, Dhawan and 
co-workers were able to regulate the timing and expression level of an intramuscularly 
injected plasmid.
Most concerns regarding the potential induction of toleragenic responses has been 
associated with the potential use of these vaccines paediatricaUy, where factors such as the 
nature of the antigen, concentration of the plasmid as well as the age of the host appear 
important (Marodon et a l, 1994). As protein antigens encoded by a DNA vaccines are 
produced endogenously and expressed in the context of self-MHC, the potential exists for 
the neonatal immune system to recognise the antigen as "self, resulting in tolerance rather 
than immunity. For example, a DNA vaccine encoding the circumsporozoite protein of 
malaria was found to induce tolerance rather than immunity in new-born mice (Mor et a l, 
1996). However, in this study, the induction of tolerance was observed only when vaccine 
was administered to mice less than 8 days of age. However, as most vaccines intended for
human use are administered to infants and children, such information may limit the 
application of such vaccines in a wider context.
Despite such queries regarding the safety of DNA vaccination, a number of volunteers 
have enrolled and taken part in a phase I and/or phase II clinical studies. These clinical trials 
are based on DNA vaccines encoding HIV antigenes, showing specific lymphocyte 
proliferation in patients, without eliciting local or systemic reactions, anti-DNA antibody or 
muscle enzyme elevations (MacGregor et a l, 1998; Hanke et a l, 2000), malaria antigens 
which triggered specific CTL responses without severe or serious adverse events or 
detectable anti-dsDNA antibodies (Le et al, 2000), and hepatitis B surface antigen, 
suggesting that the vaccine may induce a booster response, but without eliciting primary 
immune responses at the lowest DNA dose used (Tacket et a l, 1999).
1.3.2. Activation of Host Immunity by DNA Vaccines
Induction of immune responses following DNA immunisation is a very complex 
process and begins when host cells are transfected with DNA. Following transfection DNA 
must travel to the cell nucleus, where is transcribed to an immature RNA transcript. The 
primary transcript undergoes the splicing process and is converted into mature messenger 
RNA (mRNA). The mRNA is subsequently transported to the cytosol where it is translated 
to the ribosomes into protein. The protein is then either associated with MHC class I 
molecules, which are transported to the cell surface for presentation to cytotoxic immune 
cells, or the protein is released (possibly from dying cells) allowing uptake by other 
professional APCs which present to T cells through MHC class II molecules.
1.3.21. The Mechanism of Antigen Presentation Following DNA Immunisation
The mechanism by which the antigen-encoded by plasmid DNA is processed and 
presented to the immune system is still under debate. However, it is possible that antigen 
encoded on DNA vaccines are processed and presented to the immune system using three 
different routes. These include:
1. Direct priming by somatic cells (myocytes m the case of intra-muscuiar 
administration and kératinocytes in the case of intra-dermal delivery of DNA).
2. Direct transfection of professional APCs (Langerhans cells found in the skin or 
other DCs found at the site of vaccine inoculation)
3. Cross-priming, in which plasmid DNA transfects a somatic cell and/or a 
professional ARC and the released protein and/or apoptotic bodies containmg the 
expressed protein are taken up by other professional APCs and presented to T 
cells.
1.3.2.1.1. Direct Priming by Transfected Somatie Cells
In the case of intra-muscular administration, myocytes have been shown to be able to 
take up the injected plasmid (Davis et a l, 1993*’). However, the mechanism by which 
immune responses are generated in this context is unclear. Figure 1.1. illustrates the possible 
interaction, if any, of myocytes (as APCs) and CD8^  T cells (as precursors of immune 
effector cells) in inducing immune response against an antigen encoded by a DNA vaccine.
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Figure 1.1: Mechanism of immune response priming by direct transfection of somatic cells
Directly transfected myocytes may induce activation of CD8^ T cells by presentation of the 
endogenously synthesised antigen via MHC class I pathway. Though, muscle is not considered an 
immunologically active tissue, as they lack the characteristics of APCs (such as expression of MHC 
class II molecules, co-stimulatory molecules [B7.1/CD80 and/or B7.2/CD86] or cytokine secretion), 
they do express MHC class I molecules.
Muscle is not considered an immunologically active tissue, as although myocytes 
express MHC class I molecules, they constitutively lack the characteristics of APCs (such as 
expression of MHC class II molecules, co-stimulatory molecules [B7.1/CD80 and/or 
B7.2/CD86] or cytokine secretion). As co-stimulatory molecules, the role of CD80 and 
CD86 is to provide a second stimulatory signal for activation of antigen-specific CD4^T 
cells. Their expression on the surface of APC is up-regulated after their activation. They 
interact with CD28 present on the cell surface of Th lymphocytes, concomitant with the 
primary activation signal provided by the interaction between antigen-specific T cell 
receptor and MHC-peptide complex on the surface of APC. Thus, myocytes alone are 
unlikely to be able to prime naive CD4^ or CD8^ T cells. Moreover, even the co-expression 
of CO-stimulatory molecules as CD86 or of cytokines like GM-CSF or IL-12, has been 
shown to be insufficient to turn non-hematopoietic cells into efficient APCs for CTLs 
(Iwasaki e/a/., 1997^).
By contrast, a separate study found that non-hematopoietic cells such as muscle cells 
could be engineered to function as APCs, by co-administration of CD86. This was 
demonstrated using bone-marrow chimeric animals, developed in {32 micro globulin ((32m) 
knockout mice. As (32m is essential for effective transport and expression of functional 
MHC class I molecules, normal mice irradiated and subsequently transplanted with bone- 
marrow fi-om (32m knockout mice ((32m'' to (32m^ ^^ ) possess MHC class I positive muscle 
cells and MHC class I negative bone-marrow derived APCs. In contrast, (32m^ ^^  to p2m' ' 
mice possess MHC class I positive bone-marrow derived APCs and MHC class I negative 
muscle cells. When these mice were co-immunised a plasmid encoding an HIV-1 antigen 
together with a second encoding CD86 or CD80, high levels of specific CTL responses 
were only observed in animals co-immunised with the plasmid encoding CD86. This
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suggested that either the muscle cells or another non-hematopoietic cells became able to 
function as APCs when CD86 was co-administered (Agadjanyan et a l, 1999). In addition, 
Behrens and co-workers have described functionally active co-stimulatory molecules 
present on the surface of human muscle cells, which were distinct from B7.1/CD80 or from 
B7.2/CD86, but similarly involved in co-activation of antigen-specific CD4^ T cells 
(Behrens et a l, 1998).
However, the fact that the injected muscle tissue can be removed from the mouse as 
little as 10 minutes after immunisation without affecting the subsequent immune response, 
suggests that the muscle is unlikely to be the major site of antigen presentation (Torres et 
al, 1997).
The situation is much different in the case of intradermal injection of DNA vaccines 
where it has been shown that immediate removal of the skin after inoculation prevented 
immune response development (Torres et a l, 1997). In support of this, a separate study 
showed that transplantation of vaccinated skin 12 hours post vaccination could elicit an 
immune response in naive animals (Klinman et al., 1998). This might suggest that 
transfected kératinocytes play a role in priming the immune response to DNA vaccines, but 
only for a short period of time, because when the period of transplantation exceeded 24 
hours, little or no immune response could be initiated. However, it seems more likely that 
those intradermally located DCs, such as Langerhans cells, are being transfected and 
migrate to local lymph nodes within this 24h period. At such sites they can present antigen 
and activate naïve T-cells.
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1.3.2.12. The Role of APCs: Direct Transfection or Cross-Priming?
The role of professional APC (such as macrophages and DCs) in the periphery 
includes capturing and processing antigens, which when expressed with suitable co­
stimulatory molecules can activate naïve T-cells in appropriate draining lymphoid organs.
Several studies have conclusively demonstrated that bone-marrow derived APCs play 
a key role in initiating the immune response following DNA vaccination. Using bone- 
marrow chimeric mice, a number of worker (Corr et al, 1996; Iwasaki et a l, 1997*’; Doe et 
a l, 1996) have shown that priming of immune responses following DNA appears restricted 
to the haplotype of reconstituted bone-marrow. However, these studies failed to address the 
question of how these bone-marrow derived APCs obtained the antigen for presentation to 
T lymphocytes, i.e. by direct plasmid transfection of the APCs (as shown in Figure 1.2) or 
through uptake of the antigen released from transfected myocytes or kératinocytes (see 
Figure 1.3).
Evidence supporting the idea of direct transfection comes from several sources. First, 
plasmid DNA has been isolated from lymph node derived and skin-derived DCs after intra­
muscular and intra-dermal DNA immunisation (Casares et a l, 1997). Second, only DCs 
(not B cells or kératinocytes) from vaccinated mice were capable of presenting antigenic 
epitopes to antigenic-specific T cells. However, it was estimated that only a small 
proportion of DCs (0.4%) were transfected with plasmid DNA (Porgador et a l, 1998; 
Akbari et a l, 1999). These data suggest that priming of an immune response by DNA 
vaccination predominantly involve the direct transfection of a small number of DCs.
Evidence supporting the cross-priming hypothesis in which antigen is transferred from 
transfected myocytes or kératinocytes to professional APCs also exists. In these 
experiments, myoblasts transfected with influenza nucleoprotein DNA were transplanted 
into FI hybrid mice and induced CTL responses which were restricted by the MHC
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haplotype of the recipient mice (Ulmer et a l, 1997; Ulmer et a l, 1996). These workers also 
showed that transfer of antigen from myocytes to professional APCs can occur in vitro. In 
addition, cross priming can occur when professional APCs phagocytose not only secreted 
protein (from somatic cells and/ or other APCs) but also apoptotic or necrotic bodies 
containing the antigen that are released following the death of a transfected cell (Albert et 
al, 1998).
In conclusion, it would appear that APCs, but not somatic cells, are directly involved 
in priming immune responses following DNA vaccination, either by direct transfection, or 
by cross-priming.
1.3.2.2. DNA Vaccines and Host Immunity
DNA vaccination has been reported to induce long-term humoral and cellular 
immunity and protection against a variety of viral, bacterial, and eukaryotic (parasites and 
tumour) antigens. This includes the production of a strong antibody response in a number of 
animal species including mice, non-human primates and more recently, in man. In some 
cases, especially those involving antigens from viral pathogens, production of antigen 
specific antibody appeared sufficient to protect the animal against subsequent challenge 
(Fynan et al., 1993). This probably reflects the production of high titres of neutralising 
antibody against the virus, which may reflect that mechanism of antigen processing 
following this form of vaccination more closely resembles that which occurs during the 
natural infection (such in the case of Herpes Simplex Virus, Ghiasi et a l, 1995). In contrast, 
recombinant proteins may produce antisera of relatively low neutralising activity as 
presentation of certain determinants or epitopes may be inhibited. In addition, antigens 
produced in situ inside cells are additionally subjected to appropriate post-translational 
modifications, including glycosylation. This means that for viral antigens, proteins produced
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Figure 1.2: Priming o f immune response by direct transfection o f antigen presenting cells
Protein produced by transfected professional antigen presenting cells may be presented directly to 
CD4^ T cells and CD8^T cells via MHC class I and class II molecules respectively, leading to T cell
activation.
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Figure 1.3: Cross-priming theory
Protein produced by transfected somatic cells may be taken up by professional antigen 
presenting cells (APCs) and then presented to CD4^ T cells and CDS^T cells via 
MHC class I and class II molecules respectively, leading to T cell activation.
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following DNA vaccination more closely resemble those produced by the native virus. In 
contrast, bacterial glycoproteins expressed as DNA-vaccines may be subject to 
inappropriate glycosylation that may reduce the availability of irnmunodominant epitopes 
and affect immuno genicity.
I.3.2.2.I. Cellular Immunity to DNA Vaccines
1.3.2.2.11. T Helper Cells Involved in Immune Response to DNA Vaccines
Vaccination using DNA has the potential to preferentially stimulate a Thl CD4^T 
helper response to an antigen. Therefore, its application may be appropriate in the treatment 
of a number of conditions in which activation such a response would be beneficial, for 
example, in reducing intracellular infections, by inducing and optimising intracellular killing 
of infected cells. DNA vaccination may also be useful in preventing or limiting an ongoing 
Th2 response, associated with allergic or asthmatic diseases. Such an approach has been 
shown to be effective using a plasmid DNA encoding an antigen from the house dust mite 
allergen. Injection of this plasmid into rats intramuscularly resulted in long term expression 
of the allergen, which resulted in a reduction of histamine release in bronchoalveolar fluids 
and suppression IgE production. This effect appeared to be mediated by CD8^ T cells (Hsu 
e ta l, 1996).
I.3.2.2.I.2. Cytotoxic T Lymphocyte Responses
As already stated the main advantage of DNA vaccination appears to be the activation 
of specific CD8^ cytotoxic T cells. Moreover, some studies introduced the concept of cross 
pruning, in which triggering of CD8^T cell responses can occur without de novo antigen 
synthesis within the APCs. Antigens released from the transfected cells either by secretion, 
or by transfection-mediated cell death, are taken up by professional APCs and somehow are
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introduced into the MHC class I processing and presentation pathway, leading to the 
stimulation of CDS T lymphocytes (Harding et a l, 1995). In addition, it has been 
demonstrated that amongst the CD4^ T-cell population, subsets of cells can exist that 
expresses cytolytic activity. These “killer” cells, which appear to produce Thl cytokines, 
when activated, express Fas-ligand (FasL), which induces apoptosis in Fas-positive target 
cells (Hahn and Erb, 1999). It has also been proved that the magnitude of CTLs induced by 
DNA vaccination is sufficient for protection against disease. For example, a DNA vaccine 
encoding neuraminidase protected BALB/c mice from a lethal challenge with a 
heterologous influenza virus (Chen et a l, 1998).
Like antibody production, CTL responses appear to be long-lived. In addition, it was 
recently shown that the frequency of antigen-specific CD4^ T lymphocytes (as measured by 
proliferation) remained elevated for up to 40 weeks post-vaccination (Akbari et a l, 1999). 
The authors proved that antigen-specific CD4^ T lymphocytes are activated in the draining 
lymph nodes and migrate to the spleen where they can persist for up to 40 weeks in the 
absence of detectable antigen.
Persistence of this response probably reflects a low but continual production of 
antigen from the DNA construct. To support this idea some workers have demonstrated 
that intramuscular inoculation of a plasmid DNA encoding several different genes resulted 
in protein expression for about one year (Wolff et a l, 1992), whilst others have shown 
persistence of antigen-specific proliferative responses in the absence of detectable antigens 
(Akbari et a l, 1999). Therefore, it is possible that the antigen might be continuously present 
at low levels sufficient for antigen presentation but below possible levels of detection.
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I.3.2.2.2. Humoral Immunity to DNA Vaccines
Immunisation with plasmid DNA is able to induce strong antibody response to a 
variety of proteins in animal species, including mice, non-human primates and more 
recently, human subjects. The first experiments describing the protective efficacy of 
intradermal, intramuscular, intravenous, intranasal, and Gene-Gun-delivered plasmid DNA 
m mice against a lethal challenge with influenza virus belong to Fynan and co-workers 
(Fynan et a l, 1993). DNA-vaccination also induced neutralising antibodies and provided 
protection against challenge with the relevant pathogen, such in the case of a herpes simplex 
protein (Ghiasi et a l, 1995), and influenza hemagglutinin (Larsen et a l, 2001).
The type of antigen, cellular location of antigen and method of administration of DNA 
vaccines can affect the magnitude and type of antibody produced (this is discussed in further 
detail elsewhere: Section 1.3.3). Such antibodies can be detected as early as one week after 
plasmid injection, with antibody titres reaching peak levels 8-12 weeks after immunisation. 
For example, life-long humoral immunity to influenza nucleoprotein (Yankauckas et al, 
1993), influenza hemaglutinin (Justewicz et a l, 1995), and hepatitis C core protein 
(Lagginng. et a l, 1995) has been demonstrated. These levels can then persist for several 
months (Davis et a l, 1993''; Davis et a l, 1996, Deck et a l, 1997), although in some 
studies, repeated administration of DNA were required to attain a long-lasting immune 
response (Xiang et a l, 1994).
Although antibody titres achieved by DNA vaccination, are generally long-lived, the 
magnitude of the response is often much lower than that elicited by a traditional subunit 
vaccine. To overcome this defect, several groups have shown that combining DNA with a 
more traditional vaccine may significantly increase antibody levels (Jones et a l, 2001; this is 
discussed in greater detail elsewhere: Section 1.3.4).
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The ability of DNA vaccines to confer protection by inducing neutralising antibodies 
suggests that the antigen expressed in vivo following DNA vaccination assumes a native 
configuration. This is in contrast to some of recombinant proteins which may lack linear 
determinants or conformational epitopes required for activating of this type of response. In 
the case of viral antigens DNA vaccines provide further advantages over the conventional 
protein vaccines, because they use the mammalian-type pattern for post-translational 
modifications of the encoded antigen. In contrast, bacterial glycoproteins expressed as 
DNA-vaccines may be glycosylated differently from the proteins produced naturally by the 
bacteria. This may reduce the availability of immunodorninant epitopes to which protective 
antibody may be generated.
1.3.3. Impact of Delivery Route on Immunological Properties of DNA Vaccines
Several studies have now indicated that the route of delivery of DNA vaccines can 
affect both quantitative and qualitative differences in the immune response generated. To 
date, DNA vaccines have been delivered using a number of routes including intra-muscular 
and intradermal injection, epidermal delivery by Gene-Gun, mucosal administration (oral, 
intranasal, vaginal) (McCluskie et al., 1999, Fynan et a l, 1993), and more recently non- 
invasive vaccination to the skin (Shi et a l, 1999). However, the most widely used methods 
for gene-immunisation are intra-muscular and Gene-Gun delivery to the epidermis.
The main differences between these two methods include:
1. the way in which the plasmid DNA enter transfected cells,
2. the amount of plasmid DNA required for generating similar levels of specific 
immune responses,
3. the predominant type of immune response elicited in each case.
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Direct injection of naked DNA into skeletal muscle is often carried out in saline 
solution and results in the delivery of DNA to the extracellular space from where it is taken 
up mainly by myocytes or blood cells found at the locality of the injection site. However 
immune responses can be enhanced if the tissue has previously been treated with a toxin or 
local anaesthetic (e. g. bupivacaine), which cause necrosis and regeneration of the injected 
muscle. Such treatments are believed to increase the expression of the encoded antigen and 
therefore to amplify the immune response. However, it is also possible that the observed 
enhancement of the immune response is attributed to the numerous professional APCs 
recruited to the site of tissue damage rather than elevated expression of the antigen in 
regenerated muscle.
On the other hand, delivery of DNA by Gene-Gun is dependent upon the direct 
immunisation of the skin with gold particles coated with plasmid DNA. These particles are 
driven into the skin under high pressure using helium as the gas. The main cell types 
transfected following this type of vaccination are kératinocytes and Langerhans cells, which 
are found in great numbers in the epidermal layer. Due to their small size, the gold particles 
can penetrate through the cell membrane, carrying the bound DNA directly into the cell, and 
thus circumventing its residence in the extracellular space.
Using this approach, several workers have reported similar levels of antibody and 
cellular responses generated using 100-5000- fold less DNA than traditional i. m. 
immunisations (Feltquate et aL, 1997). In one study, as little as 16 ng of plasmid DNA 
delivered epidermally via Gene-Gun could induce antibody and CTL responses in mice, 
whereas intradermal or intramuscular injection of the same plasmid required 10-100 pg of 
DNA to elicit comparable responses (Pertmer et a l, 1995).
Although, both systems are able to raise a strong humoral immune response, the type 
of T-cell help induced by each method appears to differ significantly. Using intra-muscular
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injection of DNA, a predominantly Thl type response can be generated (indicated by the 
increased production of Thl cytokines such as IL-2, IFN-y, IL-12 and elevated levels of 
antigen specific IgG isotype IgG2a. In contrast, immunisation using a Gene-Gun appears to 
induce CD4^ T-cell, which secrete Th2 cytokines (generating less IFN-y, more IgGl 
antibodies and more IL-4). For example, intradermal immunisation of a plasmid vaccine 
expressing a P. bergei protein (CSP) raised a predominantly Thl response with mostly 
IgG2a anti-CSP antibodies, while Gene-Gun DNA immunisation produced a predominantly 
Th2 response with mostly IgGl specific antibodies (Weiss et a l, 2000).
One explanation for this difference may involve the quantity of plasmid DNA 
required to activate responses. Using the Gene-Gun, the amount of DNA is considerably 
lower than needed for intramuscular immunisation, which may affect the number of CpG 
motifs available for triggering the immune system. (Krieg et a l, 1998*’, O’Garra et a l, 
1998). Therefore, the less DNA is used, the weaker the effect of the non-specific 
immunostimulatory sequences on the subsequent immune response.
In addition, it is assumed that immunisation using the Gene-Gun results in the direct 
transfection of cells, which may bypass the interactions that are now believed to take place 
between CpG motifs and specific cell membrane receptors such as the recently identified 
Toll-9 receptor (Budker et a l, 2000). Interaction with such receptors is believed to 
generate the transduction of an intracellular signal leading eventually to the observed 
adjuvant effects of bacterial CpG motifs. Thus, in the absence of such interactions, this 
CpG-mediated immunostimulatory “help” cannot take place. However it may be possible 
that other factors such as the host haplotype or the nature of processed antigen may also be 
involved in preferential induction of a certain type of immune response (Cohen et a l, 1998).
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Similarly, by changing the form of the DNA expressed immunogen from cell- 
associated to secreted form, the same plasmid can be used to bias the type of CD4 helper 
response that is induced (Feltquate et a l, 1997).
1.3.4. Boosting Strategy and the Efficacy of DNA Vaccines
Although DNA vaccination has been shown to be effective at activation of immune 
responses to a wide range of pathogens, in many cases the level of immunity induced 
appears insufficient to afford protection. A novel strategy introduced to overcome this 
difficulty has involved the use of prime/boost strategies, in which an animal that has been 
primed with a DNA vaccine is subsequently boosted with a conventional vaccine such as an 
injected protein. Using this type of approach, improved protection was observed in mice 
that had been primed with a DNA plasmid encoding the protein E2 of hepatitis C virus and 
boosted with recombinant E2 protein (Song et a l, 2000). The level of protection observed 
was significantly higher than that observed when either vaccination strategies were used in 
isolation. The same strategy was also used to enhance antibody and Th cell proliferative 
responses for the antigen gD of herpes simplex virus-2 (Sin et a l, 1999). Similarly, three 
immunisations with a DNA vaccine encoding a Plasmodium falciparum erythrocyte binding 
protein, followed by a single immunisation with the recombinant protein induced high 
antibody levels that were equivalent to those induced by four recombinant protein 
immunisations. More significantly these animals showed improved protection against 
challenge with P. falciparum (Jones et a l , 2001).
Additionally, delivery of the same antigen multiple times using different carriers, with 
little or no immunogenic cross-reactivity (heterologous regimen) provides several 
advantages over the repeated delivery of an antigen with the same carrier (homologous 
boosting). For example, heterologous boosting yielded full protection in the P. berghei
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malaria model when plasmid immunisation was followed by administration of recombinant 
poxvirus (Sedegah et a l, 2000) or recombinant vaccinia virus Ankara (Sedegah et a l, 
1998). Homologous boosting was weak or ineffective in this model. Similarly, greatly 
improved immune responses and therapeutic effect were reported when a tumour model 
antigens were delivered in a heterologous prime-boost-regimen using recombinant cowpox 
or fowlpox expressing vectors (Irvine et a l, 1997). These differences may reflect the fact 
that the successful repeated use of any given vaccine may be dependent upon the generation 
of an immune response to the delivery vehicle itself.
In addition, the order in which the vaccines are delivered may affect the type and 
magnitude of immune response generated. This is particularly true when priming is 
performed using the antigenically more complex viral vector followed by boosting with a 
DNA vector. This difference might be due to the effect of immuno-suppressive viral 
products, which may interfere with the priming of T-cells against specific antigens 
(Levitskaya et a l, 1995). Such interference might have less impact on enhancement of a 
secondary response that has been primed against a specific antigen encoded by a DNA 
vaccine. In addition, the number of T-ceUs primed against an antigen may be increased by 
inclusion of several DNA priming steps. For example, McShane and co-workers compared 
the CD4^ T cell immune response elicited after a combined regimen of immunisation using 
two types of vectors: naked plasmid DNA (D) and modified vaccinia virus Ankara (M) 
expressing a variety of antigens fi'om Mycobacterium tuberculosis. Both D-M and M-D 
immunisation regimens produced significantly enhanced levels of IFNy^T cell responses, but 
the highest increase was noticed after a D-D-D-M immunisation regimen (McShane et a l, 
2001).
Interestingly, when a prime/boost strategy was applied to enhance immune responses 
at mucosal sites, the maximal mucosal immunity was achieved when a recombinant vaccinia
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virus encoding gB protein of Herpes Simplex Virus (HSV) was used for priming followed 
by boosting gB-encoding DNA vaccine. This suggests that activation of the responses at 
mucosal immune system maybe dependent upon a different set of conditions than those 
associated with systemic prime/boost strategies (Eo et a l, 2001).
1.3.5. DNA Vaccines; Design and Optimisation
DNA vaccination is essentially dependent on the cloning of the gene/genes of interest 
into a suitable plasmid vectors in which the expression of antigen is controlled by an 
eukaryotic promoter. Generally, such vectors have been engineered to ensure high 
productivity of plasmid without the expression of protein in the bacterial ceU.
The elements of the vector that enable it to multiply in bacterial cells are:
1. an origin of replication allowing for growth in bacteria and
2. selectable markers, usually antibiotic-resistance markers (which maintain selection 
of plasmid-containing clones during bacterial culture)
However, to stimulate expression of the cloned antigen in eukaryotic cells, a different 
number of factors are required on the vector. These include:
1. a suitable cloning site, usually an endonuclease-restriction site, where the gene of 
interest can be inserted,
2. a strong promoter for optimal expression in mammalian cells, and
3. polyadenylation sequences (which provide for the stabilisation of messenger RNA 
transcripts).
In addition, DNA vaccines also may contain specific nucleotide sequences of bacterial 
origin consisting of unmethylated cytidine-phosphate guanosine (CpG) dinucleotides, which 
have a strong and unequivocal immuno stimulatory role (Krieg et a l, 1998*’).
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Figure 1A  illustrates a schematic representation of a plasmid DNA vector consisting 
of a transcription unit, and an adjuvant unit.
1.3.51. Immunostimulatory Elements
The efficacy of DNA-based immunisation has been partly attributed to the intrinsic 
adjuvant properties of bacterial DNA itself. This activity appears to be a general property of 
CpG motifs found in bacterial DNA, which are 20-fold more common in prokaryotic than 
eukaryotic DNA. In addition, eukaryotic DNA appears to be heavily methylated when 
compai'ed to prokaryotic DNA, which in general is unmethylated (Sato et a l, 1996).
CpG motifs present on bacterial DNA appear to stimulate and activate several types 
of immune cells including monocytes, macrophages, DCs), and B cells. They can influence 
antibody production by B-cells and secretion of a large range of cytokines from T-cells 
including IL-6, IL-12, TNF-a, and IFN-y production (Krieg, et a l, 1998*’). This stimulatory 
effect is likely to be mediated by interactions which may take place between CpG motifs and 
membrane receptors such as Toll-like receptors {for example Toll 9 has been described to 
be specifically activated by prokaryotic DNA (Budker et al, 2000)} or between CpG 
motifs and intracellular proteins (Krieg et a l, 1998*’). Krieg and co-workers found that the 
earliest detectable effect of CpG on B cells and monocytes was the generation of reactive 
oxygen species (ROS). As production of ROS is one of the signals involved in the activation 
of nuclear factor kB (NFkB), a nuclear factor involved in the transcription of several 
immune factors, activation via these motifs is likely to affect the function of many genes in 
the immune cells.
In DNA based vaccination, these unspecific responses synergise with acquired 
immune responses against the DNA expressed protein and enhance the immune response 
generated. Thus, bacterial CpG sequences can be used as effective non-toxic adjuvants by
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Figure 1.4: A schematic representation o f the vector backbone o f a DNA vaccine
The transcription unit includes a promoter that is activated in eukaryotic cells, a gene insert 
encoding the antigen of interest, and transcription/termination sequences (polyadenylation 
signals). The adjuvant unit includes an origin of replication that allows multiplication within a 
prokaryotic host and an antibiotic resistance marker. Both of these regions are generally rich 
in stimulatory CpG motifs.
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either including a greater number of these sequences on the DNA vaccine vector itself or 
alternatively, by co-administration of these sequences in the form of synthetic 
oligonucleotides. In contrast, co-administration of mammalian DNA appears to be immuno­
suppressive (Krieg, et a l, 1998^ *). Therefore, optimisation of immune activation in humans 
is likely to depend on the identification of specific motifs that can be used to regulate 
discrete elements of the human immune system. For example, Liang and co-v^orkers found 
that a 6-base-pair motif that induces optimal stimulation in mice is less effective when tested 
on cells of primate origin (human, monkey, or chimpanzee) (Liang et a l, 1996).
1.3.5.2. Factors Affecting Expression of Antigen in the Eukaryotic Host
The main target of DNA-based vaccination is the activation of antigen specific 
immunity. Optimisation of this response is dependent upon a number of factors including 
level of antigen expression in vivo, which can be enhanced by the inclusion of a number of 
features on the vector backbone. These include introns to improve transcriptional efficiency, 
the design of the cloning site, codon optimisation for best usage in mammalian species, the 
nature of enhancer/ promoter region and the use of polyadenylation signals to enhance 
stability of the mRNA prior to translation.
1.3.6. Vaccine Candidates
Despite the fact that traditional vaccination strategies such as live, attenuated or 
whole inactivated agents have been very successful in the past, there are many 
microorganisms for which no effective vaccine currently exists. By using different strategies 
in the context of DNA vaccination it is possible to target the type(s) of the immune 
response required for protection against a particular disease. In the current study we 
intended to evaluate the impact of different immunisation strategies on the immunogenicity
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of two independent DNA vaccine candidates, Fragment C of tetanus toxin and a 
Mycobacterium bovis antigen named MPB-70.
1.3.61. Tetanus
Tetanus, along with measles and pertussis, is one of the main vaccine-preventable 
infections that can kül within the first year of life. In many children infection with the 
organism Clostridium tetani can occur within the first month of life as a result of infection 
through the umbilical stump. Although not preventable by immunisation of the child, trans­
placental transfer of circulating antibodies fi'om a protected mother to the unborn child is 
sufficient to passively protect the child through the first few months of life. In contrast, 
adults are usually infected following inoculation of C. tetani spores through puncture 
wounds of the skin. This is especially true when tissue injury and necrosis accompany the 
generation of such wounds.
Clinical symptoms usually associated with tetanus are muscle spasms (the most 
dangerous being the ones involving muscles of the neck, thorax or glottis) and spasm 
related complications including asphyxia, fiactures of the long bones and vertebrae, urinary 
retention, or pulmonary embolism. These symptoms are associated with the release of highly 
toxic protein of C. tetani, named tetanospasmin or tetanus toxin, which accumulates 
intracellularly during the grovW:h of the organism and is released on lysis. Tetanospasmin 
binds to specific glycolipids in nerve cells in the peripheral nervous system, fiom where 
retrograde transport fiom the nerves in the periphery to the spinal cord occurs (Price et al, 
1975). The toxin blocks normal post-synaptic inhibition of spinal reflexes, leading to 
generalised muscular spasms.
Following toxin identification and purification in the 1890’s, scientists were able to 
show that repeat inoculations of animals with minute quantities of toxin led to the
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production of antibodies that neutralised the effect of the toxin. Preparation and passive 
immunisation of these antibodies particularly from horse sera, became the first means of 
reducing the impact of infection. In 1924, a chemically inactivated form of the toxin, named 
anatoxin or toxoid, was prepared, which was able to induce protective, neutralising 
antibodies to the toxin. This vaccine was so effective that it is still used today for the 
generation of active immunity, whilst Human Tetanus Immuno globulin is available for 
passive protection.
Although, the current tetanus vaccine is efficient in the prevention of the disease, 
there are several reasons to suggest that this vaccine can be improved. These include the 
relatively limited duration of protection conferred by the vaccine, which has to be given 
every 10 years to maintain an appropriate level of neutralising antibodies. Second, 
immunisation is often accompanied by a local reaction following administration, which may 
be the result of the inclusion of the aluminium hydroxide or phosphate adjuvants (Stratton et 
aL, 1994). Thirdly, generation of the antigen is dependent upon the successful manufacture 
and inactivation of tetanus toxin from C. tetani, which, if performed incorrectly, may lead to 
the production of either an ineffective vaccine (Topsis et aL, 1996) or conversely 
immunisation of patients with active toxin (Gale et al, 1994).
A suitable alternative to the vaccine is the production by recombinant technology of 
the non-toxic, 50 kDa carboxy-terminal fragment (Fragment C) of the tetanus toxin 
molecule. In 1990, immunisation of mice with recombinant Fragment C resulted in the 
production of antibodies that were able to protect the mice against a challenge with tetanus 
toxin (Halpem et aL, 1990, Figueiredo et al, 1995). Fragment C of tetanus toxin was also 
proved to be strongly immunogenic and to elicit protective levels of serum anti-toxin in 
healthy human volunteers, when administered as a single-dose, orally, using as vector an 
attenuated strain of Salmonella enterica (Tacket et a l, 2000). Similarly, when mice were
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immunised intragastrically or intranasally with live Fragment C-expressing lactobacilli, 
significant levels of circulating, specific IgG were induced, and moreover, specific IgA was 
detected in broncho-alveolar lavage fluids (Shaw et aL, 2000).
DNA vaccines encoding Fragment C under the control of the CMV promoter 
(Anderson et a l, 1996), or a RSV promoter (Saikh et a l, 1998) have also been generated 
and shown to induce protective responses when given intramuscularly to mice. The 
immunogenicity of the plasmid was found to be improved when the native gene for this 
protein was replaced with a synthetic, codon optimised version of the toxin (Stratford et a l , 
2000). Although, substantial antibody titres were generated using these constructs, the level 
of antibody produced showed a reduced capacity to neutralise tetanus toxin when compared 
to polypeptide-based immunisation (Saikh et a l, 1998). In addition, the quality of the 
immune response varied considerably with the DNA vaccine apparently activating a CD4 
Thl response (indicated by high levels of IFN-y and IgG2a production), whilst the 
Fragment C polypeptide appeared to stimulate CD4 Th2 type responses.
As protection to tetanus requires a strong humoral response rather than a cell- 
mediated immunity, immunisation strategies that improve the production of long-lasting 
neutralising antibodies should be considered. Within the context of this thesis, this includes 
combining the codon-optimised gene for Fragment C together with the use of Gene-Gun 
technology to:
1. reduce the amount of plasmid that can be used to generate antibody responses
2. to evaluate the potential of the Gene-Gun-administration to generate the 
production of neutralising antibodies (possibly of a Th2 subtype).
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1.3 6.2. Tuberculosis
After a steady decline in the incidence of tuberculosis (TB) in industrialised countries, 
TB is re-emerging as an extremely serious worldwide public health problem. According to a 
global scale report of WHO, it is estimated that TB is responsible of about 3 million deaths 
per year, of which more than 95% occur in developing countries, associated with 
deteriorating social conditions. As the currently available vaccine against TB has its own 
limitations (see below. Section 1.3.5.2.2) and given the increasing incidence of multi-drug 
resistant strains of M tuberculosis that hampers preventive programmes based on 
chemotherapy, a new, effective strategy is needed to address this re-emerging problem.
13.6.2.1. Overview of the Immune Response to Mycobacteria
Briefly, TB is caused by the pathogen M. tuberculosis, but another member of the 
family, M bovis, which normally causes the disease in cattle, can be pathogenic for humans, 
when contracted through raw, unpasteurised milk. The initial infection is usually silent and 
may heal with no ftrrther symptoms, but some cases progress to pulmonary or disseminated 
TB, such as with meningeal or other extra-pulmonary involvement.
Tuberculosis is considered, in terms of its outcome and its clinical manifestations, a 
result of particular interactions between Mycobacteria and different components of the 
immune system. In most infected people, these interactions succeed to maintain a state of 
equilibrium between infection and immune response. On the other hand, disease pathology 
is thought to be a consequence of the disruption of this balance (Young and Thole, 1999).
Mycobacteria enter the body in the form of aerosolised droplets, initiating infection in 
the lung where alveolar macrophages represent their first serious encounter with the 
immune system. During a protective immune response, macrophages are probably the key
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effector cells responsible for killing of Mycobacteria, although they also provide an 
environment for mycrobacterial replication.
Under normal circumstances, macrophages kill invading pathogens by either engulfing 
them in a phagosome, which is made toxic by acidification, generation of short-lived oxygen 
and nitrogen radicals. Finally the phagosome is fused to a lysosome and hydrolytic enzymes 
are released further, destroying the bacteria. Alternatively, Mycobacteria are killed by the 
triggering of programmed cell death of the macrophage (apoptosis) by a mechanism that 
results in killing of the intracellular organism (MoUoy et a l, 1994). However, Mycobacteria 
have evolved two different strategies to circumvent the bactericidal activity of macrophages. 
The first strategy is based on the highly impermeable cell wall of Mycobacteria, which 
provides a defensive barrier against toxic solutes, hydrolytic enzymes, and fi*ee radicals 
encountered within host cells. In addition, Mycobacteria also express enzymes capable of 
detoxifying oxygen radicals, such as superoxide dismutase (SOD) and catalase. A second 
strategy, which prevents macrophage killing, involves occupation of a phagocytic 
compartment that is segregated fiom the conventional endosomal-lysosomal pathway. The 
factors that determine entry into this unusual phagosome are unknown. Live Mycobacteria 
might engage some specific receptors on the surface of the macrophage, activating a signal 
transduction mechanism that affects endosomal trafficking (Young and Thole, 1999). 
Alternatively, some functions expressed by the internalised mycobacterium might modify 
phagosome maturation and acidification (Gordon et al, 1980).
The ability of macrophages to kiU Mycobacteria or other intracellular organisms is 
dependent on the activation of these cells by specific T cells. T cell-mediated activation of 
macrophages is in turn a consequence of processing and presentation of mycobacterial 
antigens at the surface of the macrophage.
34
Mycobacterial antigens have been shown to be processed in a number of different 
ways, including presentation within the context of both MHC class I and II, and, of bacterial 
glycolipids in the context of CDl molecules (Moody et al, 2000). It is unclear how 
Mycobacterial proteins or peptides present in the segregated phagosome are able to enter 
these different antigen-processing pathways. One explanation is that Mycobacteria may 
escape into the cytoplasm, and provide a potential route for class I processing, while 
incorporation into the normal endosomal-lysosomal pathway would confer entry into the 
class II and CDl pathway (Moody et al, 2000).
The most important event of the immune response to Mycobacteria is antigen 
recognition by specific CD4^ T cells in the context of MHC class II molecules and 
subsequent release of macrophage-activating cytokines (type 1 cytokines). In addition, 
specific CD8^ T cells appear to kill Mycobacteria-mSQcXQà cells, thus making the bacteria 
available to activated phagocytes.
Mycobacterial infection activates several other cellular subsets. These include natural- 
killer cells, which probably provide an important source of IFN-y for the macrophage 
activation at the initial stage of infection. Mycobacteria also provide a potent stimulus for T 
cells with an antigen-specific yôT-cell receptor. The mechanism of antigen recognition by 
yôT cells and the molecular nature of their antigen repertoire remain poorly defined. The 
functional role of yôT cells is also unresolved, but it is possible that yÔT cells are involved in 
protection by preferentially responding to non-proteineous ligands. Cytokines produced by 
yôT cell may also augment the role of NK cells in providing an early source of IFN-y for 
macrophage activation (O’Brien et ah, 1989).
Although the antibody response against Mycobacteria is generally considered as a 
“side effect” of mycobacterial infection, antibodies directed to particular surface
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components of mycobacterium may play a role in pathogenesis. This is because 
mycobacterial entry into host cells appears dependent on specific interactions with cell 
surface receptors. Therefore inhibition of such interactions could reduce the level of 
infection. In particular, antibodies generated and released in the alveolar space may at least 
eliminate the organism, before they invade macrophages (Kaufinann, 2000). However, a 
more likely prospect is vaccine- induced immunity that attacks the pathogen after it has 
entered macrophages, which is the exclusive function of in particular CD8^ specific T cells.
I.3.6.2.2. Bacillus Calmette-Guerin- the Current Available anti-Tuberculosis Vaccine
The French scientists Calmette and Guerin developed the vaccine that is currently 
used in the fight against against TB. This vaccine known as Bacillus Calmette-Guerin 
(BCG), was developed by the in the first decade of the century and is based on an 
attenuated, avirulent strain of M bovis. Although BCG has been delivered for over 70 years 
and is the most fi*equently administered vaccine (more than 3 billion adults and 100 million 
new-boms receive the vaccine annually), there still are some issues regarding its potential 
efficacy. These include the fact that, in large, controlled prospective studies, the response to 
the vaccine in different populations is inconsistent. Although its side effects are tolerable 
and it has been proved to be able to confer protection against miliary and meningeal TB to 
an appreciable degree, BCG fails to protect against the most prevalent disease form, 
pulmonary TB. The protective efficacy of BCG in adults ranges fi*om 0% in South India to 
80 % in the UK (Fine, 1995). In addition, the exact basis for the attenuation of the virulent 
M bovis strain that led to BCG has not been yet established and also little is known about 
the duration of protection conferred by BCG. Protection after neo-natal BCG vaccination 
has been reported to be undetectable after about 15 years (Harboe et al, 1996). Such 
information is essential mainly for rational decisions of the utility of repeat vaccination.
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However, the only formal evaluation of the repeat BCG was carried out in Malawi, revealed 
that the second dose had no effect on incidence of pulmonary TB, but provided increased 
protection against leprosy (Karonga Prevention Trial Group, 1996). Finally, BCG given at 
birth was shown to interfere with prophylactic chemotherapy with isoniazid needed to 
confer protection in babies born to infected mothers (WHO vaccines and Biologicals- 
www.who.int/ vaccines/ intermediate/ tuberculosis.html).
Given all the above, fiirther strategies for TB vaccine and alternative approaches for 
TB prophylaxis, such as subunit vaccines, DNA vaccination or combined strategies are 
currently being considered.
13.6.2.3. Importance of MPB-70 in Protective Immunity against Bovine Tuberculosis
For many years, considerable efforts have been made to identify appropriate targets of 
the Mycobacteria to which protective immune responses can be generated. One candidate 
antigen to be revealed by such studies is a mycobacterial protein known as MPB-70.
MPB-70 was initially isolated in 1981 by Nagai and colleagues (Nagai et a l, 1981). 
The term MPB was introduced for the designation of a protein purified from M bovis BCG, 
and 70 denotes the relative mobility by electrophoresis on a 7.7% polyacrylamide gel run at 
pH 9.5 (Nagai et ah, 1981). MPT is used for similar designations of proteins purified from 
M. tuberculosis (Harboe et al, 1998) but there are no differences between M. bovis and M. 
tuberculosis in their sequence of the expressed proteins encoded by the mpb70 or mptlO 
genes (Wiker et al, 1998).
MPB-70 is consistently present in virulent M. bovis strain, whereas it is secreted in 
markedly lower amounts by various substrains of avirulent M. bovis BCG (Harboe et al, 
1998). Interestingly, MPB-70 is highly expressed in M. bovis and minimally expressed in M. 
tuberculosis, probably reflecting differences in the regulation of these genes (Wiker et al,
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1998). However, there is evidence to suggesting that MPB-70 is upregulated during M 
tuberculosis infection (Matsumoto et a l, 1995).
Cloning of mpbJO gene revealed the presence of a typical signal peptide, which is 
commonly found upstream of the proteins naturally secreted from the bacteria (Harboe et 
al, 1998; Wiker et al, 1991). However, previously it had been described as an adhesion 
molecule, present on the outermost layer of the bacterial cell (Matsumoto et a l, 1995). The 
protein appears to be a completely soluble secreted antigen, which is secreted with a high 
efficiency by M. bovis. Differences in the localisation of individual proteins in relation to the 
mycobacterial cell are closely correlated to the mode of interaction between multiplying 
bacilli and the infected host. Secreted proteins are probably available for presentation to the 
immune system prior to cytoplasmic constituents, being therefore expected to be of grater 
interest in finding new vaccine candidates.
The rationale for testing of MBP-70 as a vaccine candidate comes from the following 
studies. First, bovine serum IgG antibodies from cattle experimentally infected with M 
bovis appeared to strongly recognised six mycobacterial antigens, one of which was MPB- 
70 (Lyashchenko et al, 1998). Second, antigen-specific T-cell proliferation, IFNy and IL-2 
responses to a panel of mycobacterial antigens, including MPB-70, in cattle experimentally 
infected with M  bovis have been reported (Rhodes et al, 2000“). Third, MPB-70 induced a 
proliferative response in both PBMC (peripheral blood mononuclear cells), and LNC (lymph 
node cells of cattle experimentally infected withM bovis (Rhodes et al, 2000*^ ).
This data suggests that MPB-70 appears to be an antigen to be considered as a 
vaccine candidate against tuberculosis.
In addition, candidate DNA vaccines using MPB-70 as the encoding antigen have also 
been tested. These were shown to be of greater benefit (considering the number of bacteria 
in lungs of vaccinated mice), than a plasmid expressing hsp65, when administered as
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therapeutic vaccines in mice (Lowrie et al., 1999). More recently, pCMV-70 (a plasmid 
encoding MPB-70) has been shown to induce significant proliferative responses, IFN-y 
production and CD4^ T cell response in peripheral blood in 50% cattle vaccinated with this 
construct. Moreover, DNA vaccination of cattle with pCMV-70 did not alter their 
sensitivity for tuberculin skin test (Vordermeier et al., 2 0 0 0 ).
As protection to tuberculosis requires mainly a cellular immune response rather than 
antibody-mediated immunity, immunisation strategies that improve the production of 
specific memory T cells should be considered. One of the aims of the current study was to 
evaluate the capacity of i. m. administration of pCMV-70 to trigger specific immunity to 
this antigen in BALB/c mice.
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1.4. Aims of the Project
The aim of the project is to use two different bacterial antigens, Fragment C from tetanus 
toxin and MPB-70 from Mycobacteria bovis as model antigens in the context of DNA vaccination, 
to evaluate the potential for various immunisation strategies to alter the magnitude and orientation 
of the immune response generated. In particular, we wished to compare the type of immune 
response generated to these antigens when the DNA vaccine is delivered parenteraUy by injection o 
into the skin using the Gene-Gun. Previous data suggests that intramuscular immunisation induces £ 
Thl biased response, whilst immunisation using the Gene-Gun induces a Th2 response. Using these 
antigens, we hoped to establish whether this dogma was additionally true for these bacteriaUy 
derived antigens.
1.4.1. Objectives
1. To establish whether these two DNA vaccine candidates expressed antigen in eukaryotic cells 
cultured in vitro.
2. To optimise parameters for transfection of cultured cells using the Gene-Gun
3. To determine the response to the two DNA vaccines following intramuscular injection of the 
plasmid into mice and compare these responses to those achieved using the same plasmids 
delivered using the Gene-Gun.
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Chapter 2 
Materials and Methods
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2.1. Bacterial Strains
Escherichia coli XL-10 (kindly provided by Cathy Rush, Department of Infection 
and Immunity, Glasgow University) served as the bacterial host strain for all plasmids used 
in experiments described in this thesis.
2.1.1. Growth Conditions
Bacterial strains were cultured in Luria Bertani broth (L-broth: 10 g Bactotryptone, 5 
g Bacto Yeast Extract, 5 g NaCl dissolved in 1 litre of distilled water and sterilised by 
autoclaving), or on solid media on L-agar plates (L-broth containing 15 g/L Bacto Agar). 
Culture medium was supplemented where appropriate with the following antibiotics: 
ampicillin (100 pg/ml), or kanamycin (30 pg/ml).
2.1.2, Master Seed Banking
Bacterial strains containing the plasmids were stored on arrival in a master seed bank 
from which working seed banks were generated. Master banks were produced by initially 
plating the culture on L-agar plates impregnated with the appropriate antibiotic. After 
overnight incubation, colony morphology was checked to ensure the purity of the culture 
(single colony shape and size). Once purity had been established, three individual colonies 
were inoculated into 5 ml of Luria broth, and incubated for 4-5 hours at 37°C with shaking, 
to the mid log phase (ODeso = 0.4-0.6 ). A single Microbank tube containing cryobeads 
(Pro-Lab) was then inoculated with 0.5 ml of bacterial growth. The contents were mixed 
thoroughly by multiple inversions, and then the liquid content of the tube was removed 
leaving only the beads coated with bacteria inside the tubes. The stocks were immediately 
stored at -70°C and only used once to generate material for the working seed bank.
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2.1.3. Working Seed Banking
Working seed banks were prepared from each of the individual master seed banks by 
removing one bead, aseptically from the Microbank tube and placing it onto an L-agar 
plate impregnated with appropriate antibiotics. The bead coated with the bacteria was then 
spread from the bead over the surface of the plate using a sterile microbiological loop. 
After overnight incubation at 37°C, the colonies were checked for single morphology 
types, and then 2-3 identical colonies were inoculated into 5 ml of L-broth (containing 
appropriate antibiotics). The culture was grown with shaking at 37°C until it had reached 
mid log-phase (ODô5o=0 . 4  - 0.6). At this time, 0.5 ml aliquots of culture were placed into 
10 sterile 1.5 ml eppendorf tubes, 0.5 ml sterile glycerol added to each tube and the 
contents mixed. Stocks were immediately frozen and stored at -20°C. When required, an 
eppendorf was removed from -20“C, and the contents inoculated onto a L-agar plate using 
a sterile microbiological loop. Each eppendorf tube was used to recover bacteria on 
maximum three occasions before being discarded.
2.2. Plasmids
2.2.1. Plasmid Characterisation
Five previously constructed plasmids were used in the course of this study. These 
included pcDNA3/tetC (kindly provided by Gordon Dougan, Imperial College, London) 
and its corresponding vector control plasmid pcDNA3.1 (Invitrogen). The pcDNA3/tetC 
vector was initially-constructed by cloning the synthetic codon-optimised gene encoding 
Fragment C, the non-toxic binding domain of tetanus toxin into the eukaryotic expression 
vector pcDNA3.1 (Invitrogen). As can be seen in Figure 2.1 this vector contains the 
immediate early CMV promoter, the Bovine Growth Hormone polyadenylation signal 
(BGH polyA), a fl origin for single stranded DNA replication, CoIEl origin of replication
of the plasmid in E. coli, and a gene which encodes ampicillin-resistance in E. coli.
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Figure 2.1: A schematic representation o f pcDNA3.1 (A) and pcDNA3/tetC (B) 
plasmid maps
PCMV = CMV promoter; BGH pA = Bovine Growth Hormone polyadenylation signal; fl 
ori = origin for single stranded DNA replication; SV40 = simian virus 40 origin of 
replication; ColEl = origin of replication in E. coli;XbaI, Baml, Bgl-11, EcoRl, HindIII = 
restriction enzyme sites.
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Between the CMV promoter and the polyA tail, a poly linker containing endonuclease 
restriction sites for Hindlll, BamHI, EcoRI, and Xbal. Using the Hindlll upstream of the 
start of the open reading frame and Xbal immediately downstream of the end of open 
reading frame, the Fragment C gene was inserted into the vector.
Two further plasmids used in the course of this work, named pCMV-70 and its 
vector control pCMV-link, were kindly supplied by Mark Chambers, Central Veterinary 
Laboratory, Weybridge. The vector pCMV-70 was initially constructed by inserting the 
mpblO gene from Mycobacterium tuberculosis H37Rv into the plasmid backbone pCMV-
4. pCMV-4 is based on the plasmid pcDNAS.l (Invitrogen) except that it has an intron A 
from the human CMV immediate-early gene inserted immediately downstream of the 
CMV promoter (Figure 2.2). Insertion of such introns has been shown to increase levels of 
antigen expression by the vector. The control plasmid CMV-link was obtained by 
removing mpb70 from pCMV-70 using Xbal and BamHI restriction sites and replacing it 
with a polylinker containing BamHI, EcoRI, PstI, Hindlll, and Xbal restriction sites.
The final vector used was plasmid pGFP-C3 (Clontech). This plasmid contains the 
immediate early promoter from CMV for the expression of the green fluorescent protein 
(GFP) from the jellyfish Aequore victoria. The backbone of this plasmid includes a pUC19 
origin of replication for propagation in E. coli, a fl origin for single stranded DNA 
production and neomycin/kanamycin-resistance cassette (neo^) with a bacterial promoter 
upstream to this cassette (Pamp) that confers kanamycin resistance in E. coli. Restriction 
enzyme sites flanking the insert are Nhel, Eco47III, and Agel, upstream of the GFP gene 
insert and Hind III immediately downstream (Figure 2.3).
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Figure 2.2: A schematic o f pCM V-link (A) and pCM V-70 (B) plasmid maps
pCMV+Int A= CMV promoter and intron A; BGH pA = Bovine Growth Hormone 
polyadenylation signal; fl ori = origin for single stranded DNA replication; SV40 = simian 
virus 40 origin of replication; ColEl = origin of replication in E. coli', Xbal, BamHI, Bgl-II, 
EcoRI, PstI, Hindlll = restriction enzyme sites.
46
HSYTK^ l y  A
Eco 47 in
I
H in iin T
S V 4d-poly A
I ori
SV40-ori
Figure 2.3: A schematic representation o f pGFP plasmid map
pCMV= CMV promoter; polyA = polyadenylation signal; fl ori = origin for single 
stranded DNA replication; SV40 = simian virus 40 origin of replication; pUC ori= origin 
of replication in E. coli\ Nhe /, Agel, Eco47III, Hindlll = restriction enzyme sites.
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2.2.2. Competent Cells and Transformation oiEscherichia coli
To assure consistency in the potential contamination of purified plasmids, all 
constructs were first isolated and then used to transform the E.coli host strain XL-10. 
Competent bacterial cells were initially prepared using rubidium chloride method. In brief, 
a 25 ml culture of E. coli XL-10 was grown in L-Broth to early log phase (OD65o=0.45- 
0.55) and then chilled on ice for 15 minutes. The bacteria were then concentrated by 
centrifugation at 2000xg for 5 minutes, at 4°C and the bacterial pellet resuspended in 10 ml 
of ice-cold transforming buffer I (TFB I: 30mM potassium acetate, lOOmM RbCl, lOmM 
CaC12, 50mM MnC12, 15% glycerol), and left to chill for 5 minutes on ice. The bacteria 
were then centrifiiged again using the same conditions before being resuspended in 1 ml of 
transforming buffer II (TFB II; lOmM RbCl, 75mM CaC12, lOmM MES - 2-(N- 
morpholino) ethanesuhuric acid, 15% glycerol). The bacterial suspension was aliquoted 
into ten aliquots of 0.1 ml bacterial culture. These were subsequently flash-frozen in dry 
ice/ ethanol bath. These aliquots were stored at -70°C until required.
The competent cells were transformed with plasmid DNA by mixing approximately 
10-100 ng of plasmid DNA with an aliquot of competent cells, which had been thawed on 
ice. The mixture was stored on ice for 10 minutes and then heat shocked at 42°C for 2 
minutes before being returned to the ice for a fiirther 2 minutes. Transformed bacterial 
cells were allowed to recover in 0.9 ml of L-broth, which was added to the tube. The 
culture was then incubated at 37°C for 30-60 minutes before the bacteria were plated on L- 
agar plates containing the appropriate selection antibiotic.
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2.2.3. Plasmid Purification
In order to characterise the transformed strains, small- or large-scale preparations of 
plasmid DNA were made from bacterial lysates. Plasmids were purified using the Qiagen 
Miniprep kit (Qiagen Ltd., UK), or, for immunisation experiments, the endotoxin -  free 
Megaprep kit (Qiagen Ltd, UK).
2.2 3.1. Preparation of Plasmids Using the Miniprep Kit
Plasmid purification using these kits relies on the use of a modified alkaline lysis 
procedure followed by adsorption of DNA on silica in the presence of high salt. The 
protocol is designed to allow the preparation of up to 20 pg of plasmid DNA from a 
volume of 2.5 ml overnight bacterial culture. To purify plasmid, 2.5 ml of culture was 
initially centrifuged at 2000xg for 5 minutes, and the pellet resuspended in 250 pi provided 
buffer Pi in the presence of RNAse (50mM Tris-Cl, [pH 8.0]; 10 mM EDTA; 100 pg/ml 
RNAse A). The bacteria were then lysed with 250 pi buffer P2 (200 mM NaOH, 1% SDS 
{SDS solubilized the phospholipid and protein components of the cell membrane, leading 
to lysis and release of the cell contents while the alkaline condition denatured the 
chromosomal and plasmid DNAs, as well as proteins}). The lysate was neutralised and 
adjusted to high-salt binding conditions by addition of 350 pi buffer N3 (3M potassium 
acetate, [pH 5.5]), which causes proteins to denature and chromosomal DNA, cellular 
debris and SDS to precipitate, whilst leaving the smaller plasmid DNA solution. The 
solution was then centrifuged for 1 0  minutes at 3000xg and the resultant supernatant 
placed in a spin column containing a silica gel membrane for selective adsorption of 
plasmid DNA in high-salt buffer and elution in low salt buffer (RNA, cellular proteins and 
metabolites are not retained on the membrane, and can be detected in the flow-through). 
After washing the column with 0.75 ml of provided buffer PE (IM NaCl, 50mM MOPS -
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3-(N-morpholino) propanesulphuric add , [pH 7.0], 15% isopropanol) to remove trace 
nuclease activity, the plasmid DNA bound to the column was eluted by pipetting 50 pi 
distilled H2 O in the centre of the column and centrifiiging for 1 minute at 3000xg.
2.2.3.2. Preparation of Plasmids Using the Endotoxin-free Megaprep Kit
Qiagen Endotoxin-free Megaprep kit protocol for plasmid purification is also based 
on a modified alkaline lysis procedure, except that the protocol is designed for preparation 
of up to 2.5mg endotoxin-free plasmid from a volume of 2.5 litres of overnight bacterial 
culture. For preparation of plasmid DNA, endotoxin-free glass - and plastic-materials were 
used and, where appropriate, these were initially cleaned overnight in a 1% E-toxa clean 
solution (Sigma) prior to use.
The size of the culture used for preparation of the plasmid DNA varied between 
constructs, but, in general, between 1-2 L of cultures were used in each preparation. These 
bacteria were initially harvested by centrifugation at 6000xg for 15 minutes, at 4 °C, and 
the resultant pellet re-suspended in 50 ml of buffer PI, containing RNAse (50mM Tris-Cl, 
[pH 8.0]; 10 mM EDTA; 100 pg/ml RNAse A). After vortexing, the bacteria were lysed 
using 50 ml of buffer P2 (200 mM NaOH, 1% SDS) and then the lysate neutralised using 
50 ml of the buffer P3 (3M potassium acetate, [pH 5.5]). The lysate was then poured into a 
Qiafilter cartridge and left at room temperature for 10 minutes to equilibrate. The cartridge 
was then connected to a vacuum source to allow the soluble fraction of the material to be 
separated from the precipitated genomic DNA and proteins. This solution was then mixed 
with 50 ml of buffer FWB (750mM NaCl, 50mM MOPS, [pH 7.0]; 15% isopropanol) 
followed by the addition of 12.5 ml of buffer ER. The mixture was left for 30 minutes at 
room temperature before being allowed to enter the resin of an equilibrated Qiagen column 
by gravity flow. The column was washed twice with 100 ml buffer QC (IM NaCl, 50mM 
MOPS, [pH 7.0], 15% isopropanol), and the plasmid DNA eluted using 35 ml of buffer
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QN (1.25M NaCl, 50 mM Tris-Cl, [pH 8.5], 15% isopropanol) and precipitated with 24.5 
ml of isopropanol. The precipitated DNA was then collected by centrifugation at 15,000 x 
g for 30 minutes, 4 °C. The pellet was then washed with 7 ml endotoxin-free 70% ethanol 
(15,000xg, 10 minutes), air-dried for 10-20 minutes and finally resuspended in 1 ml 
endotoxin-free distilled H2 O.
2.2.4. Qualitative and Quantitative Analysis of DNA Constructs
After purification, plasmids were checked in terms of their size, sequence, and 
concentration. Plasmids were sequenced at the Molecular Biology Sequencing Unit, 
Glasgow University, using primers from Table 2.1.
Two types of methods are vddely used to quantify the amount of nucleic acid found 
in a sample. If the nucleic acid is pure (i. e. without significant amounts of contaminants 
such as proteins, phenol, agarose, or other nucleic acids), spectrophotometric measurement 
of the amount of ultraviolet radiation absorbed by the bases is simple and accurate. 
However, if the amount of DNA is very small or if the sample contains significant 
quantities of impurities, the amount of nucleic acid can be estimated by running serial 
dilutions of the sample on an agarose gel stained with ethidium bromide. Both methods 
were described and used in different sections of this study (Sections 2.2.4.2 and 2.2.4.3).
2.2 4.1. Restriction Enzymes Mediated Digestion of Plasmids
To confirm the size of the transformed plasmid, circular DNA was initially linearised 
by treatment with appropriate restriction enzymes (Table 2.2). This involved incubation of 
plasmid DNA with the appropriate restriction enzyme(s), a suitable buffer for the enzyme 
(1/10, v/v), and distilled water. Plasmid DNA was digested for 1 hour, at 37°C and then 20 
pi of digested DNA admixed with 6 x loading buffer (0.25% bromphenol blue, 0.25%
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xylene cyanol, 40% w/v sucrose) was run on an agarose gel. Location of restriction 
enzyme sites and inserts in plasmids are also shown in Figure 2.1 (for pcDNA3.1 and 
pDNA3/tetC), Figure 2.2 (for pCMV-70 and pCMV-link) and Figure 2.3 (for pGFP).
2.2.4 2. Agarose-Ethidium Bromide Gel Analysis of DNA
The agarose gel was prepared by melting 0.8 g electrophoresis grade agarose (Biorad) in 
100 ml TBE buffer [pH 8.0] (9mM Tris, 80mM boric acid, 0.5mM EDTA). After cooling 
the agarose-TBE solution to 60°C, 40 pi of a 1 mg/ml stock solution of ethidium bromide 
was added to the mixture. Wells in which the samples were to be loaded were created 
using a suitable well comb. The gel was then cast into an appropriately sized carrier and 
allowed to set. Once set, the comb was removed and the gel placed in the tank together 
with an appropriate amount of TBE buffer. Samples were loaded into the wells and the gels 
run at 75 V, for 2 hours. A standard 1 kb DNA ladder (1 pg/pl solution) (Gibco - Life 
Technologies, UK) was included on each gel. This was suitable for sizing linear double 
stranded DNA fi’agments from 500 bp to 12 kb. In addition, as the 1636 bp band of this 
ladder was known to contain 10% of the mass applied to gel, the relative intensity of this 
band to the sample could be used for estimating the amount of DNA in each sample.
2.2.4.3. Spectrophotometric Analysis of Plasmid DNA
The amount of plasmid DNA in purified samples was also determined by reading the 
absorbency of 100 pi of plasmid DNA solution at 260 nm and 280 nm against a suitable 
blank control, using a Unicam UVWIS-UV2 Spectrophotometer. The calculated amount of 
plasmid DNA in each preparation was estimated according to the fact that an OD2 6 0  of 1 
corresponds to approximately 50 pg/ml of double stranded DNA. The ratio between the 
readings at 260 nm and 280 nm (OD2 6 0 /OD2 8 0 ) provided an estimate of the purity of the 
nucleic acid with pure preparations having a value between 1.8 and 2.0.
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Table 2.1: Primers used for pcDNA3/tetC and pCMV-70 sequencing
Location inside plasmids Sequence
Forward primer pcDNA3 
(homologous to T7 promoter)
5’ GAA ATT ACG ACT CAC TAT AGG G 3’
Forward primer pCMV-70 5’ CGC AAA TGG GCG GTA GGC GTG 3’
Reverse primer pcDNA3 5’ GTC GAG GCT GAT CAG CGA GC 3’
Table 2.2: Restriction enzymes used to linearise plasmid DNA constructs
Plasmid Digestion Digestion products 
expectedEnzyme Buffer
pcDNA3.1 Hindlll (Promega) Buffer E 5.4 kb
pcDNA3/tetC Hindlll Buffer E 6 . 8  kb
Hindlll + Xbal 
(Promega)
Buffer B 5.4 kb + 1.4 kb
pCMV-link Bgl-II (Promega) Buffer M 6.3 kb
pCMV-70 Bgl-II Buffer M 6.9 kb
pGFP-Cg Hindlll Buffer E 7.4 kb
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2.3. Expression of GFP, Fragment C and MPB-70 in vitro
2.3.1. COS-7 Cells - Growth Condition
The African green monkey kidney cell line known as COS-7 (kindly provided by 
Cathy Rush, Department of Infection and Immunity, Glasgow University) was used for in 
vitro expression of GFP, Fragment C and MPB-70.
COS-7 are adherent fibroblast-like cells and grow as monolayers in complete 
medium containing Dulbeco’s Modified Eagle Medium (DMEM) supplemented with 10% 
(v/v) heat inactivated Foetal Bovine Serum-FBS, 1% (w/v) L-glutamine and 1% (w/v) 
Penicillin/Streptomycin (all supplied by Gibco-Life Technologies). Prior to use, this media 
was filtered using a 0.20 pm Syringe Filter (Pall Corporation, UK) and the cells 
propagated at 37°C in 5% CO2 .
Cells were stored long-term as frozen stocks in liquid nitrogen. These were prepared 
by freezing 1x10*" cells in 1ml of storage medium: DMEM with 20% (v/v) FBS, 10% v/v 
Dimethyl-sulphoxide, DMSO (Sigma). When required, cells were quickly thawed at 37°C, 
and transferred into a 25 cm  ^ culture flask containing 10 ml of complete medium. Five 
hours later, the medium was removed and replaced with fresh complete medium to ensure 
the removal of residual DMSO.
COS-7 cells were sub-cultured by splitting the confluent culture every 3-4 days. To 
split the cells, the monolayer was first washed with 3 ml Hanks’ Balanced Salt Solution- 
HBSS (Sigma) and the cells detached from the flask by trypsination using 1.5ml Trypsin- 
EDTA. The detached cells were then washed in 5 ml of complete medium and pelleted by 
centrifugation (lOOOxg, for 3 minutes, at room temperature). The cells were then 
resuspended in 5 ml of HBSS, recentrifuged, and finally resuspended in 5 ml complete
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medium. The number of viable cells was then determined by Trypan blue exclusion 
method using an Improved Neubauer Haemo cytometer chamber.
2.3.2. Transfection of COS-7 Cells Using Lipofectamine
To induce protein expression, COS-7 cells were transfected with DNA plasmid using 
Lipofectamine as a carrier. Lipofectamine (Gibco-Life Technologies, UK) is a cationic 
lipid reagent, which is effective at inducing transfection of DNA into a variety of adherent 
eukaryotic cell lines.
Transfection using Lipofectamine was achieved as follows: the day before 
transfection, COS-7 cells were plated at 3x10^ cells/well, in a 6 -well plate, a density that 
gives 70-90% confluence within 24 h. Plasmid DNA (1 pg) and the Lipofectamine reagent 
(10 pg) were diluted in 200 pi serum free DMEM and incubated at room temperature for 
20 minutes to allow the formation of DNA/lipid complexes. The solution containing the 
complexes was then made up to 1 ml by the addition of 800 pi of serum free DMEM and 
the entire volume of solution added to one well on the 6  well plate. After 5 hours of 
incubation at 37°C/ 5 %C0 2 , the medium above the cells was replaced with fresh complete 
medium, and the cells were maintained in culture for about 72 hours.
2.3.3. Harvest of Transfected Cells
Following 72 hours of incubation, COS-7 cells were harvested by detaching the cells 
from the bottom of the flask using the trypsin/EDTA method described previously. The 
cells were collected and concentrated by centrifugation (lOOOxg, for 5 minutes at room 
temperature) and the resultant pellet re-suspended in 1 ml of complete medium. The 
number of viable cells in the suspension was then determined by Trypan blue exclusion. 
Once determined, approximately 1- 3x10^ cells were transferred to an eppendorf tube, and
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the cells pelleted by centrifugation at lOOOxg, for 5 minutes, room temperature. Finally, the 
pellet was lysed in 100 pi of 50mM Tris-Cl buffer, [pH 7.5], 150mM NaCl, ImM 
phenylmethyl sulfonyl fluoride - PMSF (dissolved in 100% ethanol; Sigma). In order to 
establish the efficiency of transformation and antigen expression, 1 0 -fold serial dilutions of 
these cells were prepared. These were admixed in an equal volume of 2xSDS protein 
buffer (12.5% v/v IM Tris, [pH 6 .8 ], 4% w/v SDS, 20% glycerol, 10% v/v beta- 
mercaptoethanol, 0.09% bromphenol blue) before being stored at - 20°C until required.
2.3.4. Analysis of Protein Expression in COS-7 Cells
2.3.4.I. GFP Expression in Transfected COS-7
Expression of GFP in COS-7 cells transfected with pGFP-Cg was estimated by 
observing the cell 48-72 hours after transfection using an inverted microscope (Axiovert - 
Zeiss). The number of fluorescent cells per lOx microscopic field was determined and 
transfected cells were additionally visualised using an Imaging System equipped with a 
designated soft for picture processing (OpenLab-Improvision).
2.3.4 2. Fragment C and MPB-70 Expression in Transfected COS-7 Cells
Whole-cell lysates of transfected COS-7 cells were prepared as described above 
(Section 2.3.3), and separated by SDS-12.5% polyacrylamide gel electrophoresis (SDS- 
PAGE). The resultant protein bands were subsequently visualised by staining with 
Coomassie blue or by immunoblotting, using appropriate Fragment C or MPB-70 specific 
antibodies.
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2.3.4.2.I. SDS -  Polyacrylamide Gel Electrophoresis -(SDS-PAGE)
Separation of denatured proteins was performed using SDS-PAGElectrophoresis 
using a BioRad mini-gel system.
Prior to electrophoresis, a separating gel containing 12.5% polyacrylamide and a 
stacking gel containing 5% polyacrylamide were prepared as follows. 10 ml of separating 
gel were prepared by using 2.4 ml Lower Resolving Buffer (1.5mM Tris, 13,8mM Sodium 
Dodecyl Sulphate -  SDS; pH adjusted to 8 . 8  with HCl), 3.35 ml distilled water, 4.15 ml 
30% Acrylamide/Bis solution (Severn Biotech Ltd), 60 pi 10% Ammonium persulphate - 
APS, and 5 pi Tetramethylendiamine -  TEMED (Sigma). To prepare 5 ml of stacking gel 
the following were used: 1.75 ml Upper Resolving buffer, [pH 6 .8 ] (0.5M Tris, 13.8mM 
SDS, pH adjusted with HCl), 3 ml distilled water, 0.75 ml of 30% Acrylamide/Bis 
solution, 30 pi of 10% - APS, and 10 pi TEMED. Samples, mixed 1:1 with 2x sample 
buffer (12.5% v/v IM Tris, [pH 6 .8 ], 4% w/v SDS, 20% glycerol, 10% v/v beta- 
mercaptoethanol, 0.09% bromphenol blue) were boiled for 5 minutes and then loaded into 
the sample wells. See Blue Plus2 prestained markers (Invitrogen) were included on every 
gel and were used for sizing proteins or peptide fragments from 4 to 250 kDa. Loaded 
samples were run through the gel matrix at 200 V for 60 minutes using PAGE running 
buffer (27.25mM Tris, 0.2mM Glycine, 3.46mM SDS).
2.3.4.2.2. Staining Polyacrylamide Gels with Coomassie Blue
When the electrophoresis was complete, gels were transferred into a staining box 
containing 20 -  50 ml of Coomassie Blue Stain solution (1 w/v Coomassie brilliant 
blue R-250, 45% v/v methanol, and 10% v/v glacial acetic acid). Gels were stained 
overnight at room temperature with gentle shaking. To remove the stain, gels were washed 
in destain solution (20% methanol, 7% acetic acid), until background of the gel was 
transparent.
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In order to preserve the destained gels long term, gels were dehydrated using Gel Dry 
Solution (Novex). This required gels to be washed for 3x 15 minutes in deionised water to 
remove the methanol and then once in fresh Gel Dry Solution (Novex). After 15-20 
minutes, the gels were placed between two sheets of Novex cellophane on a special drying 
frame, and left at room temperature for 24 - 48 hours to dry. After drying, gels were 
scanned or photographed.
2.3.4.2.3. Western Blotting
For immunoblotting, gels were removed from the electrophoretic apparatus and 
proteins transferred to wet nitrocellulose membranes (Amersham Hybond C) in Ix 
Transfer Buffer (25mM Tris, 192mM glycine, 20% methanol) using a mini-blot system 
(BioRad). Proteins were successfully transferred using 95 V for 75 minutes. After transfer, 
membranes were washed in PBST (0.05% Tween 20 (Sigma) in Phosphate Buffer Saline 
[pH 7.3] (PBS: 1.37M NaCl, 3ImM KCl, O.IM Na2HP04), for 5 minutes and then blocked 
in 3% skimmed milk in PBS, either at room temperature for 20-30 minutes, or, overnight at 
4°C. Incubation with the primary and the secondary antibody used for detection lasted for 
at least one hour at room temperature. Antibody concentrations used for each of the 
various blots are given in Table 2.3. Between each incubation step, the blots were washed 
twice in PBST for 5 minutes, at room temperature, with shaking on a rotary shaker. In 
addition, prior to the addition of substrate, the membrane was washed additionally in PBS.
Blots were incubated with substrate (30 mg tablet of 4 chloro-l-naphtol (Sigma), 
16.7% methanol, 0.015% v/v hydrogen peroxide in PBS), until the bands appeared. When 
appropriate, the reaction was stopped by soaking the membrane in distilled water.
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Table 2.3. Concentrations of primary and secondary antibodies used in Western blot 
analysis of expression of MBP-70 and Fragment C in COS-7 cells
Antibody specificity
Concentration (in 3% 
skimmed milk in PBST)
Primary antibody
Rabbit anti-MPB-70 antibody 1 : 2 0 0
Monoclonal anti- MPB-70 antibody 1:500
Rabbit anti-Fragment C antibody (aU of 
above kindly provided by Mark 
Chambers, Centre of Veterinary 
Laboratoiy, Weybridge)
1:500
Secondary
antibody
Rabbit anti-mouse antibody Horse- 
Radish Peroxidase - HRP - conjugate 
(Dako)
1 : 1 0 0 0
Goat anti-rabbit IgG (whole molecule) 
HRP - conjugate (Sigma).
1 : 1 0 0 0
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Table 2.4: Concentrations of primary and secondary antibody used for Western blot 
detection of Fragment C expression of COS-7 cells using the Pico Chemiluminescent 
Substrate.
Blot
Fragment C 
concentration
Antibody concentration %in 3-5% Bovine Serum Albumine (BSA] 
in phosphate buffer saline[PBST])
Rabbit anti-Fragment C 
antibody
Goat anti-rabbit IgG -HRP
1
lOOng, Ing, 
lOOpg, Ipg
1:500 1:50,000
2
lOOng, Ing, 
lOOpg, Ipg
1:500 1 :1 0 0 , 0 0 0
3
lOOng, Ing, 
lOOpg, Ipg
1 : 1 0 0 0 1:50,000
4
lOOng, Ing, 
lOOpg, Ipg
1 : 1 0 0 0 1 :1 0 0 , 0 0 0
5
lOOng, Ing, 
lOOpg, Ipg
1:5000 1:50,000
6
lOOng, Ing, 
lOOpg, Ipg
1:5000 1 :1 0 0 , 0 0 0
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2.3 4.2.4. Western Blot Detection Using Pico Chemiluminescent Substrate
SuperSignal West Pico chemiluminescent substrate (Pierce), gives a highly sensitive 
signal enabling detection of picogram quantities of antigen, with relatively low levels of 
detecting antibody. To allow optimisation of antibody concentrations, six pieces of 
nitrocellulose membrane were used, on which four 2  pi spots containing 1 0 0  ng, 1 ng, 1 0 0  
pg, 1 pg respectively of antigen were dotted. The antigen dilutions were allowed to dry on 
membranes for 10-30 minutes and then the remaining non-specific sites of the membrane 
were blocked with 3-5% Bovine Serum Albumin - BSA (Sigma) in PBST. The antibody 
dilutions (given in Table 2.4) were prepared in 3-5% BSA in PBST.
Between each step the membranes were washed at least 6  times for at least 5 minutes 
each time, m PBST. Following incubation with the secondary antibody and subsequent 
washes, blots were developed by addition of equal volumes of the LuminoF Enhancer 
Solution and the stable peroxide solution (Pierce). The blots were incubated in the 
substrate for 5 minutes, washed again, placed in plastic membrane protectors, and exposed 
against a high performance chenuluminescence film (Pharmacia Biotech, UK) for 1 to 15 
minutes. The films were developed using a X-Ray film processor (Compact X-4).
2.3.5. Glycosylation Inhibition
COS-7 cells were transfected on several occasions with pCMV-70 in the presence of 
the glycosylation inhibitor, Tunicamycin (Sigma). This experiment was designed to 
establish if glycosylation was responsible for the apparent difference in size between MPB- 
70 expressed in prokaryotic cells and the MPB-70 expressed in eukaryotic cells by the 
DNA construct. Tunicamycin, a nucleoside antibiotic produced by Streptomyces sp., 
inhibits the biosynthesis of glycoproteins in eukaryotic cells. It is specific for a single step 
in the glycosylation pathway and easily penetrates eukaryotic cells. COS-7 cells were
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transfected with 1 pg of pCMV-70 and 10 pg Lipofectamine, as described (Section 2.3.2). 
Glycosylation was inhibited by adding of 1, 5, 10, or 20 pg Timicamycin/ml (stock 
prepared in DMSO and filtered using a 0.20 pm Syringe Filter) in the culture complete 
medium, immediately after the removal of the solution containing the Lipofectarmne DNA 
complexes. Two different methods were then followed, in the first protocol the medium 
above the cells was changed every 24 hours (method I, see Mulero et ah, 2000), whilst in 
the second, the medium was only changed five hours before cell harvesting (method II, see 
XuetaL,  1999).
2.4. Intramuscular Immunisation of Mice
2.4.1. Mice
Eight groups of five 6 -8 -week-old female BALB/c mice (Harlan/Olac, UK) were 
used in this study. To allow identification, mice were individually marked using an ear 
punch. The schedule of immunisation is outlined in Tables 2.5 and 2.6.
2.4.2. Vaccine Preparation
The four plasmids used for intramuscular immunisation of mice were purified using 
Endo-toxin free QIAgen Megaprep kit and characterised as described (Section 2.2.3.2.). 
For immunisations DNA was resuspended in endotoxin-free PBS [pH = 7.2] (Sigma) at a 
concentration of 1 mg/ml. For subsequent boosts with purified proteins, purified Fragment 
C (kindly provided by Neil Fairweather, Imperial College, London), and purified MPB-70 
(kindly provided by Mark Chambers, Central Veterinary Laboratory, Weybridge) were 
resuspended in endotoxin-free PBS [pH = 7.2] (Sigma) at a concentration of 1 mg/ml.
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2.4.3. Evaluation of LPS Contamination in DNA Samples Used for Immunisation
The level of contaminating lipopolysaccharide (LPS) in plasmid preparations was 
analysed using the Limulus Amebocysate Lysate (LAL) Assay (QCL, Biowhittaker), 
which makes use of the observation that Gram negative infection of Limulus polyphemus, 
the Horse shoe crab, results in fatal intravascular coagulation. This observation has now 
been developed into the generation of a quantitative, kinetic assay. This assay is based on 
the ability of Gram negative endotoxin to catalyse the activation of a proenzyme in the 
LAL that subsequently catalyses the splitting of p-nitroanile (pNA) from a colourless 
substrate. This change can be measured photometrically at 405 nm and the amount of 
endotoxin in the sample calculated by comparing the reaction time with those shown by 
solutions containing known amounts of endotoxin.
The assay was carried out as described in the manufacturer’s instructions, with all 
dilutions of the standards and samples performed using endotoxin free plastic-ware and 
endotoxin-free water. Values in the samples were calculated using the LPS standard units, 
EU/ml, and concentrations in the samples calculated using a standard curve ranging from 
50 EU/ml to 0.005 EU/ml.
2.4.4. Vaccination Regimen
All mice were immunised by inoculation in the quadriceps muscle of one hind leg, 
using a 27-gauge needle. Each dose was given in the same site regardless whether DNA or 
protein was being administered. Mice were immunised on days 0 and 8  with 100 pg of 
DNA in a volume of 100 pi. On day 37, mice were boosted with either a frirther dose of 
DNA (100 pg/100 pi) or a single dose of purified protein (10 pg/100 pi) as described in 
Tables 2.5 and 2.6.
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Table 2.5: Vaccination regimen for mice immunised i. m. with pcDNA3/tetC 
or with the control plasmid, pcDNA3.1 and boosted with Fragment C
Group 1 Group 2 Group 3 Group 4
Day 0 pcDNA3/tetC pcDNA3/tetC pcDNAS.l pcDNAS.l
Day 8 pcDNA3/tetC pcDNA3/tetC pcDNA3.1 pcDNAS.l
Day 37 pcDNA3/tetC Fragment C pcDNAS.l Fragment C
Table 2.6: Vaccination regimen for mice immunised i. m. with pCMV- 
70 or with the control plasmid, pCMV-link and boosted with MPB-70
Group 5 Group 6 Group 7 Group 8
Day 0 pCMV-70 pCMV-70 pCMV-link Naïve
Day 8 pCMV-70 pCMV-70 pCMV-link Naïve
Day 37 pCMV-70 MBP-70 MBP-70 Naïve
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2.4.5. Collection of Samples
Antibody responses in the sera were followed throughout the course of the 
experiment using sample bleeds taken from the tail veins. Samples were taken one day 
prior to the first immunisation (pre-immune sera), and subsequently on day 24 and 36 of 
the experiment (bleed 1 and bleed 2, respectively). Terminal bleeds taken by cardiac 
puncture were collected on day 50 (for the Fragment C groups) or on day 57 (for the MPB- 
70 groups). Following death by exsanguination, the spleens were removed and used in T- 
cell proliferative assays to assess the cellular immune response induced.
2.5. Evaluation of the Immune Response Elicited by the Vaccine
2.5.1. Analysis of the Humoral Immune Response
2.5.1.1. Serum Preparation from Blood Samples
To separate the serum from the blood, samples were first stored overnight at 4°C and 
then centrifuged at 3000xg, for 5 minutes, at room temperature. The serum was decanted 
from the pellet into a fresh tube and the serum re-centrifuged to pellet any remaining blood 
cells. The separated serum was then placed in a labelled tube, which was stored at -20°C.
2.5.I.2. Measurement of Serum Specific Antibodies Using ELISA
Individual sera were analysed in an enzyme linked immunosorbent assay (ELISA) 
against the purified protein (Fragment C or MPB-70). To detect antigen specific 
antibodies, 50 pi of either Fragment C (1 pg/ml) or MBP-70 2.5 pg/ml were used to coat 
the wells of a 96-weU ELISA plate (Costar). Wells were coated overnight at 4°C with 50 pi 
antigen diluted in PBS or, for the negative control wells, with PBS alone. The plates were 
then incubated for one hour at 37°C with 100 pi blocking solution/well using 1% BSA in
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PBST (0.05% Tween 20). After blocking, plates were washed three times in PBST, and 
then incubated for 2 hours with appropriate dilutions of sera, at 37°C. The starting sera 
dilution was 1:50 in PBS, followed by seven consecutive 5 fold dilutions of the same 
sample down the ELISA plate. As a positive control, the second column was incubated 
with the same dilutions from mouse-anti-Fragment C or anti-MPB-70 antisera. Inclusion of 
this control serum allows comparison of experiments carried out on different days to be 
possible. Following incubation, plates were again washed in PBST, and, then incubated for 
90 minutes, at 37°C with rabbit anti-mouse - HRP conjugated antibody (Dako; 1:1000). 
This was then removed by PBST washes before addition of the substrate (50 pFwell; 
48.48% v/v O.IM citric acid, 51.52% v/v 0.25M Na2HP04, 0.04% v/v hydrogen peroxide, 
and a 10 mg-tablet of 0-phenylenediamine dihydrochloride for 25 ml final volume). The 
enzyme reaction was finally stopped with 50 pi 3 M HCFwell. The OD4 9 0  value was the 
determined using a EL x 808 ELISA plate reader (Bio-Tech Instruments, Inc). ELISA 
titres were determined arbitrarily as the dilution of serum that gave a value of 0.3 OD units 
above that level measured in equivalent negative control wells.
2.5.1.3, Measurement of Antigen Specific Antibodies Using Western Blotting
Serum from individual or pooled samples was also assessed for antigen specificity 
using Western blots. In these blots proteins from MPB-70 or Fragment C transfected COS- 
7 cells were transferred onto nitrocellulose and then probed with the relevant sera. As a 
negative control a similar concentration of COS-7 cells tranfected with control plasmids 
were used. The concentrations of sera used as primary antibodies in these experiments 
were between 1:150 and 1:20. The Western blot method is described in detail in Section
2.3.4.2.3.
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2.5.I.4. Measurement of Specific Subtypes of Antibodies
Specific subtypes of antibodies were measured using antigen specific ELISA 
(described previously [Section 2.5.1.2]) except that Rat anti-mouse isotype specific 
biotinylated antibodies were used as secondary antibodies. The concentration of these 
antibodies had previously been standardised to detect equivalent amounts of monoclonal 
IgGl, IgG2a and IgG2b antibodies. In these assays they were used at concentrations of 
1:5000, 1:1000 and 1:5000 for IgGl, IgG2a and IgG2b antibodies, respectively. The 
amount of bound biotinylated antibody was then detected using streptavidin- HRP 
conjugate (1:1000; Dako) diluted in 0.1%BSA/PBST. The conjugate was incubated on the 
plate for Ih at 37°C before the plates were washed and substrate added. When appropriate 
colour development was then stopped as described in Section 2.5.1.2 and absorbencies 
measured at OD4 9 onm. Titres of IgGl, IgG2a and IgG2b were then calculated as described 
previously.
2.5.2. Evaluation of Cellular Immune Response
2.5.2.1. T Cell Proliferation Assay
Using sterile techniques, spleens were removed from immunised mice and placed 
into 5 ml of fi*esh complete culture medium (RPMI-1640 containing 10% FBS, 1% 
Penicillin/ Streptomycin, 1% L-glutamine, 50 pi mercaptoethano 1 in 500 ml RPMI). The 
tissue was then crushed between sterile frosted microscope slides and released cells 
removed to clean 15 ml Falcon tubes, which were centrifuged at lOOOxg for 7 minutes at 
room temperature. The cell pellets were washed in 3 ml RPMI (lOOOxg, 7 minutes, room 
temperature), and then lysed for 5 minutes in 2 ml of red blood cell lysis buffer (Gibco- 
Life Technologies). The activity of this buffer was then neutralised by adding 2x volumes 
of RPMI, and cells collected by centrifugation at 200xg for 10 minutes. The cells were
washed for a final time before being re-suspended in 2 ml complete tissue culture medium.
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The number of viable cells in each preparation was determined by Trypan blue exclusion 
using an Improved Neubauer Haemo cytometer. The concentration of cells was adjusted at 
2x10*’ lymphocytes/ml, and 180 pi of suspension were added per well to a 96 well flat 
bottom tissue culture plate (Costar-Coming), Cells were then stimulated in triplicate using 
20 pi of 3 X 10 fold dilutions of antigen (0.1, 1, and 10 pg/ml). Positive control wells in 
which samples were incubated with increasing concentrations of the mitogen Concanavalin 
A (Sigma) at concentrations of 0.5, 5, 50 pg/ml were also included. Negative controls of 
cells stimulated with 20 pi of media alone were also included in triplicate. After 72h of 
incubation at 37°C and 5% CO2 , 100 pi of the supernatant was removed from each well 
and stored for cytokine analysis. To the remaining 100 pi of supernatant, 20 pi of medium 
containing IpCi of ^H-thymidine was added to each well. The plates were then re­
incubated for 6 hours. Levels of proliferation were then determined by harvesting the cells 
onto nitrocellulose mats using a cell harvester (Wallac) and then measuring incorporated 
Thymidine in a Beta plate counter (Wallac). Stimulation indexes (SI) were determined 
using formula:
SI = no of counts in stimulated wells 4- no of counts in unstimulated wells
2.5.2.2. Cytokine Types in Culture Supernatant
The presence of IFN-y and IL-5 in the culture supernatant taken 4 days after 
stimulation of spleen cells in vitro was determined using an ELISA kit (Pharmingen) 
according to the recommended protocol. 96 well flat bottomed Costar plates were 
incubated overnight at 4°C with 50 pi per well of Capture antibody (1:2000 anti-mouse 
IFN-y and 1:250 anti-mouse IL-5 monoclonal antibody) diluted in freshly prepared Coating 
buffer (O.IM NaHCOs, 33.5mM NazCO] [pH 9.5]). After washing, plates were blocked for
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1 hour at 37°C with 100 pFwell of 1% BSA in PBST. A standard curve was created using 
doubling dilutions of recombinant IFN-y and IL-5 cytokines (starting concentration: 2000 
pg/ml for recombinant mouse IFN-y and 1000 pg/ml for recombinant mouse IL-5), which 
were placed in duplicate in a final volume of 50 pFwell. Unknown samples were tested in 
triplicate and added undiluted to the plate (50 pFwell). Standards and samples were 
incubated at room temperature for 3 hours. Afl;er washing each plate 5 times, 50 pi of 
detection solution containing either 1:250 biotinylated anti-mouse IFN-y or IL-5 antibody 
combined with 1:250 avidin HRP-conjugate in 1% BSA/PBST was added to each well. 
Plates were incubated for 1 hour at room temperature, washed and developed using 50 pi 
ELISA substrate in each well. The enzyme reaction was finally stopped with 50 pi 3M 
HCFwell. The OD4 5 0  values were determined using an ELx 808 ELISA plate reader (Bio- 
Teck Instruments, Inc) as described previously. Relative amounts of IFN-y and IL-5 in test 
wells were then calculated using curves created fi'om known standards diluted on the same 
plate.
2.6. Helios Gene-Gun Optimisation
2.6.1. Preparation of DNA/Gold Cartridges for Gene Gun Vaccination
All reagents used in the preparation of gold cartridges for Gene-Gun vaccination 
were purchased from BioRad, UK. The optimum quantities of polyvinyl pyrrolidone - 
PVP, microcarriers (1 pm diameter gold particles), spermidine (N-[3-aminopropyl]-l,4 
butanediamine) (Sigma), 1 M CaC12, and plasmid DNA are outlined in Table 2.7. The 
quantities described are appropriate for coating a single length of tubing placed in the 
tubing station, which is sufficient for the production of approximately 50 cartridges. To 
prepare the cartridges, gold microcarriers were weighed out in a 1.5 ml eppendorf tube.
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Table 2.7: The main components needed for preparation of Gene-Gun cartridges
MLQ = Microcarrier Loading Quantity (the amount of micro carrier - gold - delivered per 
shot);
DLR = DNA Loading Ratio (the amount of DNA loaded per mg of micro carriers or per 
shot;
ctg. = cartridge.
MLQ DLR
0.05M
Spermidine
IM
CaCb
PVP sol. in ethanol
mg/ctg.
mg/
length
pg/ctg.
pg/mg
gold
lig/
length
mg/ ml ml sol./length
0.5 25 1-2 2-4
50-
100
100 pi 100 pi 0 -0 .1 3.5
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100 pi of 0.05M spermidine were added to the measured gold, and the mixture was 
vortexed for a few seconds. After the final ethanol wash, the pellet was re-suspended in 
ethanoF PVP solution, which was then drawn into the tubing used for the production of 
cartridges. To the gold and spermidine solution, plasmid DNA was added, and the mixture 
was vortexed for a further 10 seconds. 100 pi of IM CaCb solution was then added 
dropwise to the solution, which was thoroughly vortexed between each addition. The 
mixture was then allowed to precipitate at room temperature for 10 minutes before 
centrifugation at 10,000g for 3 minutes to pellet the gold. The supernatant was removed 
and the pellet was resuspended in the remaining supernatant by vortexing briefly. The 
pellet was then washed three times with 1 ml of fresh endotoxm-fi-ee 100% ethanol, using 
5-second bursts of centrifugation in a bench-top Microfuge. At each stage in the process, 
supernatants that were removed from the tube were stored at -20°C. These were checked at 
the end of the experiment to establish when and if DNA was being lost from the gold 
during the coating process.
2.6.2. Loading the DNA/Gold Suspension into Gold-Coat Tubing
A schematic representation of the main steps involved in cartridge preparation 
along with Gene-Gun mediated delivery of DNA is presented in Figure 2.4.
A piece of tubing of approximately 30 inches was inserted into the Tubing Prep 
Station. Prior to loading with gold, a flow of nitrogen (grade 4.8) from a compressed 
cylinder connected to the Prep Station was used to dry the interior of tube. The flow of 
nitrogen used was G.3-0.4 LPM (litres per minute) for 15 minutes. The tubing was then 
removed from Prep Station and the flow of nitrogen was turned off. One end of the tubing 
was inserted into the end of a 16-18 inches of silicone adaptor tubing fitted to a 10 cc 
syringe, which was used to draw a homogenous DNA/gold suspension (vortexed 
immediately prior to aspiration) into the dried tubing.
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H - i Preparation o f  D N A /g o ld  suspension
Preparation o f  c artri dges
L oading the cartridges 
into cartridge's holder
Charging the 
gene-gun
G ene-G un-m e di ated 
delivery o f  D N A
Figure 2.4: A schematic representation o f the main steps involved in cartridge preparation and 
Gene-Gun mediated delivery of DNA: preparation of DNA/gold suspension; preparation of 
cartridges; charging the Gene-Gun; DNA delivery.
72
The tubing was then slid into the loading station and the gold was allowed to settle 
for 3-5 minutes. Ethanol was removed from the tubing using a 10 cc syringe fitted to a 
silicon adaptor tube at rate of 0.5-1 inches per second. (The removed ethanol was also 
stored and additionally checked for the presence of DNA at the end of the experiment).
After detaching the syringe, the tubing was immediately turned 180° and the gold 
was allowed to coat the inner surface of the tubing for 3 - 4 seconds. The bar of the Tube 
Preparation Station was then rotated and the gold was allowed to coat the tube for 20-30 
seconds. Following coating and with the tube still rotating, the valve of the flowmeter was 
opened to allow nitrogen (0.3/0.4 LPM) to dry the gold onto the inner surface of the 
tubing. After approximately 30 minutes, the tubing was removed from the station and cut 
into 0.5 inch cartridges using a tubing cutter.
2.6.3. Quantification of Plasmid DNA in Each Cartridge
To quantify the average amount of DNA per cartridge, we used a method suggested by 
Craig Watkins (Department of Veterinary Pathology, Royal School of Veterinary Studies, 
Summerhall, University of Edinburgh). According to this method five ready for use 
cartridges were placed singly into five 0.5 ml eppendorf tubes, in the base of which a small 
hole had been created using a needle. These tubes were placed individually into 5x 1.5 ml 
lidless eppendorf tubes. 50 pi of lOmM Tris-Cl buffer (pH 8.5) was then added to the top of 
each cartridge, which was then left for 3 hours at 4“C. After incubation, the larger tubes 
containing the smaller stubs were vortexed, and the contents of the smaller tube collected 
into the larger tube by centrifugation at 3000xg for 3 minutes (RT). The recovered 
gold/DNA suspension was then decanted into a fresh 1.5 ml eppendorf tube (with a lid), and 
another 50 pi of lOmM Tris-HCl buffer added to the top of each cartridge. The tubes were 
then incubated for a second time overnight at 4°C, before the solution was collected using
the vortexing and centrifugation step described above. Once the second collection was
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complete, the suspensions from each extraction were pooled. The tubes were then 
centrifuged again to pellet the gold before the supernatant from each tube was removed 
carefully into a new 1.5 ml eppendorf tube. Recovery of DNA from the cartridges was 
determined by measurement of the light absorbency at 260 nm as described (Section 
2.2.4.3). In these experiments lOmM Tris-Cl was used as the blank control sample. To 
estimate the mean amount of plasmid DNA per shot, the concentration of the 5 cartridges 
were averaged.
2.6.4. Delivery of DNA by Gene-Gun
2.6.4.I. Transfection of Mammalian Target Cells/w Vitro
The day before Gene-Gun mediated transfection, COS-7 cells were seeded in small 
individual 35 mm dishes, at a density that ensured a cell monolayer with 70-90% 
confluence within 24 hours (3x10^ cells/35 mm dish). 30 minutes prior to DNA delivery 
the complete medium, in which the cells were routinely grown, was replaced with DMEM 
without FBS, and immediately prior DNA delivery, the medium was aspirated from the 
dishes.
In order to activate the Gene-Gun for delivery, an empty cartridge holder was 
inserted into the Gene-Gun, and the Gun connected to a compressed helium cylinder (grade
4.5 [99.995%]). After the flow of helium was set up to the desired pressure the Gene-Gun 
trigger was depressed 2-3 times to discharge the device. This was done to establish the Gun 
at the appropriate discharge pressure.
For cell transfections, a loaded cartridge was inserted into the cartridge holder, and 
the holder introduced into the Gene-Gun. The Gene-Gun was then placed in proximity to 
the cells and the Gun discharged at helium pressures between 50- 200 psi (pounds per 
square inch), with an optimised pressure of 100 psi. After all cartridges were discharged,
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the cartridge holder was removed, the cartridges were removed from the holder, and the 
gun was depressurised and shut down.
After transfection of the cells with the Gene-Gun, 2 ml of complete medium was 
added to each dish and the dishes were observed under the microscope to assess the extent 
of cell monolayer damage.
2.6.4.2. Analysis of Protein Expression in COS-7 cells transfected by Gene-Gun
2.6 4.2.1. GFP Expression in COS-7 Cells Transfected by Gene-Gun
GFP expression in COS-7 cells transfected by Gene-Gun was performed as described 
previously (Section 2.3.4.1) using an inverted microscope (Zeiss), Images of the cells were 
taken and stored on the Improvision Imaging System (OpenLab-Improvision).
2.6.4.2 2. TetC Expression in COS-7 Cells Transfected by Gene-Gun
TetC expression in COS-7 cells transfected by Gene-Gun was assessed by SDS 
PAGE and Western blotting of cell lysates, using the SuperSignal Chemiluminescent 
method as described (Section 2.3.4.2.4).
2.6.4.3. Transfection of Mammalian Cells/«  Vivo by Gene-Gun
The day before immunisation, all mice were sample bled from the tail vein. In 
addition, the fur from the abdomens of all mice was removed using appropriate clippers, to 
clean and expose the target site for the Gene-Gun-mediated immunisation.
For immunisations, the gun spacer was held against the skin and the DNA discharged 
from the cartridge at a pressure of 400 psi. The immunisation regimen used for this 
experiment is given in Table 2.8. For each immunisation, one cartridge containing
75
approximately 1-2 pg of DNA was used. For intramuscular immunisations 100 pg of 
plasmid DNA was delivered in a final volume of 100 pi.
2.6.4 4. Evaluation of the Immune Response Elicited by the Gene-Gun Method of 
Vaccination
Antibody responses in the sera were followed throughout the course of the 
experiment using sample bleeds taken fi'om the tail veins. Blood samples were taken one 
day prior to the first immunisation (pre-immune sera), and subsequently on day 22 and 34 
of the experiment (bleed 1 and bleed 2, respectively). Total anti-Fragment C IgG titres and 
specific antibody subtypes were tested using ELISA assay, as described in Section 2.5.1.2 
Terminal bleeds taken by cardiac puncture were collected on day 46. Following death by 
exsanguination the spleens were removed and used in T-cell proliferative an cytokine 
secretion assays to assess the cellular immune response induced (see Sections 2.5.2,1, and
2.5.2.2, respectively).
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Table 2.8: Vaccination regimen for mice immunised by Gene-Gun with pcDNA3/tetC 
or with the control plasmid, pcDNA3.1 and boosted with Fragment C
In addition, to groups primed by Gene-Gun, a group of mice were immunised with 
pcDNA3/tetC using the intramuscular route of immunisation.
Group 1 (5 mice) Group 2 (5 mice) Group 3 (3 mice) Group 4 (2 mice)
Day 1 pcDNA3/tetC 
- Gene-Gun
pcDNAS.l 
- Gene-Gun
pcDNA3/tetC-i. m. naive
Day 8 pcDNA3/tetC 
- Gene-Gun
pcDNAS.l 
- Gene-Gun
pcDNA3/tetC-i. m. naive
Day 35 Fragment C i. m. Fragment C i. m. Fragment C i. m. Fragment C i. m.
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Chapter 3 
Results -  Section 1 
Characterisation of Plasmid Constructs
The aim of this section was the characterisation of all DNA vaccine constructs used 
in the course of this study. This included analysis of size, sequence, and sample 
concentration for each vaccine candidate.
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3.1. Transformation ofjE". co/i with DNA Vaccine Candidates
The work undertaken in the course of this thesis made use of a number of plasmids, 
all of which had been provided to us by collaborating scientists. To confirm that each 
plasmid was as described by those workers, each was initially subjected to a number of 
studies to confirm the size, sequence, and sample concentration.
All four DNA vaccine candidates used in this study (pcDNA3/tetC, pcDNA3.1, 
pCMV-70, pCMV-link) and the green fluorescent protein, GFP-encoding plasmid (pGFP- 
C3), used to optimise techniques, were initially transformed into competent E. coli XL-10 
which had been prepared as described previously (Section 2.2.2). Using the appropriate 
antibiotic, successfully transformed bacteria where selected. Initially, several colonies 
fi'om each transformation were chosen and screened for the presence of the appropriate 
plasmid initially by purification and restriction digest of the plasmid DNA.
3.1.1. Initial Characterisation of pcDNA3/tetC and pcDNA3.1
Using the restriction map of the plasmid, two restriction enzymes were identified for 
use. Both these enzymes {Xbal and Hindlll) are able to cut the plasmid at a single site. 
However, when used together in a double digest, they are able to cut out the inserted 
Fragment C gene as Hindlll and Xbal restriction sites are located immediately up and 
downstream of the end of open reading frame respectively. DNA purified from bacteria 
transformed with either pcDNA3.1 or pcDNA3/tetC were subjected to single (Figure 3.1) 
or double digest (Figure 3.2) using these enzymes and plasmid size was then determined 
following electrophoresis in a 0.8% agarose gel.
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Figure 3.1: Digestion o f pcDNAS.l and pcDNA3/tetC using Ai&a/
Serial dilutions of digested pcDNAS.l (1/20 - lane 2, 1/50 - lane 3, 1/100 - lane 4, 1/200 - 
lane 5) and pcDNA3/tetC (1/20 - lane 6, 1/50 - lane 7, 1/100 - lane 8, 1/200 - lane 9) were 
run on a 0.8% agarose gel containing 0.04% ethidium bromide. The difference in size 
between the 5.4Kb digestion fragment (pcDNAS.l) and the 6.8Kb fragment 
(pcDNAS/tetC) correlates with the size of the Fragment C gene insert (1.4Kb). An 
approximation of the correct concentration of the plasmids can also be determined by 
comparison with the 1.6Kb band of the DNA marker (lane 1), which contains 10% of the 
mass of the marker applied to the gel.
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band
pcDNAS.l vector 
(5.4 Kb)
Fragment C - coding 
insert (1.4 Kb)
Figure 3.2: Restriction digest o f pcDNA3.1 and pcDNA3/tetC with Hindlll stnd Xbal
This figure shows plasmid pcDNAS.l (lanes 2 and S) and pcDNAS/tetC (lanes 4 and 5) on 
an agarose gel (0.8%) containing 0.04% ethidium bromide following digestion with 
Hindlll and Xhal restriction enzymes. Control plasmid pcDNAS.l is linearised by 
digestion of the two sites, which are close to each other inside the multiple cloning site. 
The digested plasmid is approximately 5.4 Kb in size and is identical with the larger 
fi-agment obtained by double digestion of pcDNAS/tetC. In pcDNAS/tetC Hindlll and Xbal 
restriction sites flank the Fragment C gene insert, therefore double digestion leads to the 
production of a large fi-agment of 5.4 Kb (the vector) and a small one of 1.4 Kb (the insert).
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3.1.2. Initial Characterisation of pCMV-70 and pCMV-link
Using restriction maps of these plasmids, the enzyme Bgl-II was identified as 
suitable for cutting the plasmid at a single site. The use of this enzyme resulted in the 
linearisation of the DNA of both plasmid and the production of a 6.9 kb fi'agment for 
pCMV-70, and a 6.3 kb fragment for pCMV-link respectively (Figure 3.3). However, due 
to the small size of the MPB-70 gene insert (-0.6 kb), identification of the inserted 
fi-agment by double digestion of the plasmid was found to be difficult. As the relative sizes 
of the singly digested plasmids appeared to suggest an insert, two clones were identified 
and the DNA subjected to sequencing, to confirm the presence of the MBP-70 coding 
region.
3.2. Sequencing of the DNA Vaccine Candidates
To confirm the sequence of the expressed protein in both pcDNA3/tetC and pCMV- 
70 respectively, appropriate primers were designed (see Table 2.1) and used to generate 
sequence data fi'om both the 5’ and 3’ end of the expressed protein. Analysis of this data 
confirmed that both proteins were m frame and the sequence of the genes were as 
expected. The bacterial clone fi'om which the plasmid had been purified for sequencing 
was then used to prepare a master seed bank for each individual plasmid. This seed bank 
was used for all of the experiments described in this thesis.
3.3. Quantification of the DNA
During the course of this study, DNA was prepared on a number of occasions for 
use both in vitro and in vivo. In order to determine the amount of DNA used in these 
experiments two different methods were adopted for quantification of the DNA (Section 
2.2.4). In general, these methods were used in parallel, with data fi'om one supporting 
analysis using the other.
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Figure 3.3: Digestion o f pCMV-Iink and pCM V-70 with Bgl-II
Serial dilutions (1/20, 1/50, 1/100, 1/200) of plasmids pCMV-link (lanes 2, 3, 4, 5, 
respectively) and pCMV-70 (lane 6, 7, 8, 9, respectively) run on an agarose gel (0.8%) 
following digestion with Bgl II. The difference in size between the 6.9 Kb digestion 
fragment (pCMV-70) and the 6.3 Kb fragment (pCMV-link) correlates with the size of the 
MPB-70 gene insert of approximate 0.6 Kb.
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The average amounts of plasmid DNA that were generated from miniprep and megaprep
kits (see Section 2.2.3.1. and 2.2.3.2) are include in Table 3,1,
3.4. Analysis of LPS Contamination
Although all plasmid DNA for in vitro and in vivo experiments were prepared using 
Qiagen MegaPrep Endotoxin free kits, all batches of DNA were subject to LPS analysis 
using the LAL test prior to use (Section 2.4.3), In general, levels of LPS were less than 2 
EU of LPS in 100 pg of DNA (levels of LPS acceptable in current paediatric vaccine <5 
EU/dose), These levels of DNA were not considered to have any potential impact on any 
of the work subsequently carried out.
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Table 3.1: Average amounts of plasmid DNA generated from miniprep and megaprep
kits.
Preparation of plasmids using the Miniprep Kit
pcDNAS.l 50-200 ng/pl
pcdna3/tetC 250 ng/pl
pCMV-link 160 ng/pl
pCMV-70 160 ng/pl
Preparation of plasmids using the Endotoxin-free Megaprep Kit
pcDNAS.l 1.69 ng/pl
pcDNA3/tetC 1.76-2.35 ng/jLil
pCMV-70 1.36-2.21 ng/pil
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Chapter 4 
Results -  Section 2 
Transfection of COS-7 Cells Using Lipofectamine
The aim of the work described in this chapter was to optimise transfection of COS-7 
cells and measurement of antigen expression by DNA vaccine candidates using 
Lipofectamine as the transfection agent.
In this context, the plasmid expressing the green fluorescent protein was used to 
standardise methods, which were then used with the vaccine candidates, pcDNA3/tetC and 
pCMV-70.
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4.1. Optimisation o f/«  Vitro Transfection Experiments Using a Plasmid Encoding the 
Green Fluorescent Protein (GFP)
COS-7 cells used in transfection experiments adhere effectively to the surface of 
culture dishes, a property that makes them well suited for transfection, especially by Gene- 
Gun, when DNA dehvery is carried out in complete absence of medium. In addition, the 
adherent nature of the cells, makes them suitable for the frequent replacement of medium 
that is required during transfection.
Initial experiments were carried out using a GFP-encoding plasmid (pGFP-C3 - 
Clontech). This plasmid was chosen as expression of the green fluoresence can be easily 
and precisely detected by fluorescence microspcopy. Once produced, it is stable in the cells 
(does not break dovm rapidly) and does not require additional proteins, substrates or co­
factors to activate its natural fluoresence.
Initially, transfection of COS-7 cells was carried out using 7 or 10 pi Lipofectamine 
combined with 2pg DNA. This mixture was added to between 2 and 4x10^ cells and 
allowed to interact with the cells for various lengths of time, before the cells were washed 
and new media added. GFP expression was then determined by counting the number of 
fluorescent cells in an individual field of the microscope (as described in Section 2.3.4.1). 
These experiments revealed that the highest rate of transfection was observed when 2pgof 
DNA was incubated for 5 hours with lOpl of Lipofectamine/ 3x10^ cells.
The average number of fluorescent cells per lOx microscopic field (as can be seen in 
Figure 4.1), following 5 hours of transfection was about 115 with little variation between 
different culture dishes.
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Figure 4.1: In vitro expression o f GFP following transfection by Lipofectamine
Expression of GFP was quantified by counting the number of fluorescent cell per lOx 
microscopic field 72 hours after transfection of COS-7 cells with 2 pg pGFP-C3 
(Clontech) and 10 pg Lipofectamine (Gibco-Life Technologies)/ 3x 10^  cells. The number 
of fluorescent cells was established using an inverted microscope (Axiovert - Zeiss) 
connected to an Imaging System equipped with a designated software for picture 
processing (OpenLab-Improvision).
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In comparison, following 8 hours of incubation, an average of only 72 fluorescent 
cells per field were observed. This was further reduced to 53 cells/field following 
overnight incubation of Lipofectamine and DNA. This reduction in numbers may reflect 
the toxic nature of Lipofectamine rather than transfection efficiency, with many potentially 
transfected cells unable to survive in this envhonment.
4.2. In vitro Expression of MPB-70 in COS-7 Cells
Following optimisation of expression of pGFP-C3 in COS-7 cells, work was 
extended to allow transfection of COS-7 cells with the MPB-70-encoding-plasmid pCMV- 
70.
MPB-70 is an immunogenic mycobacterial protein with very well documented 
structural and physio chemical properties, described in detail in (Section 1.3.5.2.3). Briefly, 
MPB-70 is a monomeric protein of a 163 amino acids (the mature form), which is preceded 
by a 30 amino acids peptide representing a secretory signal. However, several groups have 
reported that under different reducing conditions, the protein can display variations in its 
molecular mass. These variations have been attributed to the presence of two widely 
spaced cysteine residues in the MPB-70 polypeptide chain, which can alter the three 
dimensional structure of the protein under non-reducing conditions. Under reducing 
conditions (P-mercaptoethanol) the molecular weight of MPB-70 has been reported to be 
about 22 kDa (Wiker et al, 1998). However, under non-reduced conditions the protein 
presents a different mobility on SDS-PAGE gels with a reported mobility of 15 kDa 
(Wiker et al, 1998). This appears to additionally affect the availability of a number of 
conformational epitopes.
89
4.2.1. Optimising the Detection of MPB-70 Expressed In Vitro
To optimise the conditions for detection of the protein by immimoblots, various 
concentrations of purified recombinant MBP70 protein were loaded onto SDS PAGE gels. 
These gels were then either stained with Coomassie blue, or used in Western blot analysis 
to determine the optimum concentrations of the polyclonal rabbit anti MPB-70 antibody 
used as the primary antibody. Three gels were used to determined optimal primary 
antibody concentration (Concentrations tested included 1:200, 1:400 and 1:800). Figure
4.2. shows that between 100-50ng (per lane) of MBP-70 could be detected when the 
antibody was used at 1:200. In contrast, using Coomassie staining, the lowest 
concentration of MBP70 that can be detected is Ipg. Subsequent analysis of protein 
expression in transfected cells used the polyclonal antibody at this concentration. A 
similar approach was also taken to optimise the concentration of a monoclonal anti MPB- 
70 antibody (kindly provided by Mark Chambers, Centre of Veterinary Laboratory). A 
concentration of 1:500 of primary monoclonal anti-MPB-70 antibody gave the greatest 
level of sensitivity on a Western blot and was used at this concentration for subsequent 
analysis.
During the course of these experiments, the reported differences in the structure of 
this protein were observed. As can be seen in Figure 4.3, the molecular mass of fully 
reduced, denatured rMPB-70 was about 22 kDa (agreeing with the reported data (Wiker et 
al, 1998)). This appeared to be the fully reduced form as when an alternative reducing 
agent, dithiothreitol (DTT), was added to the sample buffer in place of P-mercaptoethanol, 
only one band of 22 kDa was present. In the absence of a reducing agent, a 15k Da band 
corresponding to the described non-reduced form of the protein could be observed (Wiker 
et al, 1998). Interestingly, in the absence of p-mercaptoethanol, both the 15k Da and the 
22k Da protein could be seen suggesting that the protein exists in both forms in the boiled 
sample.
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Figure 4.2: Detection limit o f recombinant MPB-70
10, 5, 2.5, 1, 0.5, 0.1, and 0.05 fig of rMPB-70 were loaded into lanes 2, 3, 4, 5, 6, and 7, 
respectively on a 12.5% SDS PAGE gel.
A. This figure shows the detection of rMBP70 using Western blot, which was 
developed using concentrations of 1:200 for the primary antibody (rabbit anti- 
MPB-70) and 1:1000 for the secondary antibody (anti-rabbit - HRP 
conjugated).
B. This figure shows an identical gel stained with Coomassie Blue.
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Figure 4.3: Analysis o f recombinant M PB-70 using different reducing agents
1 fig of rMPB70 was admixed with sample buffers containing different reducing agents. 
The samples were then boiled for 10 mins, prior to analysis using a 12.5% SDS-PAGE gel. 
The samples loaded were treated as follows: lane 2: sample buffer with P-mercaptoethanol, 
lane 3: sample buffer with 2mM DTT, lane 4: sample buffer with 50mM DTT and lane 5: 
sample buffer without p-mercaptoethanol.
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4.2.2. MPB-70 Expression in COS-7 Lysates Following Transfection with pCMV-70
Once the method for detection of MBP-70 had been established, COS-7 cells were 
transfected with the plasmids, pCMY-70 or pCMV-link. Following transfection using the 
optimised conditions, ceils were harvested and a known number of lysed cells mixed v^ dth 
protein sample buffer and run on SDS page gels. Expression of the antigen was then 
determined by Western blot using the polyclonal and monoclonal antibodies described. As 
a positive controls, purified rMPB-70, M bovis culture filtrate and sonicate were included 
on the gels. Cell lysates fi'om COS-7 cells transfected with control plasmid pCMV-iink 
were also included as a negative controls.
As observed previously, the polyclonal antibody detected the rMBP-70 as a band of 
about 22kDa in these gels (Figure 4.4). Similarly, a protein of an equivalent size was also 
observed in lanes loaded with material from either M, bovis filtered or sonicated material. 
In contrast, COS-7 lysates transfected with pcCMV-70, produced a number of proteins that 
were detected bands by the antisera, however, in this case the dominant protein appeared to 
have a lower mobihty of about 28 kDa. In contrast, the apparent absence of any band in 
lanes loaded with an equivalent amount of COS-7 cells transfected with pCMV-link 
suggested that this protein was MBP-70 specific.
Equivalence of cell loading was demonstrated by Coomassie blue staining of a 
duplicated gel (Figure 4.4.B). One potential explanation for the difference in mobility 
observed is the potential for post-translation modification of protein in eukaryotic cells that 
do not occur naturally in prokaryotes.
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Figure 4.4: Detection o f M PB-70 expression in COS-7 cells transfected with pCMV- 
70:
Figure A shows analysis of expression of MBP-70 by Western blot using MBP-70 specific 
polyclonal sera. The gel was loaded as follows: lane 1: molecular weight ladder; lane 2: 2.5 
pg of recombinant MPB-70, lane 3: 10 pg of M hovis filtrate; lane 4: 10 pg of M bovis 
sonicate. Lanes 5, 6, 7, 8: 5x10^; 2.5x10^, 1.25x10^ 6.24x1 O'* COS-7 cells transfected with 
pCMV-70. Lanes 9, 10: 6x10^, 3x10  ^COS-7 cells transfected with pCMV-link.
Figure B shows a duplicate gel loaded in parallel. Staining of the total protein by 
Coommassie blue shows that the number of COS-7 cells loaded per lane were 
approximately equivalent.
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In contrast, experiments performed in parallel using the MBP-70 specific MoAb, 
failed to detect any MBP-70 specific band in lanes loaded with COS-7 cell lysates 
transfected with pCMV-70. In contrast, protein was readily detected in the lanes treated 
with either the recombinant or native version of the protein (Figure 4.5). This result 
suggests that the protein produced by COS-7 cells is either an unrelated protein that can 
react with the polyclonal antibody, or, the protein has been modified in such a manner as to 
mask important B-cell epitopes. The second explanation allows for the possibility that 
synthesis of MBP70 in the eukaryotic system results in posttranslational changes to the 
protein.
In an attempt to explain these apparent differences, two possible theories were 
considered, that;
1. the protein was failing to become fully reduced following treatment with a 
reducing agent due to the formation of additional disulphide bonds in the 
structure. However, as proteins with complex folded structures, would be 
expected to be more compact they would be also expected to have a higher 
rather than reduced mobihty as in the case of the non-reduced form of rMBP-70 
(Figure 4.3). However, if internal bonds mediate the formation of aggregates of 
the protein either in its complete or truncated form this could explain the larger 
molecular weight.
2. Alternatively, the difference in size between recombinant MPB-70 and in vitro - 
expressed protein after transfection with pCMV-70 may reflect post-translation 
modifications such as glycosylation and phosphorylation.
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Figure 4.5: Detection o f M PB-70 expression in COS-7 cells transfected with pCMV- 
70, using a monoclonal antibody
This Western blot shows expression of MPB-70 protein in COS-7 cells using antigen 
specific monoclonal antibodies. Lanes were loaded as follow: lane 1: 2.5 pg of 
recombinant MPB-70 (positive control), lane 2: 10 pg of M bovis filtrate; lane 3: 10 pg of 
M bovis sonicate. Lanes 5, 6, 7, 8: 5x10^; 2.5x10^, 1.25x10^ 6.24x10'* COS-7 cells 
transfected with pCMV-70. Lanes 9, 10: 6x10^, 3x10  ^ COS-7 cells transfected with the 
vector alone (pCMV-link).
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4.2.2.1. Reduction of Aggregate Forms of MBP-70
To check the validity of the first hypothesis, cell lysates were loaded on SDS-PAGE 
gels in the presence of sample buffers containing different concentrations of DTT. As DTT 
is a very strong reducing agent, it was expected that any disulphide bonds present in this 
potentially aggregated form would eventually be reduced. This should be reflected by a 
reduction in the immunodominant band firom 28Kda to approximately 22k Da. Although, 
three different concentrations of DTT (2, 20 and 50mM ) were used in the sample buffer, 
none were able to modify the mobility of MPB-70. This suggests that either the formation 
of such bonds is not important in the formation of this structure or that DTT had no effect 
at the concentrations used.
4.2.2.2. Role of N-GIycosylation in Post-Translation Modification of MBP-70
In an attempt to determine whether N-glycosylation was responsible for the 
difference in size between purified MPB-70 and MPB-70 expressed in vitro, COS-7 cells 
were incubated during transfection with different concentrations of Tunicamycin, an 
inhibitor of the biosynthesis of N-linked glycoproteins. Tunicamycin is a nucleoside 
antibiotic produced by Streptomyces sp., which is considered to be an ideal inhibitor of N- 
glycosylation, as it is specific for the first reaction in the glycosylation pathway and is able 
to easily penetrate cells in vitro and in vivo. It has been shown that cells incubated with 
Tunicamycin produce non-glycosylated forms of N-linked glycoproteins (Elbein, 1991).
In early experiments, Tunicamycin was included at a concentration of 10 pg per ml 
of culture medium (20 pg/ 3x10^ cells) during the whole period of transfection. Using 
these conditions MPB-70 expression could not be detected at all in the COS-7 cells.
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However, under these conditions, a reduction in the number of harvested COS-7 cells was 
observed (1.2x10^ harvested cells compared with 8.5x10^ cells in the absence of 
Tunicamycin). This suggested that the amount of 10 pg Tunicamycin might have had a 
toxic effect on the synthesis of all cellular proteins and, implicitly, on cell growth. This has 
been described previously in yeast (Elbein, 1991) and may be due to the following:
1. decreased stability and more rapid degradation of the protein in the absence of 
carbohydrate chains
2. decreased solubility and/ or aggregation of protein
3. increased susceptibUity for proteolytic attack after cell lysis
To address the potential increased susceptibility of carbohydrate-depleted proteins to 
proteolytic attack, all subsequent experiments were performed using a protease inhibitor - 
ImM phenylmethyl sulfonyl fluoride - PMSF (Sigma) added to the lysis medium used at 
the end of the experiment.
To address the problem of optimising the exposure of the cells to Tunicamycin, 
further experiments were attempted using lower concentrations of Tunicamycin (2.5 and 
Ipg/ml culture medium). These concentrations did not appear to affect the protein 
synthesis or the cell growth. Using these three concentrations of Tunicamycin (10, 2.5 and 
1 pg) and two different methods (Tunicamycin present throughout the whole transfection, 
or added 5 hours before harvesting), the presence of the protease inhibitor in the lysis 
buffer did not appear to have any effect on the size of MPB-70 expressed by transfected 
COS-7 cells as detected on western blot. Together these data suggest that the difference in 
the size of MPB-70 when expressed in COS-7 cells could not be attributed to N- 
glycosylation.
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4.3. In vitro Expression of Fragment C
In parallel but in isolation to the work on MBP-70, COS-7 cells were additionally 
transfected using Lipofectamine with pcDNA3/tetC. However, although the concentration 
of Fragment C specific antibody was initially optimised using purified Fragment C protein, 
initial experiments indicated that cells transfected with pcDNA3/tetC did not express 
Fragment C. Initially, it was unclear whether this indicated that
1. no trasfection had occurred
2. the vector was not capable of driving expression of the antigen in COS-7 cells, 
or,
3. the method used for detection of antigen expression lacked a suitable level of 
sensitivity.
As this vector had been used previously to successfully generate immune responses 
in animals we decided to investigate an alternative and potentially more sensitive method 
of antigen detection.
4.3.1. Detection of Fragment C Using a Chemiluminescent Substrate
SuperSignal West Pico (Pierce) is a chemiluminescent substrate that enables 
detection of picogram quantities of antigen. As this method is very sensitive, the 
concentration of primary and secondary antibodies must be carefully optimised to reduce 
the level of an unspecific background that may be observed. In an attempt to optimise 
conditions, decreasing concentrations of primary and secondary antibodies were tested to 
detect known concentrations of Fragment C, spotted on a nitrocellulose membrane. The 
range of concentrations varied from lOOng to lOOpg. As it is shovm in Figure 4.6, the 
combination of antibody concentrations of 1:5,000 for the primary antibody (polyclonal 
rabbit anti-Fragment C) and 1:50,000 for the secondary antibody (goat anti-rabbit HRP)
correlated with the lowest background and the highest specific signal.
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Figure 4.6: Optimisation o f antibody concentrations used in Western blot method 
using the SuperSignal substrate
Each membrane contains four 2 pi spots of 100 ng (upper left), 1 ng (upper right), 100 pg 
(lower left), 1 pg (lower right) of antigen. The greatest sensitivity of the assay was shown 
to be at 100 ng of Fragment C, developed with concentrations of 1:5,000 of primary 
antibody and 1:50,000 of secondary antibody.
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These conditions were therefore used to determine expression of Fragment C in 
transfected COS-7 cells. In addition, the exposure time of the radiographic film was also 
optimised, with the best results were obtained following the substrate incubation, the film 
was exposed to the filter for 15min.
4.3.2. Detection of In Vitro Expressed Fragment C
The level of detection of this method was initially demonstrated by running known 
concentrations of recombinant Fragment C (100 ng, 10 ng, 1 ng, 100 pg and 1 pg) on an 
SDS page that was used for immunoblot analysis with supersignal. Using this method only 
the lOOng band was detected.
Using the same method as outlined for MBP-70 (Section 2.3.2.), COS-7 cells were 
transfected with pcDNA3/tetC and following harvesting, different numbers of lysed cells 
(ranging fi"om 3 x 10^  to 3.8 x lO'* transfected COS-7 cells) were loaded onto SDS-PAGE 
gels and level of Fragment Cexpression determined using the SuperSignal kit. As can be 
seen in Figure 4.7, an immunodominant band of approx 50kDa in size was expressed in the 
trasnfected cells. Using the positive control as a guide, in which lOOng of recombinant 
Fragment C was loaded, the level of expression was estimated to be up to 100 ng in 3.8 x 
10"* cells (about 70 ng/ 2.8 x lO'* cells in comparison to about 10 ng / 2.8x104 cells 
transfected by Gene-Gun, see Section 5.2). In comparison, similar concentrations of COS- 
7 cells transfected with the control plasmid, pcDNA3.1, failed to produce any detectable 
band, suggesting that the band detected was dependent on expression of the Fragment C 
protein from the pcDNA3/tetC construct.
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Figure 4.7: Fragment C expression in COS-7 cells transfected with pcDNA3/tetC.
Protein expression was detected by Western blot using Fragment C specific polyclonal 
antibody sera. The gel was loaded as follows: Lane 2, 100 ng Fragment C (positive 
control). Lanes 3, 4, 5, 6: 3 x 10^ , 1.5 x 10^ , 7.6 x 10“*, 3.8 x lO'* COS-7 cells transfected 
with pcDNA3/tetC. Lanes 7 and 8 with 3.8 x 10^  and 1.9 x 10^  COS-7 cells transfected 
with pcDNA3.1 (negative control).
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Chapter 5 
Results -  Section 3 
Gene-Gun Mediated Transfection of COS-7 Cells
The aim of work outlined in this chapter was to optimise transfection of COS-7 cells 
and measurement of antigen expression by DNA vaccine candidates using the Gene-Gun 
as the agent of transfection.
103
SuccessM intradermal delivery of DNA vaccines has been shown to be possible 
using DNA coated gold particles fired through the skin using a Gene-Gun. As one of the 
aims of this project was to compare and contrast the type of immune response generated 
using a DNA vaccine dehvered intramuscularly or via the Gene-Gun, it was first necessary 
to show that such gold particles could be used to deliver the plasmids successfully. In order 
to develop and optimise methods to be used in the successful production and firing of 
DNA coated gold particles, all work was initially carried out in vitro.
Most of the preliminary work was carried out using the GFP encoded plasmid to 
transfect COS-7 cells. This allowed development of protocols that produced cartridges 
containing a consistent amount of DNA (when cartridges were produced on either the same 
day or different days), which could additionally be quantified.
5.1. Optimisation of Gene-Gun Cartridge Preparation and DNA Delivery
5.1.1. Impact of PVP Concentration and Ethanol Purity
DNA coated gold particles are fired firom the Gene-Gun using hehum, which drives
the vaccine firom the pre-coated “delivery cartridges” that are loaded into the firing barrel
of the Gun (see Figure 2.4). These cartridges are prepared by adsorbing known amounts of
DNA coated gold particles onto the internal surface of the cartridge tubing, which can then
be cut into single-use individual cartridges that are used for vaccination. During this
adsorbtion process, PVP is added to the mixture to enhance the successful adherence of the
suspension to the tubing. In fact the concentration of PVP added at this stage, appears to be
crucial, as if the amount of PVP is too high, the DNA/gold will not detach from the tubing
during firing of the Gene-Gun. However, when too low, some DNA will be lost during the
coating process. To determine the impact of PVP concentration on the DNA vacciuation,
several concentrations of PVP (fi-om 0.05 mg/ml to 0) were used to prepare cartridges
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coated with pGFP-C3/gold suspension. These cartridges were then used to transfect COS-7 
cells and the effect of PVP concentration assessed by measuring the amount of GFP 
expression. In addition, the amount of unbound DNA, present at each stage of the cartridge 
manufacture process, was measured.
Data from these experiments are shown in Figure 5.1 and revealed two important 
findings. First, that DNA could be lost during the ethanol washing stage prior to the 
addition of PVP (DNA can be detected in 2 of the 3 ethanol washes, used to wash the DNA 
coated gold particle prior to the addition of PVP) and second, that at the highest 
concentration of PVP, appeared to enhance binding of the DNA to the cartridge tubing. 
For example a large amount of DNA is detectable in the ethanol following adsorbtion of 
the DNA/gold to the cartridge tubing when either no PVP or less than 0.05 mg/ml was 
used. In contrast, cartridges prepared using 0.05 mg/ml showed no detectable loss of DNA.
These data also correlated with the number of fluorescent cells seen when these 
cartridges were used to transfect COS-7 cells, as cartridges prepared in the presence of 
0.05 mg/ml PVP showed higher numbers of fluorescent cells than those prepared using a 
lower concentration of PVP (see Tables 5.1. to 5.3).
5.1.2. Impact of Helium Pressure on Gene-Gun Driven Transfection
A number of other parameters included the pressure of hehum used to drive the 
DNA/gold suspension from the cartridges into the cells also appeared to âffetct the 
efiSciency of transfection. To determine this effect, hehum pressures of 50, 100 and 200 psi 
were used when transfecting dishes of cehs cultured in parahel.
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Figure 5.1: The amount o f unbound DNA present in solutions used to wash the gold 
particles during preparation o f the firing cartridges.
For each of the cartridge batches (prepared with no PVP, 0.005 or 0.05 mg/ml PVP) 
unbound DNA was measured at each of the 5 steps leading to the generation of the coated 
cartridge (Lanes 2-6 for 0.05 PVP; 7-12 for 0.005 PVP, 13-17 for no PVP). These include 
step 1, supernatant recovered from DNA/gold mixing step (lanes 2, 7, 13), step 2, 
supernatant recovered from first ethanol wash of gold particles (lanes 3, 8, 14), step 3, 
supernatant recovered from second ethanol wash of gold particles (lanes 4, 9, 15), step 4, 
supernatant recovered from third ethanol wash of gold particles of coated DNA (lanes 5, 
10, 16) and step 5 ethanol removed from tubing station after coating of cartridge tubing 
(lanes 6, 11, 17).
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This work showed that hehum pressures higher than 100 psi produced large areas of 
disruption in the ceU monolayer resulting in a lower number of fluorescent cehs (Table 5.1 
and 5.2). In contrast, at 50 psi most of the DNA/gold suspension remained on the inner 
surface of the cartridges and the number of cells fluorescing was low. It was therefore 
decided that for all subsequent in vitro experiments a pressure of 100 psi should be used.
5.1.3. Inclusion of a Screen Diffuser on Gene-Gun Driven Transfection
To try and reduce the level of damage to the cells, a screen difluser was introduced to 
the front of the Gene-Gun. The purpose of this screen was to reduce any large aggregated 
particles that may cause ceU damage. In addition, the Gene Gun was held at a distance of 
approximately 2 cm above the ceh monolayer to try and enhance the diffusion of particles 
over the entire monolayer ceh surface.
Using the diffusion screen, the area of fluorescent cehs observed after transfection 
extended from a central concentrated spot to a larger zone, closer to the periphery of the 
culture dish. FinaUy, increasing the distance between the Gene-Gun and cehs resulted in 
the highest number of fluorescent cehs observed (Table 5.3).
5.1.4. Inter- and Intra-Variability of Transfection Using Different Batches of Coated 
Cartridges
Using these optimised conditions (0.05 mg/ml PVP, 100 psi, difihision screen, and 
distance), three different batches of pGFP-C3 coated cartridges were prepared and used to 
transfect cehs. The aim of this was to determine the level of variation observed within a 
batch of cartridges and between batches of cartridges.
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Table 5.1: Number of fluorescent cells observed following transfection by Gene Gun 
using a helium pressure of 200 psi. This reflects the number of fluorescent cells in one 
microscopic field (xlO magnification). The impact of different concentrations of PVP are 
illustrated by the different number of fluorescent cells observed.
Batch 1 (0 PVP) Batch 2 (0.005 PVP) Batch 3 (0.05 PVP)
Dishl 3 7 5
Dish 2 2 3 7
Dish 3 5 2 2
Dish 4 3 6 4
Dish 5 3 4 8
Dish 6 4 2 2
Average 3.33 4 4.66
S-Dev 1.03 2.09 2.50
Table 5.2: Number of fluorescent cells observed following transfection by Gene-Gun 
using a helium pressure of 100 psi. This reflects the number of fluorescent cells in one 
microscopic field (xlO magnification) in the absence of a dtlfijsion screen. Again, the 
impact of different concentrations of PVP are illustrated by the different number of 
fluorescent cells observed.
OPVP 0.005 PVP 0.05 PVP
Dishl 0 8 19
Dish 2 6 5 7
Dish 3 5 6 9
Dish 4 2 11 21
Dish 5 3 6 8
Dish 6 6 2 9
Average 3.66 6.33 12.16
S-Dev 2.42 3.01 6.14
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Table 5.3 shows the results of these transfections, which indicate that the variation in 
transfection efficiency using different cartridges of the same batch was less than that 
observed between different batches of cartridges.
5.1.5. Expression of GFP in COS-7 Cells Using Optimised Conditions of Delivery
Using conditions described above, the level of GFP expression was found to be about 
3 times lower in cells transfected with the Gene-Gun compared to those in which 
Lipofectamine™ was used (with roughly the same amount of pGFP-C3), with the average 
of 37 fluorecent cells compared to 115 for the Lipofectamine experiment.
One explanation for the lower level of GFP expression in vitro following Gene-Gun 
transfection, is that the hehum pressure may affect the viabihty of a number of cehs. This 
explanation is supported by the differences in morphology of COS-7 observed fohowing 
transfection by Gene-Gun (Figure 5.2) which was dramaticahy different in comparison to 
cehs transfected by Lipofectamine (Figure 4.1). In dishes transfected with the Gene-Gun, 
most fluorescent cehs were detached from the bottom of the dish, and were round and 
intensely green. In comparison, fohowing Lipofectamine-mediated transfection the 
monolayer remained attached to the bottom wah of the dish, with adherent cehs appearing 
pale-green.
An alternative suggestion for the lower level of GFP expression in vitro fohowing 
Gene-Gun transfection, is that the hehum pressure (100 psi) was not sufficient to 
efficiently drive the coated gold/DNA particles from the cartridges. However, increasing 
the pressure was not considered feasible as it produced, as mentioned, an even larger area 
of disruption to the monolayer even when a diffusion screen and distance from the 
monolayer was used.
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Table 5.3: Number of fluorescent cells observed following transfection by Gene-Gun 
using cartridges loaded with 0.05 mg/ml PVP, a helium pressure of 100 psi and a 
diffusion screen. This table reflects the number of fluorescent cells observed in one 
microscopic field (xlO magnification). The difference between the efficiency of 
transfection (number of fluorescent cells) between cartridges prepared on the same day and 
those prepared as different batches on separate days does not appear to be significant.
Batch 1 Batch 2 Batch 3
Dishl 28 32 39
Dish 2 25 28 37
Dish 3 26 50 20
Dish 4 31 37 42
Dish 5 26 46 27
Dish 6 28 29 34
Average 27.33 37 33.16
S-Dev 2.16 9.16 8.23
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Figure 5.2: In vitro expression o f GFP by Gene-Gun
Expression of GFP was visualised using an inverted microscope (Axiovert - Zeiss) 
connected to an Imaging System equipped with a designated software for picture 
processing (OpenLab-Improvision). The picture represents one microscopic field (xlO 
magnification).
I l l
5.1.6. Quantification of Amount of DNA Present in Each Cartridge
At the beginning of these experiments, one concern was the uneven coating of the 
gold/DNA particles in the cartridge tubing leading to differing amounts of DNA being 
delivered. In an attempt to overcome this problem, a number of methods of extraction and 
quantification were attempted, however, the most successful was that suggested by 
Watkins (personal communication, see Section 2.6.3). Using this method, the coated DNA 
was extracted fi'om each cartridge and the DNA quantified by reading the absorbency of 
the resultant solution at 260 nm. Using this method, several cartridges taken at various 
intervals along the length of the tubing were tested. The results of this study showed that 
only very small variations in the amount of DNA were observed and gave confidence that 
all cartridges were capable of equal delivery of DNA.
Using the methods described above, gold coated cartridges were prepared for both 
pcDNA3/tetC (Table 5.4 A), or the control plasmid pcDNA3.1 (Table 5.4 B). These were 
used initially to transfect cells in vitro and as described later for immunising mice in vivo.
Due to time-limitations and the difficulty of interpretation of data generated using the 
pCMV-70 plasmid, this construct was not used in any experiments in which the Gene-Gun 
was used.
1 1 2
pcDNA3.1/tet
C
cartridges
OD 260 OD 280 DNA recovered / cartridge
1 0.213 0.147 1.065pg
2 0.247 0.186 1.230pg
3 0.225 0.123 1.120pg
4 0.215 0.105 1.068pg
5 0.244 0.114 1.220pg
B
pcDNA3.1
cartridges
OD 260 OD 280 DNA recovered/cartridge
1 0.237 0.200 1.185pg
2 0.244 0.189 1.22pg
3 0.215 0.143 1.075pg
4 0.206 0.209 1.03pg
5 0.214 0.206 1.07pg
Table 5.4: Analysis of the amount of DNA present in each cartridge
In table A cartidges were coated with approximate 2 pg of pcDNA3/tetC, whilst table B 
shows recovery from cartridges coated with an equal amount of pcDNA 3.1. About 1-1.22 
pg of DNA was recovered from cartridges belonging to the same batch, suggesting that 
approximately half the DNA used had bound to the gold particles.
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5.2. Expression of Fragment C of Tetanus Toxin in COS-7 Cells Transfected with 
pcDNA3/tetC Using the Gene-Gun
5.2.1. Optimisation of the Detection System
Using transfection conditions described above for the Gene-Gun, cells were 
transfected using pcDNA3/tetC and expression of the protein measured using the 
conditions previously described for the chemiluminiscent substrate SuperSignal West Pico 
(Section 2.3.4.2.4). However, during the course of these optimisation experiments, the goat 
anti-rabbit BDRP conjugate antibody was finished and resulted in a new batch of this 
antibody being purchased. Unfortunately, if this antibody was used at the same 
concentration as those calculated previously, the blots produced were very dirty, with high 
background staining. Therefore the optimisation procedure was repeated and appropriate 
optimised dilutions of antibody calculated to produce very specific responses (1:10,000 
concentration of the primary antibody, 1:250,000 concentration of the secondary antibody).
5.2.2. Transfection and Expression of Fragment C in COS-7 Cells
COS-7 cells were transfected using the Gene-Gun using the conditions as described
above. Expression of antigen in these cells was then established by preparation of Western
blots using whole COS-7 cell lysates. These results show that cells transfected with the
Gene Gun produced a protein of approximate 50 kDa, which reacted specifically with the
anti-Fragment C antibody (Figure 5.3). This protein was identified as Fragment C as it was
exactly the same size as the recombinant Fragment C run on the same gel and a protein
produced by COS-7 cells transfected with pcDNA3/tetC using the Lipofectamine method.
In comparison, similar concentrations of COS-7 cells transfected with the control plasmid,
pcDNAB.l, failed to produce any detectable band, suggesting that the presence of the
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protein was dependent on expression from the pcDNA3/tetC construct. The level of 
expression of antigen by these cells was estimated to be around 10 ng in 2.8x10"^  cells, 
based on the amount of recombinant protein loaded onto the gel, in comparison to about 70 
ng/ 2.8x10'  ^ cells transfected with Lipofectamine (Section 4.3.2.). Based on the success of 
these experiments we decided to test the immune response to Gene Gun vaccination of the 
pcDNA3/tetC construct in mice.
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Figure 5.3: Expression o f Fragment C in COS-7 cells transfected using the Gene-Gun 
with pcDNA3/tetC.
This figure shows the detection of Fragment C using a Fragment C specific polyclonal sera. 
The gel was loaded as follows: lane 1, 10 ng Fragment C (positive control); Lane 2, 4.6x1 O'* 
COS-7 cells transfected with pcDNA3/tetC with Lipofectamine; Lane 3, 2.8x10'* COS-7 cells 
transfected with pcDNA3/tetC by Gene-Gun; Lane 4, 2.8x10'* COS-7 cells transfected with 
pcDNA3.1.
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Chapter 6 
Results -  Section 4 
Vaccination with pcDNA3/tetC
The aim of the work outlined in this chapter was to determine whether the vaccine 
candidate pcDNA3/tetC could induce immune responses in BALB/c mice when delivered 
either parenterally or through the skin by Gene-Gun.
117
6.1. Fragment C Specific Responses Following Immunisation with pcDNA3/tetC
It has already been reported that mice vaccinated vyith pcDNA3/tetC activate strong 
humoral and cell mediated immune responses, which are protective against challenge with 
active tetanus toxin (Anderson et a l, 1996, Saikh et a/., 1998). However, these 
observations have only been made following parenteral immunisation of the muscle. To 
date, no data on the immunogenicity of Fragment C-encoding DNA vaccine administered by 
the Gene-Gun have been generated.
One of the aims of the study was to compare and contrast the immune responses 
generated when the two different routes of immunisation were used.
6.1.1. Antibody Levels Following Intramuscular Immunisation with pcDNA3/tetC
To determine the magnitude and specificity of the immune response generated by the 
DNA construct that expresses Fragment C, mice were initially immunised intramuscularly 
on day 1 and day 8, with either pc/DNA3/tetC, or the control plasmid (pcDNA3.1) (for 
immunisation schedule see Section 2.4.4, Table 2.5). Sixteen days after the second i. m. 
immunisation (day 24), sample bleeds were taken fi'om all mice and tested by ELISA for the 
presence of Fragment C specific antibodies. As shown in Figure 6.1 and in agreement with 
previous experiments (Anderson et a l, 1996, Saikh et a l, 1998, Stratford et a l, 2000), all 
ten mice immunised with pcDNA3/tetC showed detectable levels of Fragment C specific 
antibodies (average titre of about 1x10^). In addition, this response was found to increase 
with time, as sample bleeds taken from the same animals twelve days later (day 36) showed 
an average 3 fold increase in titre compared to those measured on day 24 (Figure 6.1. B). In 
contrast, mice immunised with pcDNA3.1 only showed no detectable Fragment C specific 
antibody in the sera at either time point.
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Figure 6.1: Titres of Fragment C specific IgG in the serum following two 
intramuscular doses of pcDNA3/tetC
Fragment C specific IgG titres were determined in sera of 10 individual mice on days 24 
(A) and 36 (B) following intramuscular immunisation with two doses of 100 pg 
pcDNA3/tetC or pcDNA3.1. Mice were originally immunised on day 1 and 8 of the 
experiment, respectively. Each point (♦) represents the titres of Fragment C specific 
antibodies from individual sera with each of the horizontal lines representing the median 
values for each group.
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6.1.2. Antibody Levels Following Gene-Gun Administration of pcDNA3/tetC
To determine the magnitude and specificity of the immune response, mice were 
immunised by the Gene-Gun as described in Section 2.6.4.3 (Table 2.8) on day 1 and day 8, 
with either pcDNA3/tetC, or the control plasmid (pcDNA3.1). Fourteen days following the 
second Gene-Gun immunisation (day 22), sample bleeds were taken fi’om all mice and 
tested by ELISA for the presence of Fragment C specific antibodies. As shown m Figure 6.2 
all five mice immunised with pcDNA3/tetC showed titres of Fragment C specific antibodies, 
which were comparable with those obtained followmg i. m. immunisation fi’om the previous 
experiment. However, these titres were higher than those obtained in the three mice 
included as controls within this experiment.
In both experiments, mice immunised by either route showed an increase in the 
production of antibodies with time, as sample bleeds taken firom the same animals twelve 
days later (day 34) had titres increased by about 2 fold for mice in the group immunised by 
the Gene-Gun, and about a 4 fold increase in the group immunised i. m.. In contrast, mice 
immunised with the empty vector pcDNA3.1 showed no detectable Fragment C specific 
antibody in the sera at any time point.
6.1.3. Impact of Route of Immunisation on IgG Isotype
Although the titre of response did not vary significantly between the two groups, the 
quality of the immune response was found to differ. This was highlighted by the differences 
in the antigen specific IgG isotypes measured. In agreement with most work found in the 
literature, mice immunised with pcDNA3/tetC intramuscularly produced a dominant lgG2a 
response in the sera, although antigen specific IgGl was also detected. In contrast, mice 
immunised using the Gene-Gun produced a response that was completely dominated by 
antibody of the IgGl subclass (Figure 6.3).
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Figure 6.2: IgG response against Fragment C following Gene-Gun immunisation with 
two doses of pcDNA3/tetC
Titres of Fragment C specific IgG in sera of mice on days 22 (A) and 34 (B) following 
Gene-Gun (GG) immunisation with two doses of 2 pg pcDNA3/tetC or pcDNA3.1. In 
addition, as a control, three mice were immunised i. m. with two doses of 100 pg 
pcDNA3/tetC. Each rhombus represents individual sera and each horizontal line, median 
values for each group.
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Figure 6.3: Ratio of IgGl/IgG2a Fragment C specific antibody in the sera following 
intramuscular or Gene-Gun immunisation with pcDNA3/tetC
Ratio of Fragment C specific IgGl/Ig02a in the sera of mice primed with two doses of 
pcDNA3/tetC delivered either i. m. (A) or by Gene-Gun (B). Figure shows the response 
measured 24 days after the second dose of DNA. Each point (♦) represents the titres of 
Fragment C specific antibodies from individual sera with each of the horizontal lines 
representing the median values for each group.
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6.1.4. Impact of Boosting Animals Previously Vaccinated Intramuscularly with DNA
Although DNA vaccination generated measurable antibody in the blood using either 
route of immunisation, previous experience suggested that DNA vaccination with this 
construct resulted in the generation of a very low activation of antigen specific T-cells. 
However, amplification of DNA primed cells has been shown to be possible by boosting the 
animals with a low amount of the homologous purified antigen (Stratford et al, 2001).
Using this approach, the 2 groups of 10 mice immunised intramuscularly with 
pcDNA3/tetC or pcDNA3.1 respectively, were split into 4 groups of 5. These mice were 
then subsequently immunised on day 37 with either a 3^^^ intramuscular immunisation with 
DNA or a intramuscular immunisation with purified Fragment C. Table 2.5 in the 
Materials and Methods Chapter (Section 2.4.4) describes the specific prime/boost regimen. 
Fourteen days following this boost immunisation (day 50), mice were sacrificed, the blood 
taken for analysis of the Fragment C specific antibody and the T-cells analysed for antigen 
specific proliferative responses and cytokine release.
6.14.1. Impact of Prime/Boost Regimen on Specific Antibody Levels
Analysis of the sera established that mice given a third i. m. dose of pcDNA3/tetC had 
titres of Fragment C specific IgG which were about 7 times higher than those detected prior 
to the boost, as it can be seen in Figure 6.4. This increase maybe due to combination of 
factors including both the impact of a third dose of the pcDNA3/tetC construct and the fact 
that titres may have increased naturally with time following the 2"^  immunisation.
In contrast, mice that had originally been primed with pcDNA3/tetC and then boosted 
with purified Fragment C showed a approximate 20 fold increase in Fragment C specific 
antibody in the sera, as illustrated in Figure 6.4. This increase was 3 times higher than that 
detected in similarly primed mice that had been boosted with pcDNA3/tetC.
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Figure 6.4: Titres of Fragment C specific IgG in the serum before and after boosting 
primed mice with purified Fragment C
Fragment C specific IgG titres were determined in the sera of individual mice primed 
intramuscularly with two doses of either pcDNA3.1 or pcDNA3/tetC and then boosted 
with either pcDNA3/tetC or with Fragment C. Figure A shows anti-Fragment C titres 
measured before boosting on day 36 and Figure B after boosting on day 50. Each point (♦) 
represents the titres of Fragment C specific antibodies from individual sera with each of the 
horizontal lines representing the median value for each group.
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In contrast, mice which had been immunised with either 2 doses of pcDNAS.l and 1 
dose of purified Fragment C showed titres of specific antibody that were at least one and a 
half logs lower than those detected in mice primed with pcDNA3/tetC. This result confirms 
the impact of priming with pcDNA3/tetC on the magnitude of the antibody response 
generated.
6.I.4.2. Impact of Prime/Boost Regimen on IgG Isotype
The impact of priming animals with the DNA vector pcDNA3/tetC was most clearly 
shown in the antigen specific isotypes of IgG detected measured in the sera of vaccinated 
mice. These were studied both before (day 36) and after (day 50) the booster immunisations 
that were carried out on day 37. The isotypes of IgG present after vaccination with 
pcDNA3/tetC are shown in Figure 6.5. In these mice, although all isotypes were detected, 
the predominant antibody was IgG2a. This pattern of humoral immune response was not 
drastically altered by the third immunisation with another dose of DNA or a boosting 
protein dose. In fact, the antigen specific IgG2a remained dominant and titres were 
enhanced in mice boosted on day 37 with either pcDNA3/tetC or purified Fragment C. In 
contrast, mice primed with the pcDNA3.1 vector alone and boosted with purified Fragment 
C showed a predominant IgGl subtype of specific antibody. These results suggest that in 
contrast to i. m. immunisation of purified protein, which induces a response that is strongly 
biased toward a Th2 type of response, pre-immunisation of the same antigen as a DNA 
construct result in the priming of Thl specific CD4 helper cells. Figure 6.6 illustrating the 
IgGl/IgG2a ratio. In addition, boosting with purified protein appeared to enhance the size 
of the antibody response to the antigen.
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Figure 6.5: Titres o f Fragment C specific subclasses o f IgG in mice primed with 
pcDNA3/tetC and boosted with purified Fragment C
Fragment C specific IgGl, IgG2a, IgG2 b titres were determined in the sera of individual 
mice primed intramuscularly with two doses of either pcDNAS.l or pcDNA3/tetC and then 
boosted with either pcDNA3/tetC or with Fragment C. Figure A shows the titres measured 
before boosting on day 36 and Figure B after boosting on day 50. The results shown 
represent the mean calculated titres for 5 mice per group and the error bars the standard 
deviation of the mean titre values.
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Figure 6.6: Ratio of IgGl/IgG2a Fragment C specific antibody in the sera of mice 
primed i. m. with pcDNA3/tetC and boosted with Fragment C
Ratio of Fragment C specific IgGl/IgG2a in the sera of mice primed with two doses of 
either pcDNAS.l or pcDNA3/tetC and then boosted with Fragment C. Figure A shows the 
response before boosting (day 36) and Figure B the effect following boosting with 
Fragment C (day 50). Each point (♦) represents the ratio of IgGl/IgG2a Fragment C 
specific antibodies fi'om individual sera.
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6.1.5. Impact of Boosting Animals Previously Vaccinated with pcDNA3/tetC by Gene- 
Gun
Following the initial analysis of the antibody response to Gene-Gun administration of 
pcDNA3/tetC (Section 6.1.2), it was decided to boost these animals as previously with 10 
pg i. m. of purified Fragment C. Table 2.8 in the Materials and Methods (Section 2.6.4.3) 
describes the specific prime/boost regimens employed. Twelve days following this boost 
immunisation (day 46), mice were sacrificed and the level of anti-Fragment C response 
measured by ELISA.
6.15.1. Impact of Prime/Boost Regimen on Specific Antibody Levels
The titre of specific antibody measured following the boost in mice initially primed 
with Gene-Gun delivered pcDNA3/tetC was about 6 times higher than those detected prior 
to the boost immunisation (Figure 6.7). Within the context of this experiment, an equivalent 
increase in the specific antibody response was also observed in mice boosted with protein 
that had initially been primed via the intramuscular route with pcDNA3/tetC. This result is 
in contrast to that observed in the initial experiment in which the increase of specific 
antibody was much higher (approximately 20 fold). These differences may reflect variation 
in the efficiency of immunisation between the two experiments and also the statistical effect 
of using a lower number of animals in the second experiment compared to the first. In 
particular, the result is skewed by the fact that one of the three mice used failed to respond 
to the initial immunisation, affecting the average titre within this group.
Immunisation by the Gene-Gun itself, did not appear to influence the level of antibody 
generated as mice immunised with the control plasmid (pcDNA3.1) and then boosted with 
Fragment C, had equivalent titres of Fragment C specific IgG as those obtained in naïve 
mice immunised with Fragment C alone.
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Figure 6.7: Titres of Fragment C specific IgG in the serum before and after boosting 
Gene-Gun primed mice with purified Fragment C.
Fragment C specific IgG titres were determined in the sera of individual mice primed with 
two doses of either pcDNAS.l or pcDNA3/tetC delivered using the Gene-Gun and then 
boosted with Fragment C. Figure A shows anti-Fragment C titres measured before 
boosting on day 34 and Figure B after boosting on day 46. Each point (♦) represents the 
titres of Fragment C specific antibodies from individual sera with each of the horizontal 
lines representing the median values for each group.
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6.I.5.2. Impact of Prime/Boost Regimen on IgG Isotype
One of the clearest differences between the two routes of immunisation was however 
clearly revealed by the antigen specific isotypes detected in the sera of vaccinated mice. 
These were studied both before (day 34) and after (day 46) the boost immunisations. The 
isotypes of specific IgG detected following Gene-Gun vaccination are shown in Figure 6.8.
In contrast with the pattern of IgG subtypes elicited in mice following i. m. 
immunisation, Gene-Gun mediated vaccination with pcDNA3/tetC was characterised by a 
predominant Th2 type of immune response, with a high titre of IgGl and IgG2b both before 
and after boost with Fragment C. As in previous experiment, Fragment C boost did increase 
apparently significantly the level of specific antibody, but followed the same established Th2 
orientation primed by the Gene-Gun immunisation, with the level of antigen specific IgGl 
remaining dominant. Mice primed with the pcDNA3.1 vector alone and boosted with 
purified Fragment C and those immunised with Fragment C alone also showed a 
predominant IgGl subtype of specific antibody. In contrast, the three mice immunised twice 
i. m. with pcDNA3/tetC and boosted with Fragment C had a mixed Thl/Th2 response, with 
predominant IgG2a titres, both before and after boost, which is consistent with the previous 
experiment.
Figure 6.9 shows the IgGl/IgG2a ratio for individuals within each group of mice, 
illustrating more clearly the orientation of the immune response (towards Thl or Th2) 
activated by each immunisation protocol. These results suggest that, in contrast to i. m. 
immunisation with pcDNA3/tetC, the Gene-Gun induces a response that is strongly biased 
toward Th2. In agreement with the previous experiment, the immune response that is 
primed by i. m. or Gene-Gun is only enhanced following the boost with the purified protein.
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Figure 6.8: Titres o f Fragment C specific subclasses o f IgG in mice primed with 
pcDNA3/tetC using the Gene-Gun and boosted with purified Fragment C
Fragment C specific IgGl, IgG2a, IgG2b titres were determined in the sera of individual 
mice primed with two doses of either pcDNAS.l or pcDNA3/tetC by Gene Gun and then 
boosted with either pcDNA3/tetC or with Fragment C. Figure A shows the titres measured 
before boosting on day 34 and Figure B, after boosting on day 46. The results shown 
represent the mean calculated titres for 5 mice per group and the error bars, the standard 
deviation of the mean titre values.
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Figure 6.9: Ratio of IgGl/IgG2a Fragment C specific antibody in the sera of mice 
primed with pcDNA3/tetC and boosted with Fragment C
This figure shows ratio of Fragment C specific IgGl/IgG2a in the sera of mice primed with 
two doses of either pcDNA3T or pcDNA3/tetC and then boosted with Fragment C. Figure 
shows the response before (A, day 34) and after boosting with Fragment C (B, day 46) in 
mice primed by Gene-Gun or i. m. with pcDNA3/tetC. Each point (♦) represents the ratio 
of IgGl/IgG2a Fragment C specific antibodies fiom individual sera.
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6.2. T Cell Proliferation Assay
6.2,1. T Cell Proliferation in Mice Immunised Intramuscularly with pcDNA3/tetC
Unfortunately, although T-cell assays were performed in an attempt to confirm the 
activation of specific CD4^ T-cell populations for the first experiment, due to technical 
difficulties the data proved impossible to interpret. This is because the cells in all wells 
(stimulated and unstimulated) proliferated non-specifically. This was probably due to the 
presence of some mitogen in the media used during the course of the assay. It was therefore 
decided to repeat the experiment. However, as time was limited, it was decided that, to 
ensure strong proliferation of T-cells, an adjuvant should be included with the Fragment C 
boost phase of the experiment. The adjuvant chosen for these experiments was the heat 
labile toxin fi'om E. coU (LT), which had been used previously in such prime/boost 
regimens. This toxin is able to stimulate the activation of both CD4^ T Thl and Th2 helper 
cells and it was felt would not skew the primed response toward the amplification of one 
particular cell population as is the case with many traditional adjuvants (example aluminium 
hydroxide activates specifically Th2 responses).
In the second experiment, four groups of mice were vaccinated in order to determine 
the proliferative response to Fragment C in vitro. Initially, all mice were primed twice with 
either pcDNA3/tetC or pcDNAS.l and then one group from each boosted with Fragment C 
and LT. Ten days later the mice were sacrificed and the spleens and local lymph nodes 
around the site of intramuscular immunisation removed. Single cell preparations fi'om both 
tissues were then stimulated in vitro. Seventy-two hours after stimulation, supernatants 
above the cells were removed for cytokine analysis and then the proliferative index 
determined by addition of tritiated thymidine, as described in Section 2.5.2.1.
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As seen in Figure 6.10, cells from both the spleens and lymph nodes of mice primed 
with pcDNA3/tetC and boosted with Fragment C and LT proliferated strongly on 
restimulation. In contrast, mice primed with the control plasmid (pcDNA3,l) and boosted 
with Fragment C and LT showed no lymph node cell proliferation and only a very low level 
of thymidine incorporation in spleen cells. In agreement with previous observations, no 
proliferation was observed in cells taken from mice injected twice with pcDNA3/tetC 
(Stratford -  personal communication). Similarly, cells from mice immunised with 
pcDNA3.1 failed to proliferate following restimulation with Fragment C. However, all cells 
from all groups of mice did respond to the mitogen, Concanavalin A (Con A), suggesting 
that this lack of response was not due to anergy within the cell population, (see Figure 
6.10).
In conclusion, it would appear that boosting of animals with the Fragment C in the 
presence of the adjuvant LT, enhanced the proliferative response of T-cells apparently 
primed by the initial immunisation with pcDNA3/tetC. The boosting dose itself does not 
appear responsible for the large proliferative response observed in this group as mice 
immunised with pcDNA3.1 and boosted with Fragment C and LT failed to mount such a 
large response. However, vaccination with pcDNA3/tetC alone, did not appear sufficient to 
activate these responses. One explanation for this lack of response is time taken between 
DNA priming and completion of these experiments, which were chosen to maximise the 
effect of the boost immunisation rather than the DNA vaccination. With more careful study 
it may be possible to optimise the timing to maximise measurement of the response induced 
to DNA alone.
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Figure 6.10: Stimulation o f spleen cell and lymph node cells from vaccinated mice in 
vitrOf cultured from mice primed intramuscularly with two doses o f either pcDNA3.1 
or pcDNA3/tetC and then boosted with Fragment C + LT
Proliferative responses were determined in spleen and lymph node cells from mice primed 
intramuscularly with two doses of either pcDNA3.1 or pcDNA3/tetC and then boosted 
with Fragment C + LT. Cells were restimulated with either Fragment C or Concanavalin A 
in vitro and stimulation indices were calculated as the ratio between the counts per minute 
of incorporated thymidine determined in stimulated wells divided by the counts per minute 
calculated from duplicate unstimulated cells. Assays were performed in triplicate using cell 
suspensions prepared from pooled tissues taken from 5 mice.
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6.2.2. T cell Proliferation in Mice Immunised by Gene-Gun with pcDNA3/tetC
As for the previous experiments, spleens and lymph node tissues from mice in all four 
groups were removed and the proliferative response to stimulation in vitro with Fragment C 
investigated.
Unfortunately, the proliferation observed in these experiments was very low. Not even 
mice immunised i. m. with pcDNA3/tetC and boosted with Fragment C showed any 
significant level of response. In contrast, all cells responded strongly to the mitogen 
concanavalin A (Con A), suggesting that the cells in all cases were not anergic. The 
important difference between this experiment and that in which strong responses were 
observed is that no additional adjuvant was included in the booster regimen. This suggests 
that immunisation with the antigen alone is insufficient to initiate amplification of the T-ceU 
population to a level that is detectable using this approach.
6.3. Cytokine Secretion
6.3.1. Cytokine Secretion by Re-Stimulated Splenocytes and Regional Lymph Node 
Cells from Mice Immunised Intramuscularly with pcDNA3/tetC
In order to confirm the type of CD4^ T helper cells that were proliferating m response 
to in vitro stimulation, eulture supernatant samples were tested for the presence of IL-5 and 
IFN-y, which are cytokines associated with activation of Th2 or Thl responses, 
respectively.
Supernatants from proliferating cells (splenocytes and regional lymph nodes) from 
each group were pooled and analysed in triplicate by ELISA assay in the presence of 
recombinant standard cytokines of known concentration (see Section 2.5.2.2).
136
The results indicated that a higher concentration of IFN-y was released into the 
supernatants taken from stimulated splenic cells from mice primed with 2 doses of 
pcDNA3/tetC and boosted with Fragment C and LT than those primed with 2 doses of 
pcDNA3.1 and boosted with Fragment C and LT (Table 6.1). A similar pattern of IFN-y 
secretion was also observed in culture supernatants taken from pooled regional lymph nodes 
from the same groups of mice. In contrast, levels of IL-5 were observed to be higher in the 
pooled supernatants stimulated lymph node cells from mice immunised with vector alone 
than those immunised with pcDNA3/tetC (Table 6.1). This could reflect a possible bias 
toward the secretion of Thl type of cytokines in mice prime with DNA, which may inhibit 
the Th2 response usually elicited by the protem alone. However, the significance of this 
result is unclear, as the opposite pattern of IL-5 secretion was observed in the supernatants 
taken from spleen cells using the same groups of mice.
Although these findings appear largely to agree with the isotype of IgG observed (see 
Section 6.1.4.2), it is possible that the differences observed refleet either variability that is 
inherent in the assay itself, or the data is affected by the fact that pooled supernatants were 
used in the analysis. It is possible that high levels of cytokines produced by one animal may 
have skewed the pooled data in a particular direction. In addition, as the adjuvant LT has 
been shown to activate antigen specific Thl and Th2 cells, its very use could have 
influenced specifically the production of IL-5.
6.3.2. Cytokine Secretion by Splenocytes and Lymph Node Cells from Mice 
Immunised with pcDNA3/tetC by Gene-Gun
Despite the poor T-cell responses generated in this experiment, the supernatants taken 
during the course of this experiment were additionally analysed for cytokine production.
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As it can be seen in Table 6.2 the splenocyte culture from individual mice primed by 
Gene-Gun (with either pcDNA3/tetC or pcDNA3.1) and boosted i. m. with Fragment C 
showed similar levels of IFN-y. As the mean values were almost equivalent between both 
groups, the impact of priming the animals with pcDNA3/tetC did not appear relevant.
However, this experiment lacked the control group of mice, which should have been 
immunised with pcDNA3/tetC using the Gene-Gun alone. Analysis of the responses from 
such a group compared to one in which a booster immunisation has been given may result in 
the production of a different pattern of cytokine production.
Mice immunised i. m. either with pcDNA3/tetC, and boosted with Fragment C, or 
with Fragment C alone had a slightly higher level of IFN-y in both restimulated spleen cells 
and lymph node cells. These responses were higher than those observed in the Gene-Gun 
immunised groups. This difference might suggest the stronger induction of Th2 cytokines 
that are inhibiting production of IFN-y in the Gene-Gun immunised mice, which would be 
consistent with serum IgGl/IgG2a values correlated with the same type of immune 
response in Gene-Gun- versus i. m - vaccinated mice (see Section 6.1.4.2).
The pattern of IL-5 secretion is also difficult to be interpreted, as, while in lymph 
node cells IL-5 secretion was difficult to detect in any of the groups tested, mice primed by 
Gene-Gun with pcDNA3/tetC and subsequently boosted had a slightly higher level of IL-5 
production in splenocyte culture in comparison with aU other groups of mice. Again, with 
the reservation of the lack of consistency between the situation in spleen and the one in 
lymph nodes, results might indicate a possible bias towards a Th2 type of cytokine secretion 
primed by the Gene-Gun in comparison to i. m. priming.
Due to the fact that the number of mice used in this experiment was small, the results 
cannot to be considered representative, but they suggest consistency with previous studies 
using different vaccine candidates and the same vaccination protocols.
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Table 6.1: Production of IFN-y and IL-5 from spleen and lymph node cells from mice 
primed i. m. with DNA and boosted i. m. with purified Fragment C and LT
Group 
of mice
Primed i. m. pcDNA3/tetC 
x2
Boosted with Fragment C 
+ LT xl
Primed i. m. pcDNA3.1 x2
Boosted with Fragment C 
+ LT xl
IFN-y
(pooled
supernatants)
Spleen
cells
1195.6 pg/ ml 857.4 pg/ ml
Lymph
node
cells
1541.8 pg/ ml 977.3 pg/ml
IL-5
(pooled
supernatants)
Spleen
cells
215.6 pg/ml 96.5 pg/ ml
Lymph
node
cells
91.5 pg/ml 173.3 pg/ ml
Table 6.2: Production of IFN-y and IL-5 from spleen and lymph node cells from mice 
primed by Gene-Gun with DNA and boosted i. m. with purified Fragment C
Group o ' mice
pcDNA3/tetC 
G.G. X 2 
+ Fragment C
pcDNA3.1 G.G. 
x2
+ Fragment C
pcDNA3/tetC 
i.m. x2 
+ Fragment C
Fragment C
IFN-y
(averages)
Spleen
cells
1246 pg/ ml 1326 pg/ml 1900 pg/ ml 1750 pg/ml
Lymph
node
cells
348 pg/ ml 96 pg/ ml 766 pg/ ml 394 pg/ ml
IL-5
(averages)
Spleen
cells
274 pg/ ml 84 pg/ ml 184 pg/ ml 55 pg/ ml
Lymph
node
cells
51 pg/ml 156 pg/ml 186 pg/ ml 20 pg/ ml
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Chapter 7 
Results -  Section 5 
Vaccination with pCMV-70
The aim of this work was to establish whether the DNA vaccine construct pCMV-70 was 
ahle to induce immune responses when delivered to mice intramuscularly.
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The inununogenicity of the second DNA vaccine candidate, pCMV-70, was also tested 
by intramuscular injection in BALB/c mice. This plasmid had previously been shown to be 
partially effective previously both in cattle and BALB/c mice. In cattle, i. m. administration of 
this plasmid had resulted in antibody seroconversion in 50% of the animals immunised 
(Vordermeier et al, 2001), whilst in mice, four doses of pCMV-70 had resulted in a reduction 
in the number of live bacteria in spleen and lungs of mice challenged with the organism. 
(Lowrie et al, 1999). Using a similar approach to that taken using Fragment C, we hoped to 
maximise the immune response generated.
In this experiment mice were immunised either three times i. m. with pCMV-70 or twice 
with the plasmid DNA and boosted once with the MPB-70 protein. Sera from the mice were 
subsequently analysed for the presence of MPB-70 specific antibodies. However, the results of 
these experiments proved to be very disappointing, as no or very low response was detectable 
either before or following boost either by ELISA using purified recombinant MPB-70 as the 
coating antigen, or by Western blot, using the purified antigen. However, as pCMV-70 
produced a larger than expected product when expressed in COS-7 cells, it was unclear whether 
this lack of response indicated poor immunogenicity of the plasmid, or, whether the antibodies 
generated where able to recognise the aberrant form of the protein (28 kDa) and unable to 
recognise native MPB-70. In an attempt to resolve this problem the sera was tested for activity 
against both forms by Western blot using the recombinant material and lysates from 
transformed COS-7 cells. Unfortunately, even using this method of analysis, there did not 
appear to be any specific MPB-70 antibodies in the sera.
In conclusion, DNA vaccination using the MPB-70-encoding plasmid pCMV-70 did not 
result in detectable immune response in any of BALB/c groups, regardless the vaccination 
strategy used (3x pCMV-70, 2x pCMV-70+MPB-70, or 2x pCMV-link + MPB-70).
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Chapter 8 
Discussion
142
Although traditional vaccination strategies have been very successfiil at protecting 
man from a variety of infections, there still are many pathogens (such as malaria) for which 
effective vaccines have not yet been discovered. Failure to develop such vaccines can be 
attributed to a number of factors including the poor definition of protective antigens, low 
immunogenicity, availability of appropriate delivery vehicles to stimulate the immune 
system appropriately and issues relating to safety. For example, in the case of subunit 
vaccines weak immunogenicity frequently requires repeated boosts to induce long-term 
protective immunity whilst in the case of live attenuated vaccines, reversion to wild type 
phenotype maybe observed. In this regard, many challenges remain to be overcome and 
new, effective and potent vaccines to be developed.
Although vaccination using “naked” DNA is in its infancy, many features associated 
with this form of immunisation have been shown to induce protective immune responses in 
a number of animal models, in which difficulties had previously been encountered. In 
particular, as DNA vaccination appears able to induce both cellular and humoral immune 
responses, its use in the development of viral vaccines has been particularly significant. In 
addition, there is no danger of reversion to virulence, which has been the perceived 
problem associated with live attenuated organisms that stimulate similar cellular responses. 
The potential of this form of vaccination has resulted in rapid clinical testing with several 
vaccines currently in phase I/H trials for safety and efficacy. These include testing of DNA 
vaccines against hepatitis B (Tacket et ah, 1999), HIV infection (MacGregor et a l, 1998; 
Hanke et a l, 2000) and malaria (Le et a l, 2000). The therapeutic potential of DNA 
vaccines in cancer (Chen et a l, 1999) and autoimmune (Garren et al, 2001) or allergic 
(Horner et al, 2001) diseases is also being evaluated.
In the context of this study, the potential of two different DNA vaccine candidates to 
induce immune responses was tested in BALB/c mice. In particular, the aim was to
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determine the type of immune response generated to these antigens when the naked DNA 
was introduced using two different routes of immunisation, namely by parenteral injection 
into the muscle or dermal inoculation into skin cells using a ballistic device. The 
downstream consequences of trying to alter the magnitude and type of response using 
alternative boosting strategies could then be considered. The two candidates used were the 
50 kDa non-toxic binding domain from tetanus toxin from Clostridium tetani, known as 
Fragment C, and an outer membrane protein known as MPB-70 from Mycobacterium 
bovis.
8.1, PCMV-70 Plasmid, as an anti-Tuberculosis DNA Vaccine Candidate
In our study, plasmid pCMV-70 encoding the mycobacterial antigen MPB-70 was 
tested as a vaccine candidate against tuberculosis, first for its potential to induce protein 
expression in mammalian cells, in vitro, and then for its immunogenicity in BALB/c mice, 
when administered intramuscularly.
Although pCMV-70 successfully transfected COS-7 cells in vitro, and showed high 
levels of protein expression within these cells (see Section 4.2.2), the results were difficult 
to interpret. This is because the protein expressed in COS-7 cells was different in size to 
the recombinant or native form of the protein. In addition, its lack of reactivity with an 
appropriate monoclonal antibody suggested that expression of this antigen in the context of 
an eukaryotic cell resulted in a change to the protein that affected epitope availability. 
Though, the nature of this change could not be determined within the limits of this project, 
two potential hypotheses were tested and discounted. The first hypothesis, which 
considered N-glycosylation of the protein, appeared incorrect as treatment of the cells with 
Tunicamycin, and N-glycosylation inhibitor, did not affect the size of the protein produced. 
However, the second hypothesis, which considered the difference in size to reflect the
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formation of additional disulphide bonds within the structure of the COS-7 expressed 
protein, was also irrelevant, as additional treatment of the protein with either DTT or fresh 
p-mercaptoethano 1, failed to affect its size. It is possible that other post-translational 
modifications to the protein could have resulted in the observed changes in size. These 
include O-glycosilation, palmitoylation or phosphorylation. However within the context of 
this study no time was available for additional evaluation.
Although the cells transfected with pCMV-70 produced a protein that reacted with 
polyclonal sera against MPB-70, there is no direct evidence that this protein is MPB-70. It 
is possible that this maybe an artefact of the system, although cells transfected with the 
vector alone did not produce a similar sized protein. If further study were possible, the 
identity of this antigen could be confirmed by analysis of the protein separated by two- 
dimensional electrophoresis. Those protein spots that specifically react with the MPB-70 
antisera could then be identified and isolated from such gels. It would then be possible to 
identify the composition of the protein using digested peptides analysed by matrix-assisted 
laser disruption/ ionisation mass spectrometry analysis (MALDI-TOF). If this 
methodology failed to identify the protein as MPB-70, its exact identity could then be 
determined by peptide sequencing using electrospray mass spectrometry (EMS).
In contrast to work described m the literature, in which i. m. administration of this 
plasmid to cattle had resulted in antibody seroconversion in 50% of the immunised cattle 
(Vordermeier et al, 2001), the MPB-70-encoding plasmid pCMV-70, failed to induce any 
significant level of antibody responses in BALB/c mice. This also contrasts the work of 
Lowrie et al, 1999 who showed that the number of live bacteria in spleen and lungs in 
BALB/c mice declined rapidly following four doses of i. m. pCMV-70. In our hands, the 
plasmid did not even appear to prime any responses, as when the protein was subsequently 
used to boost these animals, no detectable response was generated. However, this could
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reflect the fact that the two proteins are not identical and may be being processed by the 
immune cell via different pathways. The fact that the monoclonal antibody failed to react 
with the protein suggested that the alternative post-translational folding of the protein 
maybe occurring, resulting in changes to the immunodominant epitopes. It is also possible 
that, by increasing the number of doses of DNA vaccine given, or by including an adjuvant 
with the protein boost, any immune responses that had been primed may have been 
enhanced (Lowrie et al, 1999 used four i. m. injections). However, time limitations did not 
permit any further evaluation of this construct. It is also possible that the strain of mice 
chosen for this experiment are not the most appropriate for efficient processing and 
presentation of the H2 restricted epitopes of the MPB-70 protein. However, if the 
immunogenicity of this protem is highly dependent on the genetic background of the 
animal model chosen, it is unlikely that this protein will have application as a candidate for 
a human vaccine as the genetic background of this population is highly polymorphic. Thus, 
most likely, in the attempt to find a DNA vaccine against tuberculosis capable to cover all 
the limitations of currently available BCG vaccine, other structures, more immunogenic 
and less subjected to genetic variation within the host population have to be taken in 
consideration.
One point of interest that can be taken fi*om this study regards the correlation 
between potential level of gene expression in vitro and immunogenicity in vivo. From the 
in vitro studies, the antigen appeared to be expressed at much higher levels than the 
Fragment C construct. However, the immunogenicity of the Fragment C construct 
appeared higher in vivo. It is therefore possible that this high level of expression is 
responsible for its low immunogenicity as over expression in the cell may lead to poor 
folding and rapid degradation. It is possible that using a different vector in which 
expression is not driven so strongly this protein would appear to be more immunogenic.
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8.2. PcDNA3/tetC Plasmid, as an anti-Tetanus DNA Vaccine Candidate
Tetanus, along with measles and pertussis, is one of the main vaccine-preventable 
infections that can kill within the first year of life. Although, the current tetanus vaccine 
(based on a chemically inactivated form of the tetanus toxin, named anatoxin or toxoid) is 
efficient in the prevention of the disease, there are several reasons to suggest that this 
vaccine can be improved. These include the relatively limited duration of protection 
conferred by the vaccine, which has to be given every 10 years to maintain an appropriate 
level of neutralising antibodies. Second, immunisation is often accompanied by a local 
reaction following administration, which may be the result of the inclusion of the 
aluminium hydroxide or phosphate adjuvant included in the vaccine (Stratton et ah, 1994). 
Thirdly, as generation of the antigen is dependent upon the successfiil manufacture and 
inactivation of tetanus toxin fi*om Clostridium tetani, failure in the manufacturing process 
can lead to the production of either an ineffective vaccine (Topsis et al., 1996) or 
conversely immunisation of patients with active toxin (Gale et al, 1994). A suitable 
alternative to the vaccine is the production by recombinant technology of the non-toxic, 50 
kDa carboxy-terminal fi-agment (Fragment C) of the tetanus toxin molecule.
Although several plasmids encoding Fragment C under the control of different 
promoters (Anderson et ah, 1996; Saikh et ah, 1998; Stratford et a l, 2000) have already 
been used as DNA vaccines, the antibody titres generated in each case were not higher than 
those observed following immunisation with the purified protein. The main aim of the 
current study was to investigate how a prime-boost strategies may be used to optimise 
immune responses to antigen. This included consideration of the magnitude of this
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response and the potential impact on the Th bias of this response. Such studies had 
previously been performed using animals primed i. m. with the plasmid construct boosted 
with the purified protein. However, no prime/boost evaluations have heen performed using 
priming of animals using DNA delivered by the Gene-Gun. By carrying out i. m. and 
Gene-Gun experiments in parallel using the same plasmid, pcDNA3/tetC, allowed 
comparative analysis of the results generated.
Before in vivo experiments using the Gene-Gun could begin, it was essential to 
initially identify and standardise protocols that produced cartridges for the Gene-Gun that 
contained a consistent amount of DNA that could be accurately quantified. To eliminate 
ethical considerations and reduce cost, most of the preliminary work was performed in 
vitro, using the pGFP-C3 plasmid.
These optimisation experiments revealed several important findings. First, the 
concentration of PVP added to enhance the successful adherence of the DNA/go Id 
suspension to the tubing, appeared crucial, as if the amount of PVP was too high, the 
DNA/gold faded to detach fi’om the tubing during Gene-Gun firing. However, if it was too 
low, some of the DNA was lost during the coating process. Second, the efficiency of DNA 
appears dependent on the quality and purity of ethanol used for washings. Thirdly, pressure 
of helium used during transfection was crucial, as pressures higher than 100 psi produced 
large areas of disruption in the cell monolayer resulting in a lower number of fluorescent 
cells, whilst those lower than 50 psi failed to drive the DNA/gold firom inner surface of the 
cartridges. Thus, in our in vitro experiments, a helium pressure of 100 psi appeared to be 
optimal. Finally, to reduce any fiirther disruption to the cell monolayer, a protective 
diffusion screen was used and the Gene-Gun held at a distance of approximately 2 cm 
above the cell monolayer for firing.
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Using these optimised conditions, the level of GFP expression in COS-7 transfected 
cells was found to be about 3 times lower than when a cationic lipid reagent, Lipofectamin, 
was used as a carrier with roughly the same amount of GFP-encoding DNA. The lower 
level of GFP expression in vitro following COS-7 transfection by Gene-Gun possibly 
reflects the greater damage to the cell membrane during entry by the gold particles. This 
can clearly be seen by the difference in morphology of the cells (Figures 4.1 and 5.2) 
transfected using the two different methods, with those in which Lipofectamine was used 
maintaining typical elongated morphology compared to the rounded cells observed in wells 
transfected using the Gene-Gun. However, using this method, we were able to show that 
pcDNA3/tetC could be delivered in vitro using the Gene-Gun, and resulted in the 
production of the Fragment C protein in these cells.
To investigate the magnitude of anti-Fragment C immune responses, in our initial 
studies, two i. m. or Gene-Gun doses of pcDNA3/tetC were given to BALB/c mice and the 
magnitude of the immune responses to Fragment C determined. These results showed that 
using either route of vaccination, a Fragment C specific immune response was detectable 
in the sera. These responses could be further enhanced when mice were given either an 
additional dose of pcDNA3/tetC (for the i. m. experiment), or Fragment C (for both 
experiments). Following three doses of i. m. DNA encoding Fragment C, a seven-fold 
increase in specific Ah titre was detected.
This study showed that the responses to pcDNA3/tetC could be enhanced when mice 
were subsequently boosted with purified protein, as following a boost with Fragment C, a 
20 fold increase in Ab titre was observed in mice previously primed twice i. m.. In 
comparison, only a six- fold increase in Ab titres was observed in mice primed by Gene- 
Gun. This finding suggest that low Ab responses that might not afford protection in 
immunised subjects can be enhanced using appropriate prime-boost strategies, although
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optimising the vaccination schedule (dose, interval between immunisations) may have 
impact on the magnitude and bias of the immune response and should be further 
considered.
Furthermore, studying the orientation of immune responses elicited by DNA 
vaccination, our results suggest that, in agreement with other studies (Anderson et al, 
1996, Saikh et a l, 1998), i. m. vaccination with pcDNA3/tetC plasmid encoding Fragment 
C of tetanus toxin stimulated a mixed Thl/Th2 immune response in BALB/c mice, with a 
predominance of the Thl component. This was clearly demonstrated by a low TgGl/IgG2a 
ratio, in comparison with the group primed with the control plasmid and boosted with 
purified protein. Thus, DNA and protein based immunisations, clearly stimulated different 
types of immunity. Furthermore, the immune response established by i. m. immunisation 
with DNA, was not drastically altered when the purified protein was given as a booster 
immunisation. This was also consistent with studies describing the type of the immune 
response elicited by different DNA vaccines combined with protein boost (Levitskaya et 
al, 1995, McShane et a l, 2001). Our results also showed that inclusion of the adjuvant LT 
with the purified Fragment C boost did not appear to alter the type of immune response 
generated, but only the magnitude of that response. AU these results suggested that DNA 
administered i. m. may be successfiiUy used to prime Thl biased responses using 
vaccination strategies (as i. m. administration of protein) which, when given alone, would 
stimulate Th2 biased responses in naïve recipients.
As expected, clear differences m Th bias were observed when the type of response 
induced by the Gene-Gun deUvered DNA was compared to that induced foUowing i. m. 
injection. In contrast to the mixed Thl/Th2 response eUcited foUowing i. m. immunisation, 
Gene-Gun mediated vaccmation with pcDNA3/tetC was characterised by a predominant 
Th2 type of immune response, with a high titre of IgGl and IgG2b both before and after
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the protein boost immunisation, and the highest production of IL-5 in supernatants from 
restimulated spleen cells.
These results suggest that in contrast to i. m. immunisation with pcDNA3/tetC, the 
Gene-Gun induces a response that is strongly biased toward a Th2, and, in agreement with 
the previous experiment, that Th bias was not drastically altered by the subsequent i. m. 
boost, although the magnitude of the antibody response to the antigen was enhanced.
One explanation for the difference in the orientation of Th response elicited hy the 
two routes may involve the quantity of plasmid DNA required to activate responses. Using 
the Gene-Gun, the amount of DNA is considerably lower than needed for i. m. 
immunisation, which may affect the number of CpG motifs available for triggering the 
immune system (Krieg et a l, 199S\ O’Garra et a l, 1998). In addition, it is assumed that 
immunisation using the Gene-Gun results in the direct transfection of DCs. This may 
hypass the interactions that are now believed to take place between CpG motifs and Toll-9 
receptor found on the surface of antigen presenting cells (Budker et a l, 2000). It is this 
interaction that is believed to generate the transduction of an intracellular signal leading 
eventually to the observed adjuvant effects of bacterial CpG motife.
Unfortunately, during the course of these experiments, we were unable to assess the 
relevance of prime-boost strategy on the production of tetanus toxin specific neutralising 
antibodies, which mediate protection. However, this would be very relevant for 
determining the protective capacity of the DNA vaccine administered using these two 
different routes of immunisation. In light of our data, the antibody response following 
Gene-Gun driven delivery of DNA, both in literature and in our study, suggests that this 
method of vaccination could he used as an alternative to traditional vaccines against 
tetanus. This is because using the Gene-Gun, very low amounts of DNA could be used to 
generate titres of antigen specific antibody. These titres were equivalent to those achieved
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by i.m. immunisation in which much higher amounts of DNA were used. Despite this 
advance, the response to the Gene-Gun delivered DNA was still lower than that observed 
when the individual protein was given alone. However, it may be possible to fiirther 
increase the magnitude of responses by optimising the immunisation schedule in terms of 
the number of immunisations given, the dose of DNA used and the time interval between 
prime and boost immunisations.
Our results and interpretation of Th modulation of the response were hased on 
assessing specific IgG subclasses in serum and the type of cytokines present in culture 
supernatants from restimulated splenocytes and lymph node cells. Since measurement of 
IgG subclasses is not always considered the most appropriate measurement of Th bias due 
to the relative instability of antibody isotypes, alternative methods for following Th cell 
modulation should he considered in the future. These could include quantification of 
relative numbers of antigen specific Thl versus Th2 cells using an ELIspot assay, 
intracellular staining of cytokines by FACs analysis or quantitative measurements of 
mRNA encoding Thl/Th2 related cytokines. Further studies using larger numbers of mice 
would also help to establish the statistical significance of the results achieved.
In our study Fragment C specific CTL responses were not measured as Fragment C 
specific T- cell epitopes have not yet heen identified for BALB/c mice. Further studies 
may consider defining H-2K^ related-CTL epitopes of Fragment C and investigation of 
specific CTL responses by standard ^*Cr release assay from pulsed syngenic target cells.
Considering the great advantage of Gene-Gun which uses a small amount of DNA to 
induce similar responses to those obtained following i. m. route, DNA vaccination 
approaches against intracellular pathogens, requiring mainly Thl mediated protection, 
should not neglect the Gene-Gun approach. Despite the fact that Gene-Gun delivery of 
DNA vaccines preferentially induces a Th2 type of immunity, a number of strategies can
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be employed with the aim of improving the Gene-Gun effect on cellular immunity, these 
including:
- co-administration of GM-CFS, which is an important determinant of DC viability 
and activation, and was found to improve the immune response upon DNA vaccination 
(Fensterle et a l, 1999),
- co-immunisation with plasmid DNA encoding Thl cytokines (Fensterle et a l, 
1999),
- increasing the number of immunostimulatory sequences from the vector, which 
were identified as the main adjuvant component of bacterial DNA, shifting the immune 
response towards a type 1 response (Krieg et al, 1998*^ ),
- fusion of the antigen-coding insert with lysosome associated membrane protein, 
which has been shown to enhance the presentation of the antigen by MHC class II 
molecules (Ji et al, 1999),
- increasing the interval between the prime and boost, as apparently longer intervals 
tend toward type 1 polarisation. For example, a 45 day versus a 14 day schedule between 
the prime and the boost Gene-Gun immunisation was found to be protective against 
listeriosis (Fensterle et a l, 1999).
Alternatively, Gene-Gun-driven DNA inoculation may play an important role as a 
therapeutic tool in Thl-mediated autoimmune diseases, reverting the impact of 
immunopathology by down-regulatmg the pre-existing Thl response toward a Th2 
phenotype. However this has to he established by designing experimental studies in which 
factors controlling the ethiological Thl/Th2 balance of the autoimmune disorder have to be 
carefriUy defined.
In addition, there is evidence that, as Gene-Gun delivery of DNA vaccines in some 
models may be associated with both Thl and Th2 responses, this route of immunisation
153
maybe appropriate in the treatment of malignant disease using naked DNA (Smahel et al, 
2001).
In summary, results presented in this thesis demonstrate that DNA vaccines delivered 
hy either Gene-Gun or i. m. may provide an excellent tool for priming a particular type of 
immune response, whose magnitude and orientation may be further optimised using an 
appropriate boost immunisation. Moreover, as immunisation with the Gene-Gun is more 
likely to have application at the clinical interface, given the low amount of DNA that can 
be used, it is important to understand the type of the immune response elicited and the 
potential for modulating its orientation and magnitude. Such studies should provide 
information which will be essential if such DNA vaccines are to be used in the firture as a 
preventive and therapeutic method against infections, immune disorders or even malignant 
diseases.
154
References
Agadjanyan MG, Kim JJ, Trivedi N, Wilson DM, Monzavi-Karbassi B, Morrison LD, 
Nottingham LK, Dentchev T, Tsai A, Dang K, Chalian AA, Maldonado MA, 
Williams WV, Weiner DB. CD86 (B7-2) can function to drive MHC-restricted 
antigen-specific CTL responses in vivo. J Immunol. 1999 Mar 15;162(6):3417-27.
Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: 
transfection and activation of dendritic cells as key events for immunity. J Exp 
Med. 1999 Jan 4;189(l):169-78.
Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen fiom apoptotic cells 
and induce class I-restricted CTLs. Nature. 1998 Mar 5;392(6671):86-9.
Anderson R, Gao XM, Papakonstantinopoulou A, Roberts M, Dougan G. Immune 
response in mice following immunisation with DNA encoding fi-agment C of 
tetanus toxin. Infect Immun. 1996 Aug;64(8):3168-73.
Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, 
Rousset F, Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol. 
1994;12:881-922.
Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human 
muscle cells express a functional costimulatory molecule distinct fi’om B7.1 
(CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol. 1998 
Dec 1;161(11):5943-51.
Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on 
the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses 
are suboptimal when antigen is cytoplasmic after intramuscular DNA 
immunisation. Int Immunol. 1997 Dec;9(12): 1897-906.
Budker V, Budker T, Zhang G, Subbotin V, Loomis A, Wolff JA. Hypothesis: naked 
plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene 
Med. 2000 Mar-Apr;2(2):76-88.
Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by 
dendritic cells after immunisation with DNA encoding a major histocompatibility 
complex class Il-restricted viral epitope. J Exp Med. 1997 Nov 3;186(9):1481-6.
Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S. 
Cross-protection against a lethal influenza virus infection by DNA vaccine to 
neuraminidase. Vaccine. 2000 Aug l;18(28):3214-22.
Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA 
vaccination induces antitumor immunity against human papillomavirus type 16 
E7-expressing murine tumor métastasés in the liver and lungs. Gene Ther. 1999 
Dec;6(12):1972-81.
Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura S. 
Protection against influenza B virus infection by immunization with DNA 
vaccines. Vaccine. 2001 Jan 8;19(ll-12):1446-55.
Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic 
immunisation. FASEB J. 1998 Dec;12(15):1611-26.
Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: 
mechanism of CTL priming. J Exp Med. 1996 Oct 1;184(4): 1555-60.
Davis HL, Michel ML, Whalen RG. Use of plasmid DNA for direct gene transfer and 
immunization. AnnN Y Acad Sci. 1995 Nov 27;772:21-9.
Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence 
for immunogenicity in chimpanzees and comparison with other vaccines. Proc 
Natl Acad Sci USA.  1996 Jul 9;93(14):7213-8.
n
Davis HL, ML Michel, and RG Whalen DNA-based immunisation induces continuous 
secretion of hepatitis B surface antigen and high levels of circulating antibody 
Hum Mol Genet 1993^2: 1847-1851.
Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: 
factors affecting efficiency of transfer and stability of expression. Hum Gene Ther. 
1993‘’Apr;4(2):151-9.
Deck RR, De Witt CM, Donnelly JJ, Liu MA, Ulmer JB. Characterization of humoral 
immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine. 
1997 Jan;15(l):71-8.
Dhawan J, Rando TA, Elson SL, Bujard H, Blau HM. Tetracycline-regulated gene 
expression following direct gene transfer into mouse skeletal muscle. Somat Cell 
Mol Genet. 1995 Jul;21(4):233-40.
Doe B, Selby M, Barnett S, Baenziger J, Walker CM. Induction of cytotoxic T 
lymphocytes by intramuscular immunisation with plasmid DNA is facilitated by 
bone marrow-derived cells. Proc Natl Acad Sci U S A .  1996 Aug 6;93(16):8578- 
83.
Elbein AD. The role of N-linked oligosaccharides in glycoprotein function. Trends 
Biotechnol. 1991 Oct;9(10):346-52.
Eo SK, Gierynska M, Kamar AA, Rouse BT. Prime-boost immunization with DNA 
vaccine: mucosal route of administration changes the rules. J Immunol. 2001 May 
l;166(9):5473-9.
Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and 
antibody isotypes generated by saline and gene gun DNA immunisation. J. 
Immunol. 1997 Mar l;158(5):2278-84.
n i
Fensterle J, Grode L, Hess J, Kauônann SH. Effective DNA vaccination against 
listeriosis by prime/boost inoculation with the gene gun. J Immunol. 1999 Oct 
15;163(8):4510-8.
Figueiredo D, Turcotte C, Frankel G, Li Y, Dolly O, Wilkin G, Marriott D, Fairweather 
N, Dougan G. Related Articles Characterization of recombinant tetanus toxin 
derivatives suitable for vaccine development. Infect Immun. 1995 
Aug;63(8):3218-21.
Fine PE. Variation in protection by BCG: implications of and for heterologous 
immunity. Lancet. 1995 Nov 18;346(8986): 1339-45.
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA 
vaccines: protective immunizations by parenteral, mucosal, and gene-gun 
inoculations. Proc Natl Acad Sci USA.  1993 Dec 15;90(24):11478-82.
Gale JL, Thapa PB, Wassilak SG, Bobo JK, Mendelman PM, Foy HM. Risk of serious 
acute neurological illness after immunization with diphtheria-tetanus-pertussis 
vaccine. A population-based case-control study. JAMA. 1994 Jan 5;271(1):37-41.
Garren H, Ruiz PJ, Watkins TA, Fontoura P, Nguyen LT, Estline ER, Hirschberg DL, 
Steinman L Combination of gene delivery and DNA vaccination to protect from 
and reverse Thl autoimmune disease via deviation to the Th2 pathway. Immunity 
2001 Jul;15(l):15-2.
Ghiasi H, Cai S, Slanina S, Nesbum AB, Wechsler SL, Vaccination of mice with herpes 
simplex virus type 1 glycoprotein D DNA produces low levels of protection 
against lethal HSV-1 challenge. Antiviral Res. 1995 Oct;28(2):147-57.
GDkeson GS, Pippen AM, Pisetsky DS. Induction of cross-reactive anti-dsDNA 
antibodies in preautoimmune NZB/NZW mice by immunisation with bacterial 
DNA. J Clin Invest. 1995:95:1398-402.
IV
Gordon AH, Hart PD, Young MR. Ammonia inhibits phago some-lyso some fusion in 
macrophages. Nature, 1980 Jul 3;286(5768):79-80.
Hahn S, Erb P. The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes 
in health and disease. Int Rev Immunol. 1999;18(5-6):449-64
Halpern JL, Habig WH, Neale EA, Stibitz S. Cloning and expression of functional 
fragment C of tetanus toxin. Infect Immun. 1990 Apr;58(4): 1004-9.
Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for 
a year-2000 clinical trial in Kenya. Nat Med. 2000 Sep;6(9):951-5.
Harboe M, Andersen P, Colston MJ, Gicquel B, Hermans PW, Ivanyi J, Kaufinann SH. 
European Commission COST/STD Initiative. Report of the expert panel IX. 
Vaccines against tuberculosis. Vaccine. 1996 May;14(7):701-16.
Harboe M, Wiker HG, Ulvund G, Lund-Pedersen B, Andersen AB, Hewinson RG, 
Nagai S. MPB70 and MPB83 as indicators of protein localization in mycobacterial 
cells. Infect Immun. 1998 Jan;66(l):289-96.
Harding CV, Song R, Griffin J, France J, Wick MJ, Pfeifer JD, Geuze HJ. Processing of 
bacterial antigens for presentation to class I and II MHC-restricted T lymphocytes. 
Infect Agents Dis. 1995 Mar;4(l):l-12.
Homer AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based
immunotherapeutics for the treatment of allergic disease. Immunol Rev 2001 
Feb;179:102-18.
Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, Hsieh KH. 
Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway 
hyperresponsiveness in vivo hy genetic immunisation. Nat Med. 1996 
May;2(5):540-4.
V
Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. 
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens 
that use two different vectors. JNatl Cancer Inst. 1997 Nov 5;89(21): 1595-601.
Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL 
responses mediated by plasmid DNA immunogens encoding co stimulatory 
molecules and cytokines. J Immunol. 1997* May 15;158(10):4591-601.
Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone 
marrow-derived cells in CTL induction following plasmid DNA immunisation at 
different sites, J Immunol. 1997  ^Jul 1;159(1): 11-14.
Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC. 
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal 
compartment enhancesm the antitumor immunity of DNA vaccines against murine 
human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999 Nov 
20;10(17):2727-40
Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H, Haynes JD, Mo eh 
JK, Lucas C, Luu T, MagiU AJ, Hoffinan SL, Sim BK. Protection of Aotus 
monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost 
immunization regimen. J Infect Dis. 2001 Jan 15;183(2):303-312.
Justewicz DM, Morin MJ, HL Robinson, and RG Webster Antibody-forming cell 
response to virus challenge in mice immunized with DNA encoding the influenza 
virus hemagglutinin J. Virol. 1995. 69:7712-7717.
Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated 
BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention 
of leprosy and tuberçulosis in Malawi.. Lancet. 1996 Jul 6;348(9019): 17-24.
Kaufinann SH. Is the development of a new tuberculosis vaccine possible? Nat Med. 
2000 Sep;6(9):955-60.
VI
Klmman DM, Sechler JM, Conover J, Gu M, Rosenberg AS. Contribution of cells at the 
site of DNA vaccination to the generation of antigen-specific immunity and 
memory. J Immunol. 1998 Mar l;160(5):2388-92.
Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, 
Davis HL. Free in PMC, Protein, Nucleotide Sequence motifs in adenoviral DNA 
block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A .  
1998* Oct 13;95(21):12631-6.
Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. 
Trends Microbiol. 1998*^  Jan;6(l):23-7.
Lagging LM, Meyer K, Hoft D, Houghton DM, Belshe RB, Ray R, Immune responses to 
plasmid DNA encoding the hepatitis C virus core protein, J. Virol. 1995. 69:5859- 
5863.
Larsen DL, Karasin A, Olsen CW. Immunization of pigs against influenza virus 
infection by DNA vaccine priming followed by killed-virus vaccine boosting. 
Vaccine. 2001 Apr 6;19(20-22):2842-53.
Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S,
' Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hof&nan SL. 
Safety, tolerability and humoral immune responses afl:er intramuscular 
administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine. 
2000 Mar 17;18(18): 1893-901.
Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-MuUen PM, Klein G, Kurilla 
MG, Masueei MG. Inhibition of antigen processing by the internal repeat region of 
the Epstein-Barr virus nuclear antigen-1. Nature. 1995 Jun 22;375(6533):685-8.
Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells 
by phosphorothioate oligodeoxynucleotides. J Clin Invest. 1996 Sep 1;98(5):1119- 
29.
vn
Lightbody KA, Girvin RM, Mackie DP, Neill SD, Pollock JM. T-cell recognition of 
mycobacterial proteins MPB70 mid MPB64 in cattle immunized with antigen and 
infected with Mycobacterium bo vis. Scand J Immunol. 1998 Jul;48(l):44“51.
Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, Colston 
MJ, Hewinson RG, Moelling K, Silva CL. Therapy of tuberculosis in mice by 
DNA vaccination. Nature. 1999 Jul 15;400(6741):269-71.
Lyashchenko KP, Pollock JM, Colangeli R, Gennaro ML. Diversity of Antigen 
Recognition by Serum Antibodies in Experimental Bovine Tuberculosis. Infect. 
Immun. 1998. 66:5344-5349.
MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, 
Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, 
Weiner DB. First human trial of a DNA-based vaccine for treatment of human 
immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 
1998 Jul;178(l):92-100.
Marodon G, Rocha B. Activation and ’deletion' of self-reactive mature and immature T 
cells during ontogeny of Mis-la mice; implications for neonatal tolerance 
induction. Int Immunol. 1994 Dec;6(12): 1899-904.
Martin T, Parker SE, Hedstrom R, Le T, Hoffinan SL, Norman J, Hobart P, Lew D,. 
Plasmid DNA malaria vaccine: the potential for genomic integration after 
intramuscular injection. Hum Gene Ther 1999;10:759-68.
Matsumoto S, Matsuo T, Ohara N, Hotokezaka H, Naito M, Minami, J, Yamada T., 
Cloning and sequencing of a unique antigen MPT70 from Mycobacterium 
tuberculosis H37Rv and expression in BCG using E. coli-mycobacteria shuttle 
vector, Scand J Immunol. 1995 Mar;41(3):281-7.
McCluskie MJ, Brazolot MUlan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller 
JT, Widera G, Haynes JR, Purcell RH, Davis HL. Route and method of delivery of
vni
DNA vaccine influence immune responses in mice and non-human primates. Mol 
Med. 1999May;5(5):287-300.
Me Shane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t- 
cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara 
prime-boost vaccination regimen for murine tuberculosis. Infect Immun. 2001 
Feb;69(2):681-6.
MoUoy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected 
monocytes is coupled vnth killing of intracellular bacillus Calmette-Guerin. J Exp 
Med. 1994 Oct 1;180(4): 1499-509.
Moody DB, Guy MR, Grant E, Cheng TY, Brenner MB, Besra GS, Porcelli SA. CD lb- 
mediated T cell recognition of a glycolipid antigen generated from mycobacterial 
lipid and host carbohydrate during infection. J Exp Med. 2000 Oct 2;192(7):965- 
76.
Mor G, Yamshchikov G, Sedegah M, Takeno M, Wang R, Houghten RA, Hoffinan S, 
Klinman DM. Induction of neonatal tolerance by plasmid DNA vaccination of 
mice. J Clin Invest. 1996 Dec 15;98(12):2700-5.
Mulero JJ, Yeung G, Nelken ST, Bright JM, McGowan DW, Ford JE. Biochemical 
characterization of CD39L4. Biochemistry. 2000 Oct 24;39(42): 12924-8.
Nagai S, Matsumoto J, Nagasuga T. Specific skin-reactive protein from culture filtrate 
of Mycobacterium bo vis BCG. In&ct Immun. 1981 Mar;31(3): 1152-60.
O'Brien RL, Happ MP, Dallas A, Palmer E, Kubo R, Bom WK. Stimulation of a major 
subset of lymphocytes expressing T eell receptor gamma delta by an antigen 
derived from Mycobacterium tuberculosis. CeU. 1989 May 19;57(4):667-74.
O'Garra A. Cytokines induce the development of functionally heterogeneous T helper 
eell subsets. Immunity. 1998 Mar;8(3):275-83.
IX
Pehler K, Brasky KM, Butler TM, Attanasio R. Mycobacterium tuberculosis-secreted 
protein antigens: immunogenicity in baboons. J Clin Immunol. 2000
Jul;20(4):306-16.
Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene 
gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T 
lymphocyte responses following epidermal delivery of nanogram quantities of 
DNA. Vaccine. 1995;13:1427-30.
Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant 
role for directly transfected dendritic cells in antigen presentation to CD8+ T cells 
after gene gun immunisation. J Exp Med. 1998 Sep 21;188(6):1075-82.
Price DL, Griffin J, Young A, Peck K, Stocks A. Tetanus toxin: direct evidence for 
retrograde intraaxonal transport. Science. 1975 May 30;188(4191):945-7.
Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh 
M, Lew D, Yankauckas MA, et al. Intradermal gene immunization: the possible 
role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl 
Acad Sci U S A. 1994 Sep 27;91(20):9519-23.
Rhodes SG, Gavier-Widen D, Buddie BM, Whelan AO, Singh M, Hewinson RG, 
Vordermeier HM. Antigen specifieity in experimental bovine tuberculosis. Infect 
Immun. 2000* May;68(5):2573-8.
Rhodes SG, Buddie BM, Hewinson RG, Vordermeier HM. Bovine tuberculosis: immune 
responses in the peripheral blood and at the site of active disease. Immunology. 
2000'’Feb;99(2):195-202.
Rice J, King CA, Spellerberg MB, Fairweather N, Stevenson FK, 1999. Manipulation of 
pathogen-derived genes to influence antigen presentation via DNA vaccines. 
Vaccine 17:3030-8.
X
Saikh KU, Sesno J, Brandler P, Ulrich RG. Are DNA-based vaccines useful for 
protection against secreted bacterial toxins? Tetanus toxin test case. Vaccine. 1998 
May-Jun;16(9-10): 1029-38.
Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, 
Carson DA, Raz E. Immunostimulatory DNA sequences necessary for effective 
intradermal gene immunisation. Science. 1996 Jul 19;273(5273):352-4.
Schoenberger SP, Toes RE, van der Voort El, Offfinga R, Melief CJ. T-cell help for 
cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998 
Jun 4;393(6684):480-3.
Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA,Hoffinan SL. Boosting 
with reeombinant vaccinia increases immunogenicity and protective efficacy of 
malaria DNA vaccine. Proe Natl Acad Sci USA.  1998 Jun 23;95(13):7648-53.
Sedegah M, Weiss W, Sacci JB Jr, Charoenvit Y, Hedstrom R, Gowda K, Majam VF, 
Tine J, Kumar S, Hobart P, Hoffinan SL. Improving protective immunity induced 
by DNA-based immunisation: priming with antigen and GM-CSF-encoding 
plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J 
Immunol. 2000 Jun 1;164(11):5905-12.
Shaw DM, Gaerthe B, Leer RJ, Van Der Stap JG, Smittenaar C, Heijne Den Bak- 
Glashouwer M, Thole JE, Tielen FJ, Pouwels PH, Havenith CE. Engineering the 
microflora to vaccinate the mucosa: serum immunoglobulin G responses and 
aetivated draining cervical lymph nodes following mucosal application of tetanus 
toxin fragment C-expressing lactobacilli. Immunology. 2000 Aug;100(4):510-8.
Shi Z, Curiel DT, Tang DC. DNA-based non-invasive vaccination onto the skin. 
Vaccine. 1999 Apr;l7:2136-41.
Silva CL, Bonato VL, Lima VM, Faccioli LH, Leao SC. Characterization of the 
memory/activated T cells that mediate the long-lived host response against
XI
tuberculosis after bacillus Calmette-Guerin or DNA vaccination. Immunology.
1999 Aug;97(4):573-81.
Sin JI, Bagarazzi M, Pachuk C, Weiner DB. DNA priming-protein boosting enhances 
both antigen-specific antibody and Thl-type cellular immune responses in a 
murine herpes simplex virus-2 gD vaccine model. DNA Cell Biol. 1999 
Oct;18(10):771-9.
Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 Genes as DNA 
Vaccine against E7-Containing Oncogenic Cells. Virology. 2001 Mar 
15;281(2):231-8
Song MK, Lee SW, Suh YS, Lee KJ, Sung YC. Enhancement of immunoglobulin G2a 
and cytotoxic T-lymphocyte responses by a booster immunisation with 
recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 2000 
Mar;74(6):2920-5.
Stratford R, Douce G, Zhang-Barber L, Fairweather N, Eskola J, Dougan G. Influence of 
codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine.
2000 Nov 22;19(7-8):810-5.
Stratford R, Douce G, Bo we F, Dougan G. A vaccination strategy incorporating DNA 
priming and mucosal boosting using tetanus toxin fragment C (TetC). Vaeeine.
2001 Nov 12;20(3-4):516-25.
Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood 
vaccines other than pertussis and rubella. Summary of a report from the Institute of 
Medicine. JAMA. 1994 May 25;271(20):1602-5.
Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edeknan R. Phase 1 safety and 
immune response studies of a DNA vaccine encoding hepatitis B surface antigen 
delivered by a gene delivery device. Vaccine. 1999 Jul 16;17(22);2826-9.
XII
Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, Wasserman SS, 
Edeknan R, Chatfield S, Dougan G, Levine MM. Safety and immune responses to 
attenuated Salmonella enteriea serovar typhi oral live vector vaccines expressing 
tetanus toxin fragment C. Clin Immunol. 2000 Nov;97(2): 146-53.
Tang DC, Devit M, Johnston SA. Genetic immunisation is a simple method for eliciting 
an immune response. Nature 1992;356; 152-154.
Topsis J, Randall S, Weinstein J, Wilets I. Tolerance of initial diphtheria-tetanus- 
pertussis immunization in preterm infants. J Perinatol. 1996 Mar-Apr;16(2 Pt 
1):98-102.
Torres CA, Iwasaki A, Barber BH, Robinson HL. Differential dependence on target site 
tissue for gene gun and intramuscular DNA immunisations. J Immunol. 1997 May 
15;158(10):4529-32.
Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. Generation of MHC class I- 
restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: 
antigen presentation by non-muscle cells. Immunology. 1996 Sep;89(l):59-67.
Ulmer JB, Deck RR, De Witt CM, Fu TM, Donnelly JJ, Caulfield MJ, Liu MA. 
Expression of a viral protein by muscle eeUs in vivo induces protective cell- 
mediated immunity. Vaccine. 1997 Jun;15(8):839-41.
Vordermeier HM, Cockle PJ, Whelan AO, Rhodes S, Chambers MA, Clifford D, 
Huygen K, Tascon R, Lowrie D, Colston MJ, Hewinson RG. Effective DNA 
vaccination of cattle with the mycobaeterial antigens MPB83 and MPB70 does not 
compromise the specificity of the comparative intradermal tuberculin skin test. 
Vaccine. 2000 Dec 8;19(9-10): 1246-55.
Weiss R, Leitner WW, Seheiblhofer S, Chen D, Bemhaupt A, Mostbock S, Thalhamer J, 
Lyon JA. Genetic vaccination against malaria infection by intradermal and
xm
epidermal injections of a plasmid containing the gene encoding the Plasmodium 
berghei circumsporozoite protein. Infect Immun. 2000 Oct;68(10):5914-9.
Wiker HG, Harboe M, Nagai S. A localization index for distinction between 
extracellular and intracellular antigens of Mycobacterium tuberculosis. J Gen 
Microbiol. 1991;Apr;137:875-84.
Wiker HG, Lyashchenko KP, Aksoy AM, Lightbody KA, Pollock JM, Komissarenko 
SV, Bobrovnik SO, Kolesnikova IN, Mykhalsky LO, Gennaro ML, Harboe M. 
Immunochemical characterization of the mpb70/80 and mpb83 proteins of 
mycobacterium bovis, Infect. Immun. 1998. 66:1445-1452.
Wohf JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL. Direct 
gene transfer into mouse muscle in vivo. Science. 1990 Mar 23;247:1465-8.
Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid 
DNA and foreign gene expression in mouse muscle. Hum Mol Genet. 1992 
Sep;l(6):363-9.
WHO vaeemes and Biologicals- www.who.int/ vaccines/ intermediate/ 
tubereulosis.html.
Xiang ZQ, Spltalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. Vaccination with a 
plasmid vector carrying the rabies virus glycoprotein gene induces protective 
immunity against rabies virus. Virology. 1994 Feb 15;199(l):132-40.
Xu A, Bellamy AR, Taylor JA. Expression of translationally controlled tumour protein 
is regulated by calcium at both the transcriptional and post-transcriptional level. 
Biochem J. 1999 Sep 15;342 Pt 3:683-9.
Yankauckas MA, Morrow JE, Parker SE, Abai A, Rhodes GH, Dwarki VJ, Gromkowski 
SH. Long-term anti-nucleoprotein cellular and humoral immunity is induced by 
intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol. 
1993 Nov;12(9):771-6.
XIV
Young DB and Thole JE. The Immune Response to Mycobacteria p.27-43, from 
Intracellular Bacteria Vaccine Vectors, Immunology, Cell Biology, and Genetics, 
Ed. By Ivonne Paterson, 1999.
XV

